

April 21, 2026

<p>To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b></p> <p><b>Company Code No. AUROPHARMA</b></p>	<p>To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25<sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b></p> <p><b>Company Code No. 524804</b></p>
--	---

**Sub: Submission of Letter of Offer pertaining to buyback of up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) fully paid-up equity shares having a face value of ₹ 1/- (Rupees One only) each (“Equity Shares”) of Aurobindo Pharma Limited (“Company”) at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share payable in cash for an aggregate amount not exceeding ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only) on a proportionate basis through tender offer route (“Buyback”), pursuant to the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (“Buyback Regulations”).**

Dear Sir / Madam,

This is in regard to the captioned Buyback and is further to our letter dated April 8, 2026 whereby we submitted the Public Announcement pertaining to the captioned Buyback.

We are pleased to submit herewith the Letter of Offer dated April 21, 2026 for your reference and dissemination. In accordance with the Buyback Regulations, the Company has e-mailed the Letter of Offer to eligible shareholders holding Equity Shares of the Company as on the Record Date (being April 17, 2026), today, i.e., April 21, 2026.

You are requested to take note of the following schedule of activities in relation to the Buyback:

Activity	Date	Day
Buyback Opening Date	April 23, 2026	Thursday
Buyback Closing Date	April 29, 2026	Wednesday
Last date of receipt of completed Tender Forms and other specified documents by the Registrar	April 29, 2026	Wednesday
Last date of completion of settlement of bids by the Clearing Corporation/ BSE	May 7, 2026	Thursday

**Note:** Where last dates are mentioned for certain activities, such activities may happen on or before the respective last dates.

## AUROBINDO PHARMA LIMITED

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to such terms under the Letter of Offer.

We request you to kindly take the above on record.

This is for your information and records.

Thanking you,  
For **Aurobindo Pharma Limited**

B Adi Reddy  
**Company Secretary & Compliance Officer**

Encl: Letter of Offer

(CIN : L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED**  
[www.aurobindo.com](http://www.aurobindo.com)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**LETTER OF OFFER**



**THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION**

This letter of offer ("**Letter of Offer**") is sent to you as a registered Equity Shareholder / Beneficial Owner (*as defined below*) of Aurobindo Pharma Limited (hereinafter referred as the "**Company**") as on the Record Date (*as defined below*) in accordance with Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("**Buyback Regulations**"). If you require any clarifications about the action to be taken, you should consult your stockbroker or investment consultant or the Manager to the Buyback Offer i.e., Axis Capital Limited, or the Registrar to the Buyback Offer i.e., KFin Technologies Limited. Please refer to the section on "Definitions of Key Terms" on page no. 5 of this Letter of Offer for the definitions of the capitalized terms used herein.

	<p><b>AUROBINDO PHARMA LIMITED</b>  <b>Corporate Identification Number (CIN):</b> L24239TG1986PLC015190  <b>Registered Office:</b> Plot No. 2, Maithrivi, Ameerpet, Hyderabad- 500 038, Telangana, India  <b>Corporate Office:</b> Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India  <b>Contact Person:</b> Mr B Adi Reddy, Company Secretary and Compliance Officer  <b>Tel. No.:</b> +91 40 2373 6370/ 2374 7340; <b>Fax:</b> +91 40 2374 1080/ 2374 6833;  <b>Website:</b> <a href="http://www.aurobindo.com">www.aurobindo.com</a>; * <b>Email:</b> <a href="mailto:cs@aurobindo.com">cs@aurobindo.com</a></p>
---	--

**OFFER TO BUYBACK UP TO 54,23,728 (FIFTY FOUR LAKH TWENTY THREE THOUSAND SEVEN HUNDRED AND TWENTY EIGHT ONLY) FULLY PAID-UP EQUITY SHARES OF THE COMPANY, HAVING FACE VALUE OF ₹ 1/- (RUPEE ONE ONLY) EACH ("EQUITY SHARES"), REPRESENTING APPROXIMATELY 0.93% OF THE TOTAL NUMBER OF OUTSTANDING EQUITY SHARES OF THE COMPANY, FROM THE EQUITY SHAREHOLDERS / BENEFICIAL OWNERS OF EQUITY SHARES OF THE COMPANY AS ON FRIDAY, APRIL 17, 2026 ("RECORD DATE") ON A PROPORTIONATE BASIS, THROUGH THE "TENDER OFFER" ROUTE AT A PRICE OF ₹ 1,475/- (RUPEES ONE THOUSAND FOUR HUNDRED AND SEVENTY FIVE ONLY) PER EQUITY SHARE, PAYABLE IN CASH, FOR AN AGGREGATE AMOUNT UP TO ₹ 800,00,00,000/- (RUPEES EIGHT HUNDRED CRORE ONLY) EXCLUDING TRANSACTION COSTS.**

- The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and pursuant to Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and the rules framed thereunder including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, the Buyback Regulations read with the SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, Registrar of Companies, Telangana at Hyderabad, NSE, BSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.
- The Buyback Size constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations.
- The Letter of Offer will be electronically sent to the Equity Shareholders/ Beneficial Owners of Equity Shares as on the Record Date i.e., Friday, April 17, 2026, in accordance with the Buyback Regulations and such other circulars or notifications, as may be applicable. Further, in terms of Regulation 9(ii) of the Buyback Regulations, if the Company receives a request from any Eligible Shareholder to dispatch a copy of the Letter of Offer in physical form, the same shall be provided.
- The procedure for tendering shares and settlement is set out in paragraph 20 (*Procedure for Tendering Shares and Settlement*) on page no. 60 of this Letter of Offer. The form of acceptance cum acknowledgement ("**Tender Form**") along with share transfer form ("**Form SH-4**") is enclosed together with this Letter of Offer.
- The procedure for Acceptance is set out in paragraph 19 (*Process and Methodology for the Buyback*) on page no. 53 of this Letter of Offer. The payment of consideration is in cash to the Eligible Shareholders. For mode of payment of consideration to the Eligible Shareholders, please refer to paragraph 20.30 (*Method of Settlement*) on page no. 70 of this Letter of Offer.
- A copy of the Public Announcement is available on the websites of the Company ([www.aurobindo.com](http://www.aurobindo.com)), the Manager to the Buyback ([www.axiscapital.co.in](http://www.axiscapital.co.in)), Registrar to the Buyback ([kosmic.kfintech.com/karisma/buybackofferv2.aspx](http://kosmic.kfintech.com/karisma/buybackofferv2.aspx)), SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)). A copy of the Letter of Offer (along with the Tender Form and Form SH-4) shall be available on the websites of the Company ([www.aurobindo.com](http://www.aurobindo.com)), the Manager to the Buyback ([www.axiscapital.co.in](http://www.axiscapital.co.in)), Registrar to the Buyback ([www.kfintech.com](http://www.kfintech.com)) and is expected to be available on the websites of SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)).
- Eligible Shareholders are advised to read the Letter of Offer and in particular, refer to paragraph 17 (*Details of Statutory Approvals*) on page no. 52 of this Letter of Offer and paragraph 21 (*Note on Taxation*) on page no. 73 of this Letter of Offer before tendering their Equity Shares in the Buyback.

<p><b>MANAGER TO THE BUYBACK</b></p>  <p><b>Axis Capital Limited</b>  <b>Address:</b> 1st Floor, Axis House, P. B. Marg, Worli Mumbai - 400 025, Maharashtra, India  <b>Tel. no.:</b> +91 22 4325 2183; <b>Fax no.:</b> +91 22 4325 3000  <b>Contact person:</b> Harish Patel/ Simran Gadh  <b>Email:</b> <a href="mailto:apl.buyback@axiscap.in">apl.buyback@axiscap.in</a>; <b>Website:</b> <a href="http://www.axiscapital.co.in">www.axiscapital.co.in</a>  <b>SEBI registration no.:</b> INM000012029; <b>Validity period:</b> Permanent  <b>CIN:</b> U51900MH2005PLC157853</p>	<p><b>REGISTRAR TO THE BUYBACK</b></p>  <p><b>KFin Technologies Limited</b>  <b>Address:</b> Selenium, Tower- B, Plot No 31 &amp; 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana – 500032  <b>Tel. no.:</b> +91 40 6716 2222; <b>Fax no.:</b> +91 40 6716 1563; <b>Tollfree no.:</b> 18003094001  <b>Contact person:</b> M Murali Krishna  <b>Email:</b> <a href="mailto:aurobindo.buyback2026@kfintech.com">aurobindo.buyback2026@kfintech.com</a>; <b>Website:</b> <a href="http://www.kfintech.com">www.kfintech.com</a>  <b>Investor Grievance mail:</b> <a href="mailto:einward.ris@kfintech.com">einward.ris@kfintech.com</a>  <b>SEBI registration no.:</b> INR000000221; <b>Validity period:</b> Permanent  <b>CIN:</b> L72400MH2017PLC444072</p>
---	---

<b>BUYBACK PROGRAMME</b>	
<b>BUYBACK OPENS ON</b>	<b>THURSDAY, APRIL 23, 2026</b>
<b>BUYBACK CLOSING ON</b>	<b>WEDNESDAY, APRIL 29, 2026</b>
<b>LAST DATE OF RECEIPT OF COMPLETED TENDER FORMS AND OTHER SPECIFIED DOCUMENTS BY THE REGISTRAR TO THE BUYBACK</b>	<b>ON OR BEFORE 5.00 PM (IST) ON WEDNESDAY, APRIL 29, 2026</b>
<b>BUYBACK ENTITLEMENT</b>	
<b>CATEGORY OF ELIGIBLE SHAREHOLDERS</b>	<b>RATIO OF BUYBACK ENTITLEMENT*</b>
<b>RESERVED CATEGORY FOR SMALL SHAREHOLDERS</b>	<b>7 EQUITY SHARES FOR EVERY 61 EQUITY SHARES HELD ON THE RECORD DATE</b>
<b>GENERAL CATEGORY FOR ALL OTHER ELIGIBLE SHAREHOLDERS</b>	<b>2 EQUITY SHARES FOR EVERY 249 EQUITY SHARES HELD ON THE RECORD DATE</b>

\* In addition to the Company's contact details provided above, the investors may reach out to the Investor Service Centre of KFin Technologies Limited for any queries at +91 40 6716 2222 and [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com), details of which are also included at Paragraph 27 of the Letter of Offer.

# For further information on ratio of Buyback as per the Buyback Entitlement in each category, please refer paragraph 19.6 on page no. 56 of the Letter of Offer.

- ELIGIBLE SHAREHOLDERS CAN ALSO CHECK THEIR ENTITLEMENT ON THE WEBSITE OF THE REGISTRAR TO THE BUYBACK BY FOLLOWING THE STEPS GIVEN BELOW:**
- Click on <https://kosmic.kfintech.com/karisma/buybackofferv2.aspx>
  - Select the name of the Company - Aurobindo Pharma Limited
  - Select holding type - "Physical" or "NSDL" or "CDSL" or "PAN"
  - Based on the option selected above, enter your "Folio Number" or "NSDL DPID/Client ID" or "CDSL Client ID" or "PAN"
  - Click on submit
  - Then click on 'View' button
  - The entitlement will be provided in the pre-filled 'FORM OF ACCEPTANCE-CUM ACKNOWLEDGEMENT'

## TABLE OF CONTENTS

1.	SCHEDULE OF ACTIVITIES .....	4
2.	DEFINITION OF KEY TERMS .....	5
3.	DISCLAIMER CLAUSE .....	9
4.	TEXT OF RESOLUTION PASSED AT THE BOARD MEETING .....	12
5.	DETAILS OF PUBLIC ANNOUNCEMENT .....	20
6.	DETAILS OF THE BUYBACK.....	21
7.	AUTHORITY FOR THE BUYBACK .....	23
8.	NECESSITY FOR THE BUYBACK.....	23
9.	MANAGEMENT DISCUSSION AND ANALYSIS OF THE LIKELY IMPACT OF THE BUYBACK ON THE COMPANY .....	24
10.	BASIS OF CALCULATING THE BUYBACK PRICE .....	32
11.	SOURCES OF FUNDS FOR THE BUYBACK .....	32
12.	DETAILS OF ESCROW ACCOUNT AND AMOUNT DEPOSITED THEREIN AND FIRM FINANCIAL ARRANGEMENT.....	33
13.	CAPITAL STRUCTURE AND SHAREHOLDING PATTERN.....	33
14.	BRIEF INFORMATION OF THE COMPANY .....	37
15.	FINANCIAL INFORMATION ABOUT THE COMPANY.....	46
16.	STOCK MARKET DATA.....	50
17.	DETAILS OF STATUTORY APPROVALS .....	52
18.	DETAILS OF THE REGISTRAR TO THE BUYBACK.....	53
19.	PROCESS AND METHODOLOGY FOR THE BUYBACK .....	53
20.	PROCEDURE FOR TENDERING SHARES AND SETTLEMENT .....	60
21.	NOTE ON TAXATION .....	73
22.	DECLARATION FROM THE BOARD OF DIRECTORS .....	77
23.	STATUTORY AUDITOR'S REPORT .....	78
24.	DOCUMENTS FOR INSPECTION.....	82
25.	DETAILS OF THE COMPLIANCE OFFICER .....	83
26.	DETAILS OF REMEDIES AVAILABLE TO SHAREHOLDERS/ BENEFICIAL OWNERS.....	83
27.	DETAILS OF THE INVESTOR SERVICE CENTRE.....	83
28.	DETAILS OF THE MANAGER TO THE BUYBACK.....	83
29.	DECLARATION BY THE DIRECTORS.....	84
	TENDER FORMS .....	85

**NO OFFER TO SUBSCRIBE/PURCHASE/SELL, OR AN INVITATION TO SUBSCRIBE/PURCHASE/SELL, ANY SECURITIES OF THE COMPANY IN ANY JURISDICTION OR AS A SOLICITATION OR AN INVITATION TO SUBSCRIBE/PURCHASE/SELL ANY SECURITIES INCLUDING THE EQUITY SHARES OF THE COMPANY**

- This Letter of Offer together with the Public Announcement has been prepared for the purposes of compliance with applicable Indian laws and regulations. This Letter of Offer has not been filed, registered or approved in any jurisdiction outside India. Accordingly, the information disclosed may not be the same as that which would have been disclosed if this document had been prepared in accordance with the laws and regulations of any jurisdiction outside of India. Except as otherwise required by applicable Indian law, the Company and the Manager to the Buyback are under no obligation to update the information contained herein at any time after the date of this Letter of Offer. This Letter of Offer does not in any way constitute an offer in any form, or an invitation in any form to subscribe/purchase/sell, any securities of the Company in any jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation and as a consequence, subject the Company or the Manager to the Buyback to any new or additional requirements or registrations;
- The Letter of Offer shall be dispatched through electronic mode to all Eligible Shareholders whose names appeared on the register of members of the Company / register of beneficial owners as downloaded from the Depositories, as of the Record Date. The Company shall provide a copy of the Letter of Offer in physical form in case of receipt of request from any such Eligible Shareholder. However, receipt of the Letter of Offer by any Eligible Shareholder in a jurisdiction in which it would be illegal to make this offer, or where making this offer would require any action to be taken (including, but not restricted to, registration of this Letter of Offer under any local securities laws), shall not be treated by such Eligible Shareholder as an offer being made to them and shall be construed by them as being sent for information purposes only; and
- Potential users of this information are required to inform themselves of any relevant restrictions in their respective jurisdictions. Any Eligible Shareholder who tenders Equity Shares in the Buyback Offer shall be deemed to have declared, represented, warranted and agreed that such Eligible Shareholder is authorized under the provisions of any applicable laws, rules, regulations and statutes to participate in the Buyback.

## 1. SCHEDULE OF ACTIVITIES

Activity	Schedule of activities	
	Date	Day
Date of Board Meeting approving the proposal for the Buyback	April 6, 2026	Monday
Date of the Public Announcement for the Buyback	April 7, 2026	Tuesday
Date of publication of the Public Announcement for Buyback	April 8, 2026	Wednesday
Record Date for determining the Buyback Entitlement and the names of Eligible Shareholders	April 17, 2026	Friday
Last date for dispatch of this Letter of Offer	April 21, 2026	Tuesday
Buyback Opening Date	April 23, 2026	Thursday
Buyback Closing Date	April 29, 2026	Wednesday
Last date of receipt of completed Tender Form and other specified documents by the Registrar	April 29, 2026	Wednesday
Last date of verification of Tender Forms by Registrar to the Buyback	May 4, 2026	Monday
Last date of providing acceptance/ non-acceptance of tendered Equity Shares to BSE by the Registrar	May 6, 2026	Wednesday
Last date of completion of settlement of bids by the Clearing Corporation/ BSE	May 7, 2026	Thursday
Last date of dispatch of share certificate(s) by the Registrar to the Buyback/ unblocking/ return of unaccepted Equity Shares to Eligible Shareholders/ Seller Member	May 7, 2026	Thursday
Last date for payment of consideration to Eligible Shareholders who participated in the Buyback	May 7, 2026	Thursday
Last date of extinguishment of Equity Shares bought back	May 18, 2026	Monday

**Note:** Where last dates are mentioned for certain activities, such activities may happen on or before the respective last dates.

## 2. DEFINITION OF KEY TERMS

- 2.1 This Letter of Offer uses certain definitions and abbreviations which, unless the context otherwise indicates or implies or specifies otherwise, shall have the meaning as provided below. References to any legislation, act, regulation, rules, guidelines or policies shall be to such legislation, act, regulation, rules, guidelines or policies as amended, supplemented, or re-enacted from time to time and any reference to a statutory provision shall include any subordinate legislation made from time to time under that provision.
- 2.2 The words and expressions used in this Letter of Offer, but not defined herein shall have the meaning ascribed to such terms under the Buyback Regulations, the Companies Act, the Depositories Act, 1996, and the rules and regulations made thereunder.

Term	Description
<b>Acceptance/ Accept/ or Accepted</b>	Acceptance of Equity Shares tendered by Eligible Shareholders in the Buyback
<b>Act or Companies Act</b>	The Companies Act, 2013, as amended and rules framed thereunder
<b>Acquisition Window</b>	The facility for acquisition of Equity Shares through the mechanism provided by BSE in the form of a separate window in accordance with SEBI Circulars
<b>Additional Equity Shares</b>	Additional Equity Shares tendered by an Eligible Shareholder over and above the Buyback Entitlement of such Eligible Shareholder up to the extent of Equity Shares held by such Eligible Shareholder on the Record Date
<b>Articles or Articles of Association</b>	Articles of Association of the Company, as amended
<b>Board or Board of Directors</b>	Board of Directors of the Company, which expression shall include any committee constituted by the Board to exercise its powers, including the powers conferred by the resolution passed by the Board at its meeting held on Monday, April 6, 2026
<b>Board Meeting</b>	Meeting of the Board held on Monday, April 6, 2026 <i>inter alia</i> to approve the Buyback
<b>BSE</b>	BSE Limited
<b>Buyback or Buyback Offer or Offer</b>	Offer to buy back up 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share, payable in cash, from the Eligible Shareholders, on a proportionate basis through the Tender Offer route as prescribed under the Buyback Regulations read with the SEBI Circulars using the Stock Exchange Mechanism
<b>Buyback Closing Date</b>	Wednesday, April 29, 2026, being the last date up to which the tendering of Equity Shares by Eligible Shareholders will be allowed
<b>Buyback Committee or Committee</b>	The Buyback committee, comprising of K Nithyananda Reddy, Vice Chairman & Managing Director, M. Madan Mohan Reddy, Whole-time Director and S. Subramanian, Chief Financial Officer, constituted and authorized for the purposes of the Buyback by a resolution passed by the Board at its meeting held on Monday, April 6, 2026

<b>Buyback Entitlement or Entitlement</b>	The number of Equity Shares that an Eligible Shareholder is entitled to tender, in the Buyback, based on the number of Equity Shares held by such Eligible Shareholder, on the Record Date and the ratio / percentage of Buyback applicable in the category to which such Eligible Shareholder belongs
<b>Buyback Opening Date</b>	Thursday, April 23, 2026
<b>Buyback Price or Buyback Offer Price</b>	Price at which Equity Shares will be bought back from the Eligible Shareholders i.e., ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share, payable in cash
<b>Buyback Period</b>	The period between the date of the Board Meeting to approve the Buyback, i.e., Monday, April 6, 2026, and the date on which the payment of consideration is made to the Eligible Shareholders who have accepted the Buyback
<b>Buyback Regulations</b>	SEBI (Buy-Back of Securities) Regulations, 2018, as amended from time to time, including any statutory modification or re-enactments thereof
<b>Buyback Size</b>	Number of Equity Shares proposed to be bought back, i.e. up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares multiplied by the Buyback Price (i.e., ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share aggregating to an amount up to ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only). The Buyback Size excludes Transaction Costs.
<b>CDSL</b>	Central Depository Services (India) Limited
<b>CIN</b>	Corporate Identity Number
<b>Clearing Corporation</b>	Indian Clearing Corporation Limited
<b>“Company” or “Our Company” or “we” or “us” or “our”</b>	Aurobindo Pharma Limited
<b>Company’s Broker</b>	Axis Capital Limited
<b>Company Demat Account</b>	Demat account of the Company designated for the Buyback
<b>Compliance Officer</b>	Mr B Adi Reddy
<b>Depositories</b>	Collectively, National Securities Depository Limited and Central Depository Services (India) Limited
<b>Designated Stock Exchange</b>	BSE
<b>Director(s)</b>	Director(s) of the Company
<b>DIN</b>	Director Identification Number
<b>DP</b>	Depository Participant
<b>Equity Share(s) or Share(s)</b>	Fully paid-up equity shares of the Company of face value of ₹ 1/- (Rupee One only) each
<b>Eligible Person(s) or Eligible Shareholder(s)</b>	Equity Shareholders eligible to participate in the Buyback and would mean all Equity Shareholders/ Beneficial Owners of the Equity Shares of the Company on the Record Date, being Friday, April 17, 2026, and do not include such Equity Shareholders/ Beneficial Owners of the Equity

	Shares who are not permitted under the applicable law to tender Equity Shares in the Buyback
<b>Escrow Account</b>	Escrow account titled “ <i>Aurobindo Pharma Limited - Buyback Escrow Account</i> ” opened with the Escrow Agent in accordance with Buyback Regulations
<b>Escrow Agent / Escrow Bank</b>	Axis Bank Limited
<b>Escrow Agreement</b>	The escrow agreement dated Tuesday, April 7, 2026 entered into between the Company, the Escrow Agent, and the Manager to the Buyback
<b>FATCA</b>	Foreign Account Tax Compliance Act
<b>FEMA</b>	Foreign Exchange and Management Act, 1999, as amended from time to time, including the regulations, circulars, directions and notifications issued thereunder
<b>FII(s)</b>	Foreign Institutional Investor(s)
<b>FPI(s)</b>	Foreign Portfolio Investor(s)
<b>General Category</b>	Eligible Shareholders other than the Small Shareholders
<b>IPV</b>	In person verification
<b>IT Act/ Income Tax Act</b>	The Income Tax Act, 2025
<b>Letter of Offer/LOF</b>	This letter of offer dated Tuesday, April 21, 2026 containing disclosures in relation to the Buyback as specified in Schedule III of the Buyback Regulations
<b>Listing Regulations</b>	SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time
<b>“Manager to the Buyback” or “Manager to the Offer” or “Manager”</b>	Axis Capital Limited
<b>Management Rules</b>	Companies (Management and Administration) Rules, 2014, as amended
<b>Memorandum of Association or MOA</b>	Memorandum of Association of the Company, as amended from time to time
<b>N.A./ NA</b>	Not applicable
<b>Non-Resident Shareholders</b>	Eligible Shareholders residing outside India including non-resident Indians, foreign nationals, foreign corporate bodies (including erstwhile overseas corporate bodies), FII/ FPI, etc.
<b>NSDL</b>	National Securities Depository Limited
<b>NSE</b>	National Stock Exchange of India Limited
<b>Offer Period or Tendering Period</b>	Period of 5 (five) Working Days from the Buyback Opening Date i.e., Thursday, April 23, 2026, to Buyback Closing Date i.e., Wednesday, April 29, 2026 (both days inclusive)
<b>OSV</b>	Original seen and verified
<b>PA or Public Announcement</b>	The public announcement dated Tuesday, April 7, 2026, made in accordance with the Buyback Regulations, published on Wednesday, April 8, 2026, in the newspapers set out in paragraph 5 ( <i>Details of</i>

	<i>Public Announcement</i> ) of this Letter of Offer
<b>PAN</b>	Permanent Account Number
<b>Promoter &amp; Promoter Group</b>	The promoter and promoter group of the Company as defined under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended
<b>RBI</b>	Reserve Bank of India
<b>Record Date</b>	The date for the purpose of determining the Buyback Entitlement and the names of the Eligible Shareholders to whom the Letter of Offer (including the Tender Form) will be sent, and who are eligible to participate in the Buyback in accordance with the Buyback Regulations. The Record Date for the Buyback is Friday, April 17, 2026
<b>“Registrar to the Buyback” or “Registrar to the Offer” or “Registrar”</b>	KFin Technologies Limited
<b>Reserved Category</b>	The Small Shareholders eligible to tender Shares in the Buyback
<b>ROC</b>	Registrar of Companies, Telangana at Hyderabad
<b>SEBI</b>	Securities and Exchange Board of India
<b>SEBI Circulars</b>	SEBI circular no. CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 read with SEBI circular no. CFD/DCR2/CIR/P/2016/131 dated December 09, 2016, SEBI circular no. SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021 and SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/35 dated March 8, 2023 and such other circulars or notifications, as may be applicable, including any amendments or statutory modifications for the time being in force
<b>Seller Member</b>	The stockbroker (who is member of BSE) of an Eligible Shareholder through whom the order for selling the Equity Shares of Eligible Shareholders will be placed in the Acquisition Window
<b>Small Shareholder</b>	As defined under Regulation 2(i)(n) of the Buyback Regulations and in relation to the Buyback means an Eligible Shareholder who holds Equity Shares of market value of not more than ₹ 2,00,000/- (Rupees Two Lakh only), on the basis of closing price on the recognized stock exchange registering the highest trading volume as on the Record Date
<b>Share Capital Rules</b>	Companies (Share Capital and Debentures) Rules, 2014, as amended from time to time
<b>Shareholders or Equity Shareholders or Members or Beneficial Owners</b>	Holders of Equity Shares and includes beneficial owners thereof
<b>Stock Exchanges</b>	Collectively, BSE and NSE
<b>Stock Exchange Mechanism</b>	The “Mechanism for acquisition of shares through Stock Exchange” notified by SEBI Circulars
<b>Tender Form</b>	Form of Acceptance–cum–Acknowledgement to be filled in and sent to the Registrar by the Eligible Shareholder(s) to participate in the Buyback
<b>Tender Offer</b>	Method of buyback as defined in Regulation 2(i)(q) of the Buyback Regulations
<b>Transaction Costs</b>	Brokerage costs, fees, turnover charges, applicable taxes such as

	securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the Buyback like filing fees payable to SEBI, advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.
<b>TRS</b>	Transaction Registration Slip generated by the exchange bidding system
<b>Working Day</b>	Working day as defined in the Buyback Regulations

## 2.3 Certain conventions, currency of presentation, use of financial information and stock market data

### Page Numbers and Paragraph Numbers

Unless otherwise stated, all references to page numbers and paragraph numbers in this Letter of Offer are to page numbers and paragraph numbers of this Letter of Offer.

### Currency and Units of Presentation

All references to “₹”, “Rupee(s)” or “Rs.” are to Indian Rupees, the official currency of the Republic of India.

### Financial and Other Data

Unless stated or the context requires otherwise, our financial information in this Letter of Offer is derived from our audited standalone and consolidated financial statements for the fiscal year ended on March 31, 2025, March 31, 2024 and March 31, 2023, and the unaudited limited reviewed standalone and consolidated financial statements for the nine months period ended December 31, 2025.

Our Company’s fiscal year commences on April 1 of each year and ends on March 31 of the next year (referred to herein as “Fiscal”, “Fiscal Year” or “FY”).

### Stock Market Data

Unless stated or the context requires otherwise, stock market data included in this Letter of Offer is derived from the website of BSE and NSE.

## 3. DISCLAIMER CLAUSE

- 3.1 As required under the Buyback Regulations, a copy of this Letter of Offer has been submitted to SEBI. It is to be distinctly understood that submission of this Letter of Offer to SEBI should not, in any way be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of the Company to meet the Buyback commitments or for the correctness of the statements made or opinions expressed in the Letter of Offer. The Manager to the Buyback has certified that the disclosures made in the Letter of Offer are generally adequate and are in conformity with the provisions of the Companies Act and Buyback Regulations. This requirement is to facilitate Eligible Shareholders to take an informed decision for tendering their Equity Shares in the Buyback.

3.2 It should also be clearly understood that while the Company is primarily responsible for the correctness, adequacy and disclosure of all relevant information in the Letter of Offer, the Manager to the Buyback is expected to exercise due diligence to ensure that the Company discharges its duty adequately in this behalf and towards this purpose, the Manager to the Buyback is furnishing to SEBI a due diligence certificate dated Tuesday, April 21, 2026 in accordance with Buyback Regulations which reads as follows:

*“We have examined various documents and materials contained in the annexure to this letter, as part of the due-diligence carried out by us in connection with the finalization of the public announcement dated Tuesday, April 7, 2026 for the Buyback (“**Public Announcement**”) which was published on Wednesday, April 8, 2026 and the Letter of Offer dated Tuesday, April 21, 2026 (“**Letter of Offer**”). On the basis of such examination and the discussions with the Company, we hereby state that:*

- *the Public Announcement and the Letter of Offer are in conformity with the documents, materials and papers relevant to the Buyback;*
- *all the legal requirements connected with the said Buyback including the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended, have been duly complied with;*
- *the disclosures in the Public Announcement and the Letter of Offer are, to the best of our knowledge, true, fair and adequate in all material respects for the Eligible Shareholders to make a well-informed decision in respect of the Buyback; and*
- *funds used for Buyback shall be as per the provisions of the Companies Act, 2013, as amended.”*

3.3 The filing of the Letter of Offer with SEBI, does not, however, absolve the Company from any liabilities under the provisions of the Companies Act or from the requirement of obtaining such statutory or other clearances as may be required for the purpose of the proposed Buyback.

3.4 The members of the Promoter & Promoter Group/ Board of Directors declare and confirm that no information/ material likely to have a bearing on the decision of Eligible Shareholders has been suppressed/ withheld and/ or incorporated in the manner that would amount to mis-statement/ mis-representation and in the event of it transpiring at any point of time that any information/ material has been suppressed/ withheld and/ or amounts to a mis-statement/ mis-representation, the members of the Promoter & Promoter Group and the Board of Directors and the Company shall be liable for penalty in terms of the provisions of the Companies Act and the Buyback Regulations.

3.5 The Board of Directors also declare and confirm that funds borrowed from banks and financial institutions will not be used for the Buyback.

### 3.6 **Disclaimer for persons from the United States of America**

The information contained in this Letter of Offer is exclusively intended for persons who are not US Persons as defined in Regulations of the US Securities Act of 1933, as amended, and who are not physically present in the United States of America. This Letter of Offer does not in any way constitute an offer to sell, or an invitation to sell, any securities in the United States

of America or in any other jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Potential users of the information contained in this Letter of Offer are requested to inform themselves about, and to observe any such restrictions.

### **3.7 Disclaimer for persons in foreign countries other than the United States of America**

This Letter of Offer has not been filed, registered or approved in any jurisdiction outside India. This Letter of Offer does not in any way constitute an offer to sell or an invitation to sell, any securities in any jurisdiction in which such offer or invitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation would subject the Company or the Manager to the Buyback to a new or additional requirements or registration. Potential users of the information contained in this Letter of Offer are requested to inform themselves about and to observe any such restrictions.

### **3.8 Important Notice to All Equity Shareholders**

This Letter of Offer has been prepared for the purposes of compliance with the Buyback Regulations. Accordingly, the information disclosed may not be the same as that which would have been disclosed if this document had been prepared in accordance with the laws and regulations of any jurisdiction outside of India. The Company and the Manager to the Buyback are under no obligation to update the information contained herein at any time after the date of this Letter of Offer. The Letter of Offer shall be dispatched to all Shareholders whose names appear on the register of members of the Company, as of the Record Date, as per the Buyback Regulations and such other circulars or notifications, as may be applicable. However, receipt of the Letter of Offer by any Equity Shareholders in a jurisdiction in which it would be illegal to make this Tender Offer, or where making this Tender Offer would require any action to be taken (including, but not restricted to, registration of the Letter of Offer under any local securities laws), shall not be treated by such Shareholders as an offer being made to them. Potential users of the information contained in this Letter of Offer are requested to inform themselves about and to observe any such restrictions. Any Eligible Shareholder who tenders his, her or its Equity Shares in the Buyback shall be deemed to have declared, represented, warranted and agreed that he, she or it is authorized under the provisions of any applicable local laws, rules, regulations and statutes to participate in the Buyback.

### **3.9 Forward Looking Statements**

This Letter of Offer contains certain forward-looking statements. These forward-looking statements generally can be identified by words or phrases such as 'aim', 'anticipate', 'believe', 'expect', 'estimate', 'intend', 'objective', 'plan', 'project', 'will', 'will continue', 'will pursue' or other words or phrases of similar import. Similarly, statements that describe our strategies, objectives, plans or goals are also forward-looking statements. All forward-looking statements are subject to risks, uncertainties and assumptions about the Company that could cause actual results to differ materially from those contemplated by the relevant forward-looking statement.

Actual results may differ materially from those suggested by forward-looking statements due to risks or uncertainties associated with expectations relating to, *inter alia*, regulatory changes pertaining to the industries in which the Company operates and its ability to respond to them, the Company's ability to successfully implement its strategy, its growth and expansion, technological changes, exposure to market risks, general economic and political conditions in

India or other key markets where it operates which have an impact on its business activities or investments, the monetary and fiscal policies, inflation, deflation, unanticipated turbulence in interest rates, foreign exchange rates, equity prices or other rates or prices, the performance of the financial markets in India and globally, changes in domestic laws, regulations and taxes and changes in competition in the industries in which the Company operates.

#### 4. TEXT OF RESOLUTION PASSED AT THE BOARD MEETING

The Buyback has been authorized and approved by the Board of Directors at their meeting held on Monday, April 6, 2026. The text of the resolution passed by the Board is as follows:

##### Quote

**RESOLVED THAT** in accordance with Article 40 (b) of the Articles of Association of Aurobindo Pharma Limited ("**Company**") and pursuant to the provisions of Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, 2013, as amended (the "**Companies Act**"), rules framed under the Companies Act, including the Companies (Share Capital and Debentures) Rules, 2014 as amended and the Companies (Management and Administration) Rules, 2014, as amended, to the extent applicable, and in compliance with the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended (the "**Buyback Regulations**") and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("**Listing Regulations**"), and including any amendments, statutory modification(s) or re-enactment(s) for the time being in force, and subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed or imposed by the Securities and Exchange Board of India ("**SEBI**"), Registrar of Companies, Telangana at Hyderabad (the "**ROC**"), BSE Limited ("**BSE**"), National Stock Exchange of India Limited ("**NSE**") and/ or other authorities institutions or bodies (the "**Appropriate Authorities**") while granting such approvals, permissions, sanctions and exemptions, which may be agreed to by the board of directors of the Company (the "**Board**", which expression shall include any committee constituted by the Board to exercise its powers, including the powers conferred by this Board resolution), the Board hereby approves the buyback of up to 54,23,728 (Fifty four lakhs twenty three thousand seven hundred and twenty eight only) fully paid-up equity shares of the Company, each having a face value of INR 1/- (Indian Rupee one only) ("**Equity Shares**"), representing up to 0.93% of the total number of equity shares in the paid-up share capital of the Company as on December 31, 2025 and March 31, 2026, at a price of INR 1,475/- (Indian Rupees one thousand four hundred and seventy five only) per Equity Share ("**Buyback Price**"), subject to any increase to the Buyback Price as may be approved by the Board or any committee thereof, payable in cash for an aggregate amount up to INR 800,00,00,000/- (Indian Rupees eight hundred crores only) (excluding transaction costs viz. brokerage costs, fees, turnover charges, applicable taxes such as securities transaction tax, goods and services tax, stamp duty, etc., expenses incurred or to be incurred for the Buyback like filing fees payable to the SEBI, advisors/ legal fees, public announcement publication expenses, printing and dispatch expenses and other incidental and related expenses, etc.) ("**Buyback Size**"), being 3.93% and 2.62% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively (which is within the statutory limits of 10% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company, based on both standalone and consolidated financial statements of the Company,

under the Board approval route as per the provisions of the Companies Act and Buyback Regulations), on a proportionate basis through the “**tender offer**” route as prescribed under the Buyback Regulations, from all of the equity shareholders/ beneficial owners of the Company, including the promoters and members of the promoter group of the Company (as defined under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and to be referred as “**Promoter & Promoter Group**”) who hold Equity Shares as of the record date i.e., Friday, April 17, 2026 (the “**Record Date**”) and such buyback (the “**Buyback**”).

**RESOLVED FURTHER THAT** the Company shall implement the Buyback using the “Mechanism for acquisition of shares through Stock Exchange pursuant to Tender-Offers under Takeovers, Buy Back and Delisting” notified by the SEBI *vide* circular CIR/CFD/POLICYCELL/1/2015 dated April 13, 2015 read with SEBI circular CFD/DCR2/CIR/P/2016/131 dated December 09, 2016 and SEBI circular SEBI/HO/CFD/DCR-III/CIR/P/2021/615 dated August 13, 2021, including any amendments or statutory modifications for the time being in force (“**SEBI Circulars**”).

**RESOLVED FURTHER THAT** the Company shall implement the Buyback out of its securities premium account, free reserves and/ or current surplus and/or cash and cash equivalents and/or internal accruals and/or liquid resources and/or such other sources as may be permitted by law, and the Buyback shall be through tender offer in such manner as may be prescribed under the Companies Act and the Buyback Regulations, and on such terms and conditions as the Board may deem fit.

**RESOLVED FURTHER THAT** in terms of Section 69 of the Companies Act, the Company shall transfer from its free reserves or securities premium account and/ or current surplus and/or cash and cash equivalents and/or internal accruals and/or liquid resources and/or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback, to the capital redemption reserve account and the details of such transfer shall be disclosed in its subsequent audited financial statements.

**RESOLVED FURTHER THAT** pursuant to Regulation 42 of the Listing Regulations and Regulation 9(j) of the Buyback Regulations, the Record Date for ascertaining the eligibility of the shareholders to participate in the buyback shall be Friday, April 17, 2026.

**RESOLVED FURTHER THAT** all equity shareholders/ beneficial owners of the Equity Shares, including Promoter & Promoter Group, who hold Equity Shares as on the Record Date (“**Eligible Shareholders**”), will be eligible to participate in the Buyback except any shareholders who may be specifically prohibited under the applicable laws by Appropriate Authorities.

**RESOLVED FURTHER THAT** as required by Regulation 6 of the Buyback Regulations, the Company shall buyback Equity Shares from the Eligible Shareholders, on a proportionate basis under the tender offer, provided 15% of the number of Equity Shares which the Company proposes to Buyback or number of Equity Shares entitled as per the shareholding of small shareholders at the Record Date, whichever is higher, shall be reserved for small shareholders, as defined in the Buyback Regulations.

**RESOLVED FURTHER THAT** the Buyback from the Eligible Shareholders who are residents outside India including non-resident Indians, foreign nationals, foreign corporate bodies (including erstwhile overseas corporate bodies), foreign institutional investors / foreign portfolio investors, shall be subject to such approvals, if any and to the extent necessary or required from the concerned authorities including approvals from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 and the rules and regulations framed thereunder, and that such approvals shall be required to be taken by such non-resident shareholders.

**RESOLVED FURTHER THAT** the Buyback would be subject to the condition of maintaining minimum public shareholding requirements as specified in Regulation 38 of the Listing Regulations.

**RESOLVED FURTHER THAT** the Company shall not use borrowed funds, whether secured or unsecured, of any form and nature, from banks and financial institutions for paying the consideration to the equity shareholders who have tendered their Equity Shares in the Buyback.

**RESOLVED FURTHER THAT** the Company shall earmark adequate sources of funds for the purpose of the Buyback, and Mr. K. Nityananda Reddy, Vice Chairman & Managing Director or Mr. M. Madan Mohan Reddy, Whole-time Director of the Company be and are hereby severally authorized to sign and submit a firm financing certificate, and to do all such acts, deeds and things as may be necessary to give effect to the above resolution.

**RESOLVED FURTHER THAT** in terms of Regulation 24(iii) of the Buyback Regulations, Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby appointed as the Compliance Officer for the Buyback.

**RESOLVED FURTHER THAT** the Company shall maintain a register of securities bought back wherein details of Equity Shares bought back, consideration paid for the Equity Shares bought back, date of cancellation of Equity Shares and date of extinguishing and physically destroying of Equity Shares and such other particulars as may be prescribed, shall be entered and that Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company be and is hereby authorised to authenticate the entries made in the said register.

**RESOLVED FURTHER THAT** as required under the provision to Section 68(6) of the Companies Act and Regulation 8(i)(b) of the Buyback Regulations, the draft of the affidavit for declaration of solvency prepared in the prescribed form along with supporting documents, placed before the meeting be and is hereby approved, and that Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director and Mr. M. Madan Mohan Reddy, Whole-time Director of the Company be and are hereby authorized to finalise and sign the same, for and on behalf of the Board, and Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby authorized to file the same with ROC and SEBI and or other concerned authorities, as may be necessary in accordance with applicable law.

**RESOLVED FURTHER THAT** as required by Clause (x) of Schedule I of the Buyback Regulations, the Board hereby confirms that it has made full enquiry into the affairs and prospects of the Company and has formed an opinion that:

- a) immediately following the date of board meeting (i.e., Monday, April 6, 2026) (“**Board Meeting**”) approving the Buyback, there will be no grounds on which the Company can be found unable to pay its debts;
- b) as regards the Company’s prospects for the year immediately following the date of Board Meeting, and having regards to the Board’s intention with respect to the management of the Company’s business during that year and to the amount and character of the financial resources, which will, in the Board’s view, be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of one year from the date of the Board Meeting; and
- c) in forming its opinion aforesaid, the Board has taken into account the liabilities (including prospective and contingent liabilities) as if the Company were being wound up under the provisions of the Companies Act, or the Insolvency and Bankruptcy Code, 2016, as applicable.

**RESOLVED FURTHER THAT** the Board hereby confirms that:

- a) all the Equity Shares of the Company are fully paid-up;
- b) the Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus) or convert any outstanding employee stock options / outstanding instruments into Equity Shares, from the date of the Board Meeting till the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback;
- c) unless otherwise specifically permitted by any relaxation issued by SEBI and / or any other regulatory authority, the Company shall not raise further capital for a period of one year, as prescribed under the provisions of Regulation 24(i)(f) of the Buyback Regulations, from the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback, except in discharge of its subsisting obligations;
- d) the Company, as per the provisions of Section 68(8) of the Companies Act, will not make a further issue of the same kind of shares or other securities including allotment of new shares under Section 62(1)(a) or other specified securities within a period of six months except by way of a bonus issue or in the discharge of subsisting obligations such as conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into Equity Shares;
- e) the Company shall not withdraw the Buyback after public announcement of the offer to Buyback is made;
- f) the Company will ensure consequent reduction of its share capital post Buyback and the Equity Shares bought back by the Company will be extinguished and physically destroyed in the manner prescribed under the Buyback Regulations and the Companies Act within the specified timelines;
- g) the Company shall not buyback locked-in Equity Shares and non-transferable Equity Shares until the pendency of the lock-in or till the Equity Shares become transferable;
- h) the consideration for the Buyback shall be paid by the Company only in cash;
- i) the Company shall not buyback its Equity Shares or other specified securities from any person through negotiated deals whether on or off the stock exchanges or through spot transactions or through any private arrangement in the implementation of Buyback;
- j) there are no defaults (either in the past or subsisting) in the repayment of any deposits (including interest payable thereon), redemption of debentures or preference shares, payment of dividend or repayment of any term loans to any financial institution or banks (including interest payable thereon), as the case may be, and in case of defaults which have ceased to subsist, if any, a period of more than 3 (three) years has lapsed.
- k) in the event of non-fulfilment of the obligations under the Buyback Regulations by the Company, the monies deposited in the Escrow Account / Special Account in full or in part shall be forfeited and distributed pro rata amongst the shareholders who accepted the offer and balance if any shall be utilized for investor protection in accordance with the Buyback Regulations;
- l) that the Company has been in compliance with Sections 92, 123, 127 and 129 of the Companies Act;
- m) the aggregate amount of the Buyback i.e. up to INR 800,00,00,000/-(Indian Rupees eight hundred crores only) does not exceed 10% of the aggregate of the fully paid-up equity share capital and free reserves (including securities premium) of the Company as per the

latest audited standalone and consolidated financial statements of the Company as at March 31, 2025;

- n) the number of Equity Shares proposed to be purchased under the Buyback (up to 54,23,728 Equity Shares), does not exceed 25% of the total number of Equity Shares in the paid-up equity share capital of the Company as at December 31, 2025 and March 31, 2026.
- o) the Company has not undertaken a buyback of any of its securities during the period of one year immediately preceding the date of the Board Meeting;
- p) the Company shall not make any offer of buyback within a period of one year reckoned from the date of expiry of the Buyback period i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback;
- q) the Company shall comply with the statutory and regulatory timelines in respect of the Buyback in such manner as prescribed under the Companies Act and /or the Buyback Regulations and any other applicable laws;
- r) the Buyback shall be completed within a period of one year from the date of passing of Board resolution approving the Buyback;
- s) there is no pendency of any scheme of amalgamation or compromise or arrangement involving the Company pursuant to the provisions of the Companies Act, as on date;
- t) the ratio of the aggregate of secured and unsecured debts owed by the Company shall not be more than twice its paid-up capital and free reserves after the Buyback, based on audited standalone and consolidated financial statements of the Company as on March 31, 2025, as prescribed under the Companies Act and rules made thereunder and Buyback Regulations;
- u) the Company is not buying back its Equity Shares so as to delist its shares or other specified securities from the stock exchanges;
- v) the Company shall not directly or indirectly purchase its Equity Shares through any subsidiary company including its own subsidiary companies, or through any investment company or group of investment companies;
- w) in accordance with Regulation 5(i)(c) and Clause (xii) of Schedule I of the Buyback Regulations, the Company shall not undertake the Buyback unless it has obtained prior consent of its lenders, in case of breach of any covenant with such lenders, and accordingly, the Company has obtained the prior consent of its lenders, as necessary, for undertaking the Buyback;
- x) the information pertaining to the Company as may be set out in the public announcement, letter of offer, any corrigenda and all offer documents with respect to the Buyback shall be true, fair and adequate information in all material aspects and shall not contain any misleading information; and
- y) as per Regulation 24(i)(e) of the Buyback Regulations, the Promoter & Promoter Group, and their associates, shall not deal in the Equity Shares or other specified securities of the Company either through the stock exchanges or off-market transactions (including inter-se transfer of Equity Shares among the Promoter and Promoter Group) from the date of Board resolution approving the Buyback till the closing of the Buyback offer.

**RESOLVED FURTHER THAT** no information / material that is likely to have a bearing on the decision of investors has been suppressed or withheld and /or incorporated in the manner that would amount to a mis-statement or misrepresentation and in the event of it transpiring at any point of time that any information has been suppressed or withheld and / or amounts

to a mis-statement or misrepresentation, the Board and the Company shall be liable for penalty in terms of the provisions of the Companies Act and the Buyback Regulations.

**RESOLVED FURTHER THAT** nothing contained herein shall confer any right on any shareholder to offer or any obligation on the Company or the Board to buyback any Equity Shares or impair any power of the Company or the Board to terminate any process in relation to the Buyback, if so permissible by law.

**RESOLVED FURTHER THAT** Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, Mr. M. Madan Mohan Reddy, Whole-time Director, Mr. S. Subramanian, Chief Financial Officer and Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company, be and are hereby severally authorized to file necessary e-forms with the ROC and to do all such acts, deeds and things or incidental for signing and filing of forms, payment of fees, etc. and to do all such other acts, things and deeds, as may be required for the aforesaid purpose or other services as that may be necessary.

**RESOLVED FURTHER THAT** Mr. B. Adi Reddy, Company Secretary and Compliance Officer of the Company, be and is hereby authorised to represent the Company before the Ministry of Corporate Affairs, SEBI, the stock exchanges, any regulatory/ statutory bodies/ authorities or any other agencies connected with the Buyback and to sign and submit all forms, letters, documents or other papers that may be required.

**RESOLVED FURTHER THAT** any actions taken so far in connection with the Buyback by the officers of the Company be and are hereby ratified, confirmed and approved.

**RESOLVED FURTHER THAT** a copy of the foregoing resolution certified by any Director and/or Company Secretary be forwarded to concerned persons/ authority as may be required.”

**“RESOLVED THAT** a committee comprising of Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, Mr. M. Madan Mohan Reddy, Whole-time Director and Mr. S. Subramanian, Chief Financial Officer of the Company be constituted for the purpose of the Buyback (**“Buyback Committee”**) and that the Buyback Committee be and is hereby authorized to do all such acts, deeds, matters and things as it may, in its absolute discretion deem necessary, expedient, usual, or proper as the Buyback Committee may consider to be in the best interests of the Company and its shareholders, without any further approval of the Board, including but not limited to the following:

- a) seeking all regulatory approvals required for the Company to implement the Buyback, as applicable;
- b) appointing all intermediaries including but not limited to brokers, registrar, advertising agency, investor service centre, escrow bank, legal advisors, other advisors, depository participant, printers, consultants or representatives, if any, and settlement of terms of appointment including the remuneration for all such intermediaries / agencies / persons, including by the payment of commission, brokerage, fee, charges etc. and enter into agreements / letters in respect thereof;
- c) opening, operating and closing all necessary accounts, including bank accounts (including Escrow Account and Special Account) and entering into agreements with and to give instructions in connection therewith and / or to delegate the operation of such accounts as required under applicable laws (including the Buyback Regulations), depository accounts (demat account / trading account / buyer broker account) and another account as may be necessary for the Buyback and deciding the authorized signatories for such accounts and for the purpose of payment and authorizing persons to operate the said accounts;
- d) entering into escrow arrangements as may be required by the Buyback Regulations and

- depositing and / or instructing the deposit of the requisite amount into Escrow Account and finalising the composition / combination of such deposit into Escrow Account in accordance with the provisions of the Buyback Regulations and the escrow arrangement;
- e) increasing the Buyback Price and decreasing the number of Equity Shares proposed to be bought back, such that there is no change in the Buyback Size, till one working day prior to the Record Date, in terms of Regulation 5(via) of the Buyback Regulations;
  - f) finalizing the terms and timeline of the Buyback including not limited to the schedule of activities, entitlement ratio, opening date and closing date of the offer period and the timeframe for completing the Buyback and re-affirming declaration of solvency as and when required;
  - g) dealing with the stock exchanges (including their clearing corporation), deciding on the appointment of a designated stock exchange, and to sign, execute, and deliver such documents as may be necessary or desirable in connection with implementing the Buyback using the “Mechanism for acquisition of shares through Stock Exchange” notified by SEBI Circulars;
  - h) taking all actions to verify offers and acceptances received, finalize the basis of acceptance, pay the shareholders consideration for shares bought back, extinguishment of the Equity Shares bought back by the Company and filing of necessary documents in relation to the same;
  - i) preparation, finalizing, signing and filing of the public announcement, the letter of offer, all certifications and undertakings and any other document required in relation to the Buyback with the SEBI, ROC, the stock exchanges and other Appropriate Authorities;
  - j) making all applications to the Appropriate Authorities for their requisite approvals including approvals as may be required from the Reserve Bank of India under the Foreign Exchange Management Act, 1999 and the rules and regulations framed there under, if any;
  - k) signing, executing and delivering such other documents, deeds and writings and to do all such acts, matters and things as it may, in its absolute discretion deem necessary, expedient or proper, to be in the best interest of the shareholders for the implementation of the Buyback, and to initiate all necessary actions for preparation and issue of various documents and such other undertakings, agreements, papers, documents and correspondence as may be necessary for the implementation of the Buyback to the SEBI, RBI, ROC, stock exchanges, depositories and/or other authorities;
  - l) uploading all required information such as details of the Equity Shares bought back on the website of the Company and filing the same with the stock exchanges as required under applicable law;
  - m) affixing the Common Seal of the Company on relevant documents required to be executed for the buyback of shares in accordance with the provisions of the articles of association of the Company;
  - n) settling and resolving any queries raised by the SEBI, stock exchanges, ROC and any other authorities whatsoever in connection to any matter incidental to and ancillary of the Buyback;
  - o) authorising/ appointing persons to represent the Company, if required, before the ROC, SEBI, stock exchanges, or any other authority in connection with the Buyback and to sign and submit all forms, letters, documents or other papers that may be required;
  - p) creating and maintaining requisite statutory registers and records as required under the

Companies Act and to furnish appropriate returns to the Appropriate Authorities;

- q) obtaining all necessary certificates and reports from statutory auditors and other third parties as required under applicable law;
- r) giving such directions as may be necessary or desirable and settling any questions or difficulties whatsoever that may arise in relation to the Buyback;
- s) to settle and resolve any queries or difficulties raised by SEBI, stock exchanges, ROC and any other authorities whatsoever in connection to any matter incidental to and ancillary to the Buyback;
- t) to give any information, explanation, declarations and confirmations in relation to the public announcement and any other advertisements, as may be required by the relevant authorities including SEBI;
- u) earmarking and making arrangements for adequate sources of funds for the purpose of the Buyback;
- v) closing the Buyback and completing all the required formalities as specified under the Companies Act, Buyback Regulations and the Listing Regulations and other applicable laws;
- w) to finalize and execute necessary certifications, confirmations, undertakings etc. that may be required to be provided on behalf of the Board in regard to the Buyback;
- x) to finalize, sign, execute and submit necessary documents, deeds, affidavits, undertakings, certifications, agreements, forms, returns, applications, letters, etc., seek approval(s) and to represent the Company with the SEBI, stock exchanges, ROC, National Securities Depository Limited, Central Depository Services (India) Limited and any other regulatory authority in connection with the Buyback;
- y) to incur such other expenses as may be necessary with regard to the Buyback including fees to be paid to SEBI / other regulatory authorities, registrar's fees, fees for demat escrow agent and other intermediaries, fee for any consultants / advisers that may be hired, publication expenses, postage expenses, transaction costs viz. brokerage, applicable taxes such as securities transaction tax, goods and services tax, stamp duty, etc. and such other expenses that may be necessary or incidental in this regard.
- z) drafting, making alterations to, additions to, deletions to, variations to, amendments or corrections to and issuing and filing with appropriate statutory/other authorities, the public announcement, the letter of offer and all other documents, resolutions, advertisements, confirmations, intimations and declarations, and the certificate for extinguishment and physical destruction of shares certificates (if any), and other documents required in connection with the Buyback and causing the declaration of solvency and supporting affidavit to be executed in accordance with applicable law and such alterations, additions, omissions, variations, amendments or corrections will be deemed to have been approved by the Board; and
- aa) doing such other acts, deeds, matters, or things, and executing such documents, forms, letters, confirmations, and taking all steps as may be necessary to sign, submit and file all necessary forms, letters, applications, e-forms and other documents as they may in their absolute discretion, deem necessary, expedient, usual or proper or are necessary, expedient, usual or proper with regard to the implementation in connection with or in furtherance of the Buyback.

**RESOLVED FURTHER THAT** the quorum for any meeting of the Buyback Committee for implementing the Buyback shall be any two members and Buyback Committee may regulate its own proceedings and meet as often as required, to discharge its functions.

**RESOLVED FURTHER THAT** subject to the relevant provisions of the Companies Act, the Buyback Committee is permitted to pass any resolution by circulation and the resolution passed by circulation shall have the same effect and force as if the resolutions have been passed in the meeting of the Buyback Committee.

**RESOLVED FURTHER THAT** the Buyback Committee shall have the power and authority to delegate all or any of the authorities conferred upon it to any officer(s) and/or representatives of the Company, in order to give effect to the aforesaid resolutions and to revoke and substitute such delegation / sub-delegation of authority from time to time.

**RESOLVED FURTHER THAT** all acts, deeds, matters and things done by the Buyback Committee for the purpose shall have the same effect as if done by the Board.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board and the Buyback Committee be and are hereby severally authorized to accept and make any alteration(s), modification(s) to the terms and conditions as they may deem necessary, concerning any aspect of the Buyback, in accordance with the statutory requirements or any conditions laid down by any regulatory or other authority while giving its approval as well as to give such directions as may be necessary or desirable, to settle any questions, difficulties or doubts that may arise and generally, to do all such acts, deeds, matters and things as it may, in its absolute discretion deem necessary, expedient, usual or proper in relation to or in connection with or for matters consequential to the Buyback without seeking any further consent or otherwise to the end and intent that they shall be deemed to have given their approval thereto expressly by the authority of this resolution.”

**RESOLVED FURTHER THAT** the Buyback Committee shall stand dissolved on the date of completion of Buyback process.

**RESOLVED FURTHER THAT** a copy of the foregoing resolution certified by any Director and/or Company Secretary be forwarded to concerned persons/ authority as may be required.

**Unquote**

**5. DETAILS OF PUBLIC ANNOUNCEMENT**

In accordance with Regulation 7(i) of the Buyback Regulations, the Company has made a Public Announcement for the Buyback dated Tuesday, April 7, 2026, which was published on Wednesday, April 8, 2026 in the newspapers mentioned below, which is within 2 (two) Working Days from the date of the Board Meeting approving the Buyback, i.e., Monday, April 6, 2026:

Publication	Language	Editions
Financial Express	English	All editions
Jansatta	Hindi	All editions
Nava Telangana	Telugu*	Hyderabad edition

\* Telugu being the regional language where the registered office of the Company is located.

The Company will publish further notices or corrigenda, if any relating to the Public Announcement, in the abovementioned newspapers. A copy of the Public Announcement is available on the websites of the Company at ([www.aurobindo.com](http://www.aurobindo.com)), the Manager to the Buyback ([www.axiscapital.co.in](http://www.axiscapital.co.in)), Registrar to the Buyback ([www.kfintech.com](http://www.kfintech.com)), SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)).

## 6. DETAILS OF THE BUYBACK

- 6.1 At the Board Meeting held on Monday, April 6, 2026, the Board, subject to such approvals of regulatory and/or statutory authorities as may be required under applicable laws, has approved the buyback of up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares, representing approximately 0.93% of the total number of outstanding Equity Shares of the Company, at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share, subject to any increase to the Buyback Price as may be approved by the Board or the Buyback Committee, payable in cash, for an aggregate amount up to ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only), excluding Transaction Costs, from all of the equity shareholders/ beneficial owners of the Company, including the members of the Promoter & Promoter Group, who hold Equity Shares as of the Record Date on a proportionate basis through the "Tender Offer" route in accordance with the provisions of the Buyback Regulations, Companies Act, rules framed thereunder including the Share Capital Rules and Management Rules, and the Listing Regulations, to the extent applicable, and the SEBI Circulars.
- 6.2 The Buyback Size constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations. Further, since the Equity Shares proposed to be bought back represents approximately 0.93% of the total number of outstanding Equity Shares of the Company as of March 31, 2025 and December 31, 2025, the same is within the 25% limit as per the provisions of the Companies Act and Regulation 4(i) of the Buyback Regulations.
- 6.3 The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, BSE, NSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.
- 6.4 The Equity Shares are listed on BSE and NSE. The Buyback shall be undertaken on a proportionate basis (subject to reservation for Small Shareholders) from all the equity shareholders/ beneficial owners of the Company, including the members of the Promoter & Promoter Group, who hold Equity Shares as on the Record Date through the Tender Offer process prescribed under Regulation 4(iv)(a) of the Buyback Regulations and shall be implemented using the Stock Exchange Mechanism as specified in the SEBI Circulars. In this regard, the Company will request BSE to provide the Acquisition Window for facilitating tendering of Equity Shares under the Buyback and, for the purposes of this Buyback, BSE will be the Designated Stock Exchange.

- 6.5 The funds for implementation of the proposed Buyback will be sourced out of the free reserves of the Company and/ or such other sources as may be permitted by Buyback Regulations or the Companies Act. Funds borrowed from banks and financial institutions, if any, will not be used for the Buyback.
- 6.6 The Company shall transfer from its free reserves and/ or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback to the capital redemption reserve account and the details of such transfer shall be disclosed in its subsequent audited financial statements.
- 6.7 The Buyback from the Eligible Shareholders who are Non-Resident Shareholders, shall be subject to such approvals, if any, and to the extent necessary or required from the concerned authorities including approvals from the RBI under the FEMA, and that such approvals shall be required to be taken by such Non-Resident Shareholders.
- 6.8 The aggregate shareholding of the members of the Promoter & Promoter Group and persons in control of the Company as on the date of the Public Announcement and this Letter of Offer is as follows:

Sr. No.	Name	Category	Number of Equity Shares held	% shareholding
1.	Venkata Ramprasad Reddy Penaka	Promoter	1,78,33,646	3.07
2.	K Nithyananda Reddy	Promoter	2,53,59,572	4.37
<b>Total (A)</b>			<b>4,31,93,218</b>	<b>7.44</b>
3.	M Sivakumaran	Promoter Group	1,43,57,432	2.47
4.	K Rajeshwari	Promoter Group	18,08,631	0.31
5.	Suneela Rani Penaka	Promoter Group	1,28,799	0.02
6.	Prasada Reddy Kambham	Promoter Group	2,98,373	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	15,85,214	0.27
9.	Kirithi Reddy Kambam	Promoter Group	2,00,62,852	3.45
10.	Kambam Spoorthi	Promoter Group	69,39,173	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil
12.	Trident Chemphar Limited	Promoter Group	7,82,241	0.13
13.	Axis Clinicals Limited	Promoter Group	6,51,920	0.11
14.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	Promoter Group	19,45,61,357	33.50
15.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	Promoter Group	1,65,72,131	2.85
<b>Total (B)</b>			<b>25,77,55,503</b>	<b>44.38</b>
<b>Total (A+B)</b>			<b>30,09,48,721</b>	<b>51.82</b>

- 6.9 In terms of the Buyback Regulations, under Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group *vide* their letters dated Tuesday, April 7, 2026, have expressed their intention to participate in the Buyback. For further details, please refer to Paragraph 9.7 of this Letter of Offer.

- 6.10 The Buyback will not result in any benefit to Promoter & Promoter Group or any directors of the Company except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as equity shareholders of the Company, and the change in their shareholding as per the response received in the Buyback, as a result of the extinguishment of Equity Shares, which will lead to reduction in the equity share capital of the Company post Buyback. Any change in voting rights of the Promoter & Promoter Group of the Company pursuant to completion of Buyback will not result in any change in control over the Company.
- 6.11 Pursuant to the proposed Buyback and depending on the response to the Buyback, the aggregate voting rights in the Company of the members of the Promoter & Promoter Group and persons in control of the Company may change from the existing shareholding of the total equity capital and voting rights of the Company. Assuming response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement, the aggregate shareholding of the members of the Promoter & Promoter Group and the persons in control of the Company, post Buyback may increase to 51.88% of the post Buyback equity share capital of the Company. For further details, please refer to paragraph 13.6 of this Letter of Offer.
- 6.12 The Buyback would be subject to the condition of maintaining minimum public shareholding requirements as specified in Regulation 38 of the Listing Regulations.
- 6.13 Participation in the Buyback by Eligible Shareholders may trigger capital gains taxation in India and in their country of residence. The transaction of Buyback would also be chargeable to securities transaction tax in India. However, in view of the particularized nature of tax consequences, Eligible Shareholders are advised to consult their own legal, financial and tax advisors prior to participating in the Buyback. In terms of the Buyback Regulations, under the Tender Offer route, the Promoter and Promoter Group have the option to participate in the Buyback.

## **7. AUTHORITY FOR THE BUYBACK**

The Buyback is being undertaken by the Company in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, BSE, NSE, and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.

## **8. NECESSITY FOR THE BUYBACK**

The Buyback is being undertaken, *inter-alia*, for the following reasons:

- 8.1 The Buyback will help the Company to reward its shareholders and enhance the overall return to shareholders;
- 8.2 The Buyback is expected to improve earnings per share and other key ratios such as return on net worth and return on assets over a period of time; and

8.3 The Buyback, which is being implemented through the Tender Offer route as prescribed under the Buyback Regulations, would involve allocation of number of Equity Shares as per their entitlement or 15% of the number of Equity Shares to be bought back, whichever is higher, reserved for Small Shareholders. The Company believes that this reservation for Small Shareholders would benefit a large number of public shareholders, who would get classified as “**Small Shareholders**” as per Regulation 2(i)(n) of the Buyback Regulations.

## 9. MANAGEMENT DISCUSSION AND ANALYSIS OF THE LIKELY IMPACT OF THE BUYBACK ON THE COMPANY

9.1 We believe that the Buyback is not likely to cause any impact on the profitability or earnings of the Company, except to the extent of reduction in the amount available for investment, which the Company could have been otherwise deployed towards generating investment income. Assuming there is full participation in the Buyback, the funds deployed by the Company towards the Buyback (excluding Transaction Costs) would be up to ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only). This shall impact the investment income earned by the Company, on account of reduced amount of funds available for investments. With a likely reduction in the equity share capital base, the Buyback will likely improve the return on net worth or return on equity ratio.

9.2 We believe that the Buyback will not in any manner impair the ability of the Company to pursue growth opportunities or meet its cash requirements for business operations. The Buyback is being undertaken, *inter alia*, for helping the Company to reward the Eligible Shareholders broadly in proportion to their shareholding, thereby, enhancing the overall return to the Equity Shareholders.

9.3 The Buyback will not result in a change in control or otherwise affect the existing management structure of the Company.

9.4 The aggregate shareholding of the members of the Promoter & Promoter Group and person in control of the Company as on the date of the Public Announcement and this Letter of Offer is as follows:

Sr. No.	Name	Category	Number of Equity Shares held	% shareholding
1.	Venkata Ramprasad Reddy Penaka	Promoter	1,78,33,646	3.07
2.	K Nithyananda Reddy	Promoter	2,53,59,572	4.37
<b>Total (A)</b>			<b>4,31,93,218</b>	<b>7.44</b>
3.	M Sivakumaran	Promoter Group	1,43,57,432	2.47
4.	K Rajeshwari	Promoter Group	18,08,631	0.31
5.	Suneela Rani Penaka	Promoter Group	1,28,799	0.02
6.	Prasada Reddy Kambham	Promoter Group	2,98,373	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	15,85,214	0.27
9.	Kirthi Reddy Kambam	Promoter Group	2,00,62,852	3.45
10.	Kambam Spoorthi	Promoter Group	69,39,173	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil

12.	Trident Chemphar Limited	Promoter Group	7,82,241	0.13
13.	Axis Clinicals Limited	Promoter Group	6,51,920	0.11
14.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	Promoter Group	19,45,61,357	33.50
15.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	Promoter Group	1,65,72,131	2.85
<b>Total (B)</b>			<b>25,77,55,503</b>	<b>44.38</b>
<b>Total (A+B)</b>			<b>30,09,48,721</b>	<b>51.82</b>

9.5 The aggregate shareholding of the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company:

Sr No	Name of Company/ Trust forming part of the Promoter & Promoter Group	Name of the Director/ Trustee	No. of Equity Shares	% shareholding
1.	Axis Clinicals Limited	Jayachandra Reddy Atluri	29,000	0.01
2.	RPR Sons Advisors Private Limited	Venkata Ramprasad Reddy Penaka	1,78,33,646	3.07
		Suneela Rani Penaka	1,28,799	0.02

9.6 The aggregate shareholding of the directors and key managerial personnel of the Company (other than members of the Promoter & Promoter Group) in the Company:

Sr. No.	Name	Number of Equity Shares held	% shareholding
1.	S. Subramanian	7,063	Negligible
2.	M. Madan Mohan Reddy	2,010	Negligible
<b>Total</b>		<b>9,073</b>	<b>Negligible</b>

9.7 Intention of members of the Promoter & Promoter Group and persons in control of the Company to participate in the Buyback:

In terms of the Buyback Regulations, under Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group *vide* their letters dated April 7, 2026, have expressed their intention to participate in the Buyback and tender up to the number of Equity Shares set out in the table below, or such lower number of Equity Shares as permitted under the applicable law:

Sr. No.	Name	Number of Equity Shares held	Maximum number of Equity Shares intended to be tendered up to
1.	Venkata Ramprasad Reddy Penaka	1,78,33,646	3,22,000
2.	K Nithyananda Reddy	2,53,59,572	4,58,000
3.	M Sivakumaran	1,43,57,432	2,60,000
4.	Rajeshwari Kambham	18,08,631	33,000
5.	Suneela Rani Penaka	1,28,799	3,000
6.	Prasada Reddy Kambham	2,98,373	6,000
7.	K Suryaprakash Reddy	7,380	Nil
8.	M Sumanth Kumar Reddy	15,85,214	29,000
9.	Kirthi Reddy Kambam	2,00,62,852	3,62,000
10.	Kambam Spoorthi	69,39,173	1,26,000
11.	Trident Chemphar Limited	7,82,241	15,000
12.	Axis Clinicals Limited	6,51,920	12,000
13.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	19,45,61,357	35,07,000
14.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	1,65,72,131	3,00,000
<b>Total</b>		<b>30,09,48,721</b>	<b>54,33,000</b>

9.8 The entire shareholding of the members of the Promoter & Promoter Group is in dematerialised form. The details of the date and price of acquisition of the Equity Shares proposed to be tendered in the Buyback by the members of the Promoter & Promoter Group and persons in control of the Company who intend to participate in the Buyback are set out below:

9.8.1 **Venkata Ramprasad Reddy Penaka**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	3,22,000	Nil

**Note:** (1) Received a total of 90,00,000 equity shares pursuant to the bonus issuance, of which 1,66,354 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.2 **K Nithyananda Reddy**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	4,58,000	Nil

**Note:** (1) Received a total of 1,37,62,350 equity shares pursuant to the bonus issuance.

### 9.8.3 M Sivakumaran

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	2,60,000	Nil

**Note:** (1) Received a total of 73,45,680 equity shares pursuant to the bonus issuance, of which 1,33,928 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

### 9.8.4 K Rajeshwari

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	33,000	Nil

**Note:** (1) Received a total of 8,87,750 equity shares pursuant to the bonus issuance, of which 16,869 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

### 9.8.5 Suneela Rani Penaka

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	September 30, 2021 <sup>(1)</sup>	Gift from member of Promoter & Promoter Group	1	3,000	Nil

**Note:** (1) Received a total of 1,30,000 equity shares from Penaka Neha Reddy, a member of the Promoter & Promoter Group, of which 1,201 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

### 9.8.6 Prasada Reddy Kambham

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	6,000	Nil

**Note:** (1) Received a total of 2,00,578 equity shares pursuant to the bonus issuance, of which 2,783 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.7 **M Sumanth Kumar Reddy**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	29,000	Nil

**Note:** (1) Received a total of 8,00,000 equity shares pursuant to the bonus issuance, of which 14,786 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.8 **Kirthi Reddy Kambam**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	3,62,000	Nil

**Note:** (1) Received a total of 1,03,50,000 equity shares pursuant to the bonus issuance, of which 1,87,148 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.9 **Kambam Spoorthi**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in the ratio of 1:1	1	1,26,000	Nil

**Note:** (1) Received a total of 38,00,000 equity shares pursuant to the bonus issuance, of which 60,827 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.10 **Trident Chemphar Limited**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	March 18, 2020 <sup>(1)</sup>	Market purchase	1	15,000	392.82

**Note:** (1) Acquired a total of 1,30,000 equity shares through market purchase at a weighted average price of ₹ 392.82/-, of which 7,296 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.8.11 **Axis Clinicals Limited**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	July 22, 2015 <sup>(1)</sup>	Bonus issue in	1	12,000	Nil

		the ratio of 1:1			
--	--	------------------	--	--	--

**Note:** (1) Received a total of 26,18,745 equity shares pursuant to the bonus issuance, of which 6,080 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

**9.8.12 RPR Sons Advisors Private Limited, Suneela Rani Penaka (Joint holding)**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	January 19, 2017 <sup>(1)</sup>	Contribution by partners through an off-market transfer	1	35,07,000	12.12

**Note:** (1) 19,63,76,250 Equity Shares of the Company were contributed by Suneela Rani Penaka a member of the Promoter & Promoter Group, at a weighted average price of ₹12.12/- per equity share, of which 18,14,893 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

**9.8.13 Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (Joint holding)**

Sr. No.	Date of Acquisition	Nature of transaction	Face Value (in ₹)	Number of Equity Shares acquired	Issue price/ transfer price per Equity Share (in ₹)
1	March 30, 2017 <sup>(1)</sup>	Contribution by partners through an off-market transfer	1	3,00,000	32.64

**Note:** (1) 45,79,490 equity shares of the Company were contributed by Axis Clinicals Limited and 1,21,47,226 Equity Shares of the Company were contributed by Trident Chemphar Limited both members of the Promoter & Promoter Group, at a weighted average price of ₹ 32.64/- per equity share, of which 1,54,585 equity shares have been accepted in the previous buyback undertaken by the Company which was settled on August 19, 2024.

9.9 No Equity Shares or other specified securities in the Company were either purchased or sold by (a) the members of the Promoter & Promoter Group and persons who are in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company; and (c) directors and key managerial personnel of the Company, during the 6 (Six) months preceding the date of the Board Meeting, and during the 12 (Twelve) months preceding the date of the Public Announcement, except as follows:

Name	Aggregate no. of Equity Shares allotted / transferred	Nature of transaction	Maximum price per Equity Share (₹)*	Date of maximum price	Minimum price per Equity Share (₹)*	Date of minimum price
Jayachandra Reddy Atluri	1,680	Sale	1,270	March 10, 2026	1,268	March 10, 2026

\* Excluding transaction costs such as brokerage, securities transaction tax etc.

- 9.10 The Buyback will not result in any benefit to the members of the Promoter & Promoter Group, persons in control of the Company or any Director except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as Equity Shareholders of the Company, and the change in their shareholding as per the response received in the Buyback, as a result of the extinguishment of Equity Shares which will lead to reduction in the equity share capital of the Company post Buyback.
- 9.11 Assuming the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including the members of the Promoter & Promoter Group, the aggregate shareholding and the voting rights of the members of the Promoter & Promoter Group, may increase to 51.88% post Buyback from the current pre Buyback shareholding of 51.82%, and the aggregate shareholding of the public Shareholders in the Company may decrease to 48.12% post Buyback from the current pre Buyback shareholding of 48.18%. The members of the Promoter & Promoter Group are already in control over the Company and therefore any further increase in the voting rights of the members of the Promoter & Promoter Group will not result in any change in control of the Company.
- 9.12 Consequent to the Buyback and based on the number of Equity Shares bought back from the Non-Resident Shareholders, Indian financial institutions, banks, mutual funds and the public including other bodies corporate, the shareholding of the members of the Promoter & Promoter Group would undergo a change. Please refer to paragraph 13.6 for further details.
- 9.13 The debt-equity ratio post Buyback on standalone as well as consolidated basis will be compliant with the permissible limit of 2:1 prescribed under Section 68(2)(d) of Companies Act and Regulation 4(ii) of the Buyback Regulations, even if the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders.
- 9.14 The Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus), from the date of the Board Meeting till the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback, except in discharge of subsisting obligations through conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into equity shares. There are no subsisting obligations to issue or allot any Equity Shares or other specified securities through conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into equity shares.
- 9.15 The Company has outstanding facilities with its lenders. In accordance with Regulation 5(i)(c) and Clause (xii) of Schedule I of the Buyback Regulations, the Company shall not undertake the Buyback unless it has obtained prior consent of its lenders, in case of breach of any covenant with such lenders. The Company confirms that it has obtained the prior consent of its lenders, as necessary, for undertaking the Buyback.

- 9.16 Unless otherwise specifically permitted by any relaxation issued by SEBI and/ or any other regulatory authority, the Company shall not raise further capital for a period of 1 (One) year, as prescribed under the provisions of Regulation 24(i)(f) of the Buyback Regulations, from the expiry of the Buyback Period, i.e., the date on which the payment of consideration is made to the Eligible Shareholders who have accepted the Buyback, except in discharge of its subsisting obligations. Further, the Company shall not issue and allot any Equity Shares or other specified securities (including by way of bonus), from the date of the Board Meeting till the expiry of the Buyback period, i.e., the date on which the payment of consideration is made to the shareholders who have accepted the Buyback, except in discharge of subsisting obligations through conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into equity shares. The Company, as per the provisions of Section 68(8) of the Companies Act, will not make a further issue of the same kind of shares or other securities including allotment of new shares under Section 62(1)(a) of the Companies Act or other specified securities within a period of 6 (six) months except by way of a bonus issue or in the discharge of subsisting obligations such as conversion of warrants, stock option schemes, sweat equity or conversion of preference shares or debentures into equity shares.
- 9.17 As per Regulation 24(i)(e) of the Buyback Regulations, the members of the Promoter & Promoter Group, and their associates, shall not deal in the Equity Shares or other specified securities of the Company either through the Stock Exchanges or off-market transactions (including by way of inter-se transfer of Equity Shares among the members of the Promoter & Promoter Group) from the date of the Board Meeting till the closing of the Buyback.
- 9.18 Salient financial parameters consequent to the Buyback based on standalone and consolidated audited financial statement of the Company for the financial year ended March 31, 2025 are set forth below:

Parameter	Standalone		Consolidated	
	Pre-Buyback	Post Buyback <sup>(1)</sup>	Pre-Buyback	Post Buyback <sup>(1)</sup>
Networth (in ₹ Million)	203,498.7	195,498.7	305,805.4	297,805.4
Return on Net worth (%)	8.58%	8.94%	11.40%	11.71%
Basic Earnings per share (₹)	29.97	30.25	59.81	60.37
Book value per share (₹)	350.38	339.77	526.52	517.58
Price/ Earnings Ratio	38.7	38.4	19.4	19.2
Total Debt/Equity Ratio	0.23	0.24	0.26	0.27

**Note:**

(1) Assuming full acceptance.

The key ratios have been computed as below:

Key Ratios	Basis
Basic Earnings per share	Profit after tax / Weighted average number of equity shares outstanding
Book value per share	Net worth / Total number of outstanding shares
Total Debt-Equity Ratio	Total Debt <sup>(1)</sup> / Net worth
Price / Earning ratio	Calculated as closing market price of the Equity Shares on NSE as on March 28, 2025 (INR 1,160.50) divided by earnings per share for the period ended March 31, 2025

Net Worth	Paid-up equity share capital + security premium + general reserve + retained earnings of the Company
-----------	--

**Note:**

(1) *Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Non-current borrowings*

**10. BASIS OF CALCULATING THE BUYBACK PRICE**

10.1 The Equity Shares are proposed to be bought back at a price ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share.

10.2 The Buyback Price has been arrived at after considering various factors including, but not limited to the trends in the volume weighted average prices and the closing price of the Equity Shares at the Stock Exchanges.

10.3 The Buyback Price represents:

10.3.1 premium of 20.86% and 21.82% over the volume weighted average market price of the Equity Share on BSE and NSE, respectively, during the 3 (Three) months preceding Tuesday, March 31, 2026, being the date of intimation to the Stock Exchanges for the Board Meeting to consider the proposal of the Buyback ("**Intimation Date**").

10.3.2 premium of 12.72% and 14.21% over the volume weighted average market price of the Equity Share on BSE and NSE, respectively, during the 2 (Two) weeks preceding the Intimation Date.

10.3.3 premium of 13.18% and 13.08% over the closing price of the Equity Share on BSE and NSE, respectively, as on the trading day immediately preceding the Intimation Date, i.e., Monday, March 30, 2026.

10.3.4 premium of 10.09% and 10.04% over the closing price of the Equity Share on BSE and NSE, respectively, as on Monday, April 6, 2026, being the date of the Board Meeting.

10.4 The closing market price of the Equity Shares on the trading day immediately preceding the Intimation Date, i.e., Monday, March 30, 2026, was ₹ 1,303.20/- and ₹ 1,304.40/- and as on the date of the Board Meeting was ₹ 1,339.80/- and ₹ 1,340.40/- on BSE and NSE, respectively.

10.5 For trends in the market price of the Equity Shares, please refer to paragraph 16 (*Stock Market Data*) of this Letter of Offer. For details of salient financial parameters, both pre-Buyback and post-Buyback, based on the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2025, please refer to paragraph 9.18 of this Letter of Offer.

**11. SOURCES OF FUNDS FOR THE BUYBACK**

11.1 The maximum amount required for Buyback will not exceed ₹ 800,00,00,000/- (Rupees Eight Hundred Crore only) (excluding Transaction Costs). The Buyback Size constitutes 3.93% and 2.62% of the aggregate of the total paid-up share capital and free reserves (including securities premium) of the Company, as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, which is within the statutory

limit of 10% of the aggregate of the total paid-up equity capital and free reserves (including securities premium) of the Company as at March 31, 2025, under the Board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations.

- 11.2 The funds for the implementation of the proposed Buyback will be sourced out of the free reserves (including securities premium) of the Company and/ or such other sources as may be permitted by Buyback Regulations or the Companies Act. Funds borrowed from banks and financial institutions, if any, will not be used for the Buyback.
- 11.3 The Company shall transfer from its free reserves and/ or such other sources as may be permitted by law, a sum equal to the nominal value of the Equity Shares bought back through the Buyback to the capital redemption reserve account and the details of such transfer shall be disclosed in its audited financial statements, as required.

## **12. DETAILS OF ESCROW ACCOUNT AND AMOUNT DEPOSITED THEREIN AND FIRM FINANCIAL ARRANGEMENT**

- 12.1 In accordance with Regulation 9(xi) of the Buyback Regulations, an escrow agreement has been entered into amongst the Company, Manager to the Buyback and the Escrow Agent on Tuesday, April 7, 2026.
- 12.2 In accordance with the Buyback Regulations and pursuant to the Escrow Agreement, an Escrow Account in the name and style "**Aurobindo Pharma Limited - Buyback Escrow Account**" bearing account number 926020012864440 has been opened with the Escrow Agent, namely, Axis Bank Limited, having its registered office at 'Trishul', 3rd Floor, Opposite Samarsheshwar Temple, Law Garden, Ellis Bridge, Ahmedabad 380 006, Gujarat, acting through its branch situated at 6-3-879/ B, First Floor, G. Pullareddy Building, Greenlands, Begumpet Road, Hyderabad -500016. The Company has deposited an amount of ₹ 95,00,00,000/- (Rupees Ninety Five Crore only) in the Escrow Account in cash i.e., an amount equivalent to the aggregate of 25% of ₹ 100 Crore and 10% of the Buyback Size beyond ₹ 100 Crore, by way of security for fulfilment of its obligations under the Buyback, in compliance with the provisions under Regulation 9(xi) of the Buyback Regulations. In accordance with the Buyback Regulations, the Manager to the Buyback has been empowered to operate the Escrow Account.
- 12.3 The Company has adequate and firm financial resources to fulfil the obligations under the Buyback. G Pavan Kumar Reddy (Membership No. 229495), partner at G P M & Associates, Chartered Accountants (Firm Registration No. 015343S) having its office at Flat No. B-207, B-Block, Galaxy Apartments, Survey No. 74, Kondapur Village, Serilingampally Mandal, Hyderabad - 500 084, has certified through its certificate dated Monday, April 6, 2026 ("**Certificate**") that the Company has firm and adequate financial arrangements for meeting its obligations arising out of the Buyback.
- 12.4 Based on the Certificate, the Manager to the Buyback confirms that it is satisfied that firm arrangements for fulfilling the obligations under the Buyback are in place and that the Company has the ability to implement the Buyback in accordance with the Buyback Regulations.

## **13. CAPITAL STRUCTURE AND SHAREHOLDING PATTERN**

- 13.1 The present capital structure of the Company as on date of this Letter of Offer is as follows:

Parameters	Pre-Buyback
<b>Authorised Share Capital</b>	
4,54,29,93,820 Equity Shares of ₹ 1/- each	₹ 4,54,29,93,820
2,12,10,000 preference shares of ₹ 100/- each	₹ 2,12,10,00,000
<b>Total</b>	<b>₹ 6,66,39,93,820</b>
<b>Issued, Subscribed and Fully Paid-Up Share Capital</b>	
58,08,01,623 Equity Shares of ₹ 1/- each	₹ 58,08,01,623
<b>Total</b>	<b>₹ 58,08,01,623</b>

- 13.2 Assuming full acceptance in the Buyback of 54,23,728 Equity Shares, the capital structure post Buyback would be as follows:

Parameters	Post-Buyback <sup>(1)</sup>
<b>Authorised Share Capital</b>	
4,54,29,93,820 Equity Shares of ₹ 1/- each	₹ 4,54,29,93,820
2,12,10,000 preference shares of ₹ 100/- each	₹ 2,12,10,00,000
<b>Total</b>	<b>₹ 6,66,39,93,820</b>
<b>Issued, Subscribed and Fully Paid-Up Share Capital</b>	
57,53,77,895 Equity Shares of ₹ 1/- each	₹ 57,53,77,895
<b>Total</b>	<b>₹ 57,53,77,895</b>

**Note:** (1) Post-Buyback issued, subscribed and paid-up capital may differ depending upon the actual number of Equity Shares bought back.

- 13.3 As on the date of this Letter of Offer, the Equity Shares are fully paid up and there are no partly paid-up equity shares.
- 13.4 As on the date of this Letter of Offer, there are no convertible debentures or preference shares or any other convertible instruments of the Company.
- 13.5 The details of buyback programs undertaken by the Company in the last 3 (three) years are as set out below:

Opening Date	Closing Date	Method of Buyback	Equity Shares bought back
August 5, 2024	August 9, 2024	Tender offer	51,36,986

- 13.6 The shareholding pattern of the Company before the Buyback (i.e., as on the Record Date), and after the Buyback (assuming full acceptance of 54,23,728 Equity Shares in the Buyback), is as follows:

Category of Shareholder	No. of Equity Shares pre-Buyback	% to the existing equity share capital	No. of Equity Shares post Buyback <sup>(1)</sup>	% to the Post Buyback equity share capital
<b>Promoter &amp; Promoter Group and persons acting in concert (A)</b>	30,09,48,721	51.82	29,85,30,407	51.88
<b>Shareholding of non-promoters (B)</b>	27,98,52,902	48.18	27,68,47,488	48.12
Foreign Investors (OCBs/ FIIs/ NRIs/ Non-residents/ Non-domestic companies)	9,06,24,695	15.60		
Indian Financial Institutions/ Banks/ Mutual Funds/ Government Companies	14,50,76,920	24.98		
Others (Individuals, Bodies Corporate, Employees, etc.)	4,41,51,287	7.60		
<b>Total (A+B)</b>	<b>58,08,01,623</b>	<b>100.00</b>	<b>57,53,77,895</b>	<b>100.00</b>

**Note:** (1) Assuming the full Acceptance of 54,23,728 Equity Shares in the Buyback in accordance with the Buyback Entitlement for all Eligible Shareholders. However, the post-Buyback shareholding pattern may differ depending upon the actual number of Equity Shares bought back.

13.7 The aggregate shareholding in the Company of (a) the members of the Promoter & Promoter Group and persons in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group; and (c) the directors (other than members of the Promoter & Promoter Group) and key managerial personnel, as on the date of the Public Announcement, is as follows:

13.7.1 Aggregate shareholding of the members of the Promoter & Promoter Group and persons in control of the Company in the Company:

Sr. No.	Name	Category	Number of Equity Shares held	% shareholding
1.	Venkata Ramprasad Reddy Penaka	Promoter	1,78,33,646	3.07
2.	K Nithyananda Reddy	Promoter	2,53,59,572	4.37
<b>Total (A)</b>			<b>4,31,93,218</b>	<b>7.44</b>
3.	M Sivakumaran	Promoter Group	1,43,57,432	2.47
4.	K Rajeshwari	Promoter Group	18,08,631	0.31
5.	Suneela Rani Penaka	Promoter Group	1,28,799	0.02
6.	Prasada Reddy Kambham	Promoter Group	2,98,373	0.05
7.	K Suryaprakash Reddy	Promoter Group	7,380	0.00
8.	M Sumanth Kumar Reddy	Promoter Group	15,85,214	0.27
9.	Kirthi Reddy Kambam	Promoter Group	2,00,62,852	3.45
10.	Kambam Spoorthi	Promoter Group	69,39,173	1.19
11.	Penaka Neha Reddy	Promoter Group	Nil	Nil
12.	Trident Chemphar Limited	Promoter Group	7,82,241	0.13
13.	Axis Clinicals Limited	Promoter Group	6,51,920	0.11

14.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	Promoter Group	19,45,61,357	33.50
15.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	Promoter Group	1,65,72,131	2.85
<b>Total (B)</b>			<b>25,77,55,503</b>	<b>44.38</b>
<b>Total (A+B)</b>			<b>30,09,48,721</b>	<b>51.82</b>

13.7.2 Aggregate shareholding of the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company:

Sr No	Name of Company/ Trust forming part of the Promoter & Promoter Group	Name of the Director/ Trustee	No. of Equity Shares	% shareholding
1.	Axis Clinicals Limited	Jayachandra Reddy Atluri	29,000	0.01
2.	RPR Sons Advisors Private Limited	Venkata Ramprasad Reddy Penaka	1,78,33,646	3.07
		Suneela Rani Penaka	1,28,799	0.02

13.7.3 Aggregate shareholding of the directors (other than the members of the Promoter & Promoter Group) and key managerial personnel of the Company in the Company:

Sr. No.	Name	Number of Equity Shares held	% shareholding
1.	S. Subramanian	7,063	Negligible
2.	M. Madan Mohan Reddy	2,010	Negligible
<b>Total</b>		<b>9,073</b>	<b>Negligible</b>

13.8 No Equity Shares or other specified securities in the Company were either purchased or sold by (a) the members of the Promoter & Promoter Group and persons who are in control of the Company; (b) the director(s)/ trustee(s) of the companies/ trusts forming part of the Promoter & Promoter Group in the Company; and (c) directors and key managerial personnel of the Company, during the 6 (Six) months preceding the date of the Board Meeting, and during the 12 (Twelve) months preceding the date of the Public Announcement, except as follows:

Name	Aggregate no. of Equity Shares allotted / transferred	Nature of transaction	Maximum price per Equity Share (₹)*	Date of maximum price	Minimum price per Equity Share (₹)	Date of minimum price
Jayachandra Reddy Atluri	1,680	Sale	1,270	March 10, 2026	1,268	March 10, 2026

\* Excluding transaction costs such as brokerage, securities transaction tax etc.

13.9 Assuming response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including all members of the Promoter &

Promoter Group who have expressed their intention to participate, the aggregate shareholding of the members of the Promoter & Promoter Group, post Buyback may increase to 51.88% from 51.82%.

- 13.10 There is no ongoing scheme of amalgamation or compromise or arrangement pursuant to the provisions of the Companies Act, as on date.

#### 14. BRIEF INFORMATION OF THE COMPANY

14.1 The Company was incorporated on December 26, 1986 as a private limited company under the provisions of the Companies Act, 1956 and converted into a public limited company with effect from April 30, 1992. The registered office of the Company is presently situated at Plot No. 2, Maithrivihar, Behind Maitrivanam, Ameerpet, Hyderabad - 500 038.

14.2 The Equity Shares were listed at BSE (scrip code: 524804) on April 06, 1995, and NSE (symbol: AUROPHARMA) on July 19, 2000. The ISIN of the Equity Shares is INE406A01037.

14.3 The paid-up equity share capital of the Company for the year ended March 31, 2025 was ₹ 580.8 million and total free reserves for the year ended March 31, 2025 was ₹ 202,917.9 million, on a standalone basis and ₹ 305,224.6 million on a consolidated basis.

#### 14.4 History and Growth of Business:

The Company manufactures and markets generic formulations, specialty formulations (branded drugs) and Active Pharmaceutical Ingredients (API) and has emerged as one of the prominent players in the global pharmaceutical landscape. The Company's corporate office is situated in Hyderabad and it has over 30 manufacturing facilities for its API and formulations business.

#### 14.5 Financial Growth:

For the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, the Company recorded, on a standalone basis, total income from continuing operations of ₹ 112,614.2 million, ₹ 112,617.0 million and ₹ 89,009.2 million, respectively. The net profit after tax from continuing operations for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 was ₹ 17,467.9 million, ₹ 19,001.0 million and ₹ 12,421.7 million, respectively. For the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, the Company recorded, on a consolidated basis, total income of ₹ 323,455.8 million, ₹ 295,592.5 million and ₹ 251,459.7 million respectively. The net profit after tax (attributable to owners of the Company before other comprehensive income) on a consolidated basis for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 was ₹ 34,858.8 million, ₹ 31,729.7 million and ₹ 19,275.0 million, respectively. For further details on financial information about the Company for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, please refer to paragraph 15 (*Financial Information about the Company*) of this Letter of Offer.

14.6 Following is the equity share capital history of the Company since inception:

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
December	20	100.00	100.00	Cash	20	2,000	Subscription to MOA

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
26, 1986							
November 25, 1987	9,980	100.00	100.00	Cash	10,000	10,00,000	Preferential issue to promoters
March 30, 1989	7,000	100.00	100.00	Cash	17,000	17,00,000	Preferential issue to promoters
March 31, 1990	5,750	100.00	100.00	Cash	22,750	22,75,000	Preferential issue to promoters
November 18, 1991	1,250	100.00	100.00	Cash	24,000	24,00,000	Preferential issue to promoters
March 30, 1992	5,500	100.00	100.00	Cash	29,500	29,50,000	Preferential issue to promoters
April 30, 1992	2,65,500	10.00	-	Stock split	2,95,000	29,50,000	Stock split of ₹ 100/- to ₹ 10/-
May 04, 1992	2,95,000	10.00	-	NA	5,90,000	59,00,000	Bonus issue in the ratio of 1:1
December 31, 1992	15,000	10.00	10.00	Cash	6,05,000	60,50,000	Preferential issue to promoters
March 31, 1993	9,050	10.00	25.00	Cash	6,14,050	61,40,500	Preferential issue to promoters
June 08, 1993	12,28,100	10.00	-	NA	18,42,150	1,84,21,500	Bonus issue in the ratio of 2:1
September 30, 1993	7,000	10.00	30.00	Cash	18,49,150	1,84,91,500	Preferential issue to promoters
October 30, 1993	850	10.00	30.00	Cash	18,50,000	1,85,00,000	Preferential issue to promoters
April 26, 1994	72,500	10.00	30.00	Cash	19,22,500	1,92,25,000	Preferential issue to promoters
April 27, 1994	12,25,000	10.00	150.00	Cash	31,47,500	3,14,75,000	Preferential issue to non-promoters
April 30, 1994	2,500	10.00	30.00	Cash	31,50,000	3,15,00,000	Preferential issue to a director
November 02, 1994	11,02,500	10.00	-	NA	42,52,500	4,25,25,000	Bonus issue in the ratio of 7:20
March 27, 1995	4,72,500	10.00	-	Other than Cash	47,25,000	4,72,50,000	Allotment to the shareholders of Chaitanya Organics Private Limited pursuant to a scheme of amalgamation
November 27, 1998	47,25,000	10.00	-	NA	94,50,000	9,45,00,000	Bonus issue in the ratio of 1:1
September 10, 1999	5,51,000	10.00	490.00	Cash	1,00,01,000	10,00,10,000	Preferential issue to non-promoters
April 07, 2000	1,00,01,000	10.00	-	NA	2,00,02,000	20,00,20,000	Bonus issue in the ratio of 1:1
July 05, 2001	1,98,000	10.00	-	Other than Cash	2,02,00,000	20,20,00,000	Allotment to shareholders of Sri Chakra Remedies Limited pursuant to a scheme of amalgamation
March 20, 2002	4,00,000	10.00	226.00	Cash	2,06,00,000	20,60,00,000	Preferential issue to promoters

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
March 27, 2002	70,000	10.00	226.00	Cash	2,06,70,000	20,67,00,000	Preferential issue to promoters
April 12, 2002	5,30,000	10.00	226.00	Cash	2,12,00,000	21,20,00,000	Preferential issue to promoters
April 14, 2002	10,00,000	10.00	226.00	Cash	2,22,00,000	22,20,00,000	Preferential issue to non-promoters
September 27, 2002	10,50,000	10.00	226.00	Cash	2,32,50,000	23,25,00,000	Preferential issue to non-promoters
September 04, 2003	9,50,000	10.00	226.00	Cash	2,42,00,000	24,20,00,000	Preferential issue to promoters
October 31, 2003	2,42,00,000	5.00	-	NA	4,84,00,000	24,20,00,000	Stock split of ₹ 10/- to ₹ 5/-
February 18, 2004	23,70,000	5.00	375.00	Cash	5,07,70,000	25,38,50,000	Preferential issue to non-promoters
July 15, 2005	10,00,000	5.00	375.00	Cash	5,17,70,000	25,88,50,000	Preferential issue to promoters
August 02, 2005	15,00,000	5.00	375.00	Cash	5,32,70,000	26,63,50,000	Preferential issue to promoters
July 31, 2006	24,661	5.00	362.60	Cash	5,32,94,661	26,64,73,305	Conversion of stock options
December 15, 2006	53,976	5.00	362.60	Cash	5,33,48,637	26,67,43,185	Conversion of stock options
July 11, 2007	3,74,046	5.00	522.04	Cash	5,37,22,683	26,86,13,415	Conversion of foreign currency convertible bonds ("FCCB")
July 31, 2007	16,638	5.00	362.60	Cash	5,37,39,321	26,86,96,605	Conversion of stock options
December 10, 2007	25,947	5.00	362.60	Cash	5,37,65,268	26,88,26,340	Conversion of stock options
November 04, 2009	83,121	5.00	522.04	Cash	5,38,48,389	26,92,41,945	Conversion of FCCB
December 15, 2009	1,50,030	5.00	362.60	Cash	5,39,98,419	26,99,92,095	Conversion of stock options
January 06, 2010	11,42,920	5.00	522.04	Cash	5,51,41,339	27,57,06,695	Conversion of FCCB
February 01, 2010	50,869	5.00	522.04	Cash	5,51,92,208	27,59,61,040	Conversion of FCCB
February 24, 2010	1,33,491	5.00	522.04	Cash	5,53,25,699	27,66,28,495	Conversion of FCCB
March 12, 2010	4,03,138	5.00	522.04	Cash	5,57,28,837	27,86,44,185	Conversion of FCCB
April 20, 2010	3,32,485	5.00	522.04	Cash	5,60,61,322	28,03,06,610	Conversion of FCCB
May 18, 2010	2,25,592	5.00	522.04	Cash	5,62,86,914	28,14,34,570	Conversion of FCCB
June 08, 2010	1,66,243	5.00	522.04	Cash	5,64,53,157	28,22,65,785	Conversion of FCCB
July 19, 2010	27,007	5.00	362.60	Cash	5,64,80,164	28,24,00,820	Conversion of stock options
July 27, 2010	14,54,625	5.00	522.04	Cash	5,79,34,789	28,96,73,945	Conversion of FCCB
August 02, 2010	2,86,769	5.00	522.04	Cash	5,82,21,558	29,11,07,790	Conversion of FCCB

Date of allotment	No. of Equity Shares	Face Value per Equity Share (₹)	Issue Price per Equity Share (₹)	Nature of Consideration	Cumulative no. of Equity Shares	Cumulative equity share capital (₹)	Nature of Issue
December 30, 2010	2,700	5.00	362.60	Cash	5,82,24,258	29,11,21,290	Conversion of stock options
February 11, 2011	23,28,97,032	1.00	-	NA	29,11,21,290	29,11,21,290	Stock split of ₹ 5/- to ₹ 1/-
January 09, 2013	90,000	1.00	91.60	Cash	29,12,11,290	29,12,11,290	Conversion of stock options
January 09, 2014	1,27,500	1.00	91.60	Cash	29,13,38,790	29,13,38,790	Conversion of stock options
March 10, 2014	68,231	1.00	187.40	Cash	29,14,07,021	29,14,07,021	Conversion of stock options
March 10, 2014	50,000	1.00	200.70	Cash	29,14,57,021	29,14,57,021	Conversion of stock options
October 07, 2014	7,700	1.00	187.40	Cash	29,14,64,721	29,14,64,721	Conversion of stock options
January 17, 2015	3,31,200	1.00	91.60	Cash	29,17,95,921	29,17,95,921	Conversion of stock options
March 12, 2015	1,08,354	1.00	187.40	Cash	29,19,04,275	29,19,04,275	Conversion of stock options
March 12, 2015	3,000	1.00	161.30	Cash	29,19,07,275	29,19,07,275	Conversion of stock options
March 12, 2015	75,000	1.00	200.70	Cash	29,19,82,275	29,19,82,275	Conversion of stock options
July 22, 2015	29,19,82,275	1.00	-	NA	58,39,64,550	58,39,64,550	Bonus issue in the ratio of 1:1
January 19, 2016	8,55,000	1.00	45.80	Cash	58,48,19,550	58,48,19,550	Conversion of stock options
March 09, 2016	3,50,036	1.00	93.70	Cash	58,51,69,586	58,51,69,586	Conversion of stock options
March 09, 2017	6,97,823	1.00	93.70	Cash	58,58,67,409	58,58,67,409	Conversion of stock options
March 30, 2017	15,000	1.00	80.65	Cash	58,58,82,409	58,58,82,409	Conversion of stock options
March 28, 2018	17,200	1.00	93.70	Cash	58,58,99,609	58,58,99,609	Conversion of stock options
March 28, 2018	8,000	1.00	80.65	Cash	58,59,07,609	58,59,07,609	Conversion of stock options
March 27, 2019	8,000	1.00	80.65	Cash	58,59,15,609	58,59,15,609	Conversion of stock options
August 07, 2019	23,000	1.00	80.65	Cash	58,59,38,609	58,59,38,609	Conversion of stock options
August 19, 2024	(51,36,986)	1.00	1,460.00	Cash	58,08,01,623	58,08,01,623	Buyback of shares

14.7 The details of the Board of Directors of the Company as on the date of Public Announcement is as follows:

Name, Occupation, Age and DIN	Designation	Qualifications	Date of Appointment/ re-appointment	Other Directorships
Mangalam Ramasubramanian Kumar <b>Occupation:</b> Retired from Life Insurance Corporation of India <b>Age:</b> 64 years <b>DIN:</b> 03628755	Chairman & Independent Director	Science graduate from University of Madras	April 01, 2024	<ol style="list-style-type: none"> <li>1. Bank of India</li> <li>2. Aurobindo Pharma USA Inc</li> <li>3. Cholamandalam Investment and Finance Company Limited</li> </ol>
K Nithyananda Reddy <b>Occupation:</b> Industrialist <b>Age:</b> 68 years <b>DIN:</b> 01284195	Vice Chairman & Managing Director	Postgraduate in Science	December 26, 1986	<ol style="list-style-type: none"> <li>1. Raidurgam Developers Limited</li> <li>2. APL Healthcare Limited</li> <li>3. Pattancheru Envirotech Ltd.</li> <li>4. Apitoria Pharma Private Limited</li> <li>5. Aurobindo Pharma Foundation</li> <li>6. Aurobindo Antibiotics Private Limited</li> <li>7. Lyfius Pharma Private Limited</li> <li>8. Qule Pharma Private Limited</li> <li>9. All Pharma (Shanghai) Trading Co Ltd, China</li> </ol>
Mettu Madan Mohan Reddy <b>Occupation:</b> Industrialist <b>Age:</b> 66 years <b>DIN:</b> 01284266	Whole-time Director	Postgraduate in Science	September 18, 2006	<ol style="list-style-type: none"> <li>1. Eugia Pharma Specialities Limited</li> <li>2. Aurozest Private Limited</li> <li>3. Eugia Sez Private Limited</li> <li>4. Curateq Biologics Private Limited</li> <li>5. Eugia Steriles Private Limited</li> <li>6. Auro Vaccines Private Limited</li> <li>7. Theranym Biologics Private Limited</li> <li>8. Aurobindo Pharma USA Inc</li> <li>9. MMR Family Advisors Private Limited</li> <li>10. Engenra Biologics Private Limited</li> </ol>

Name, Occupation, Age and DIN	Designation	Qualifications	Date of Appointment/ re-appointment	Other Directorships
Venkata Ramprasad Reddy Penaka <b>Occupation:</b> Industrialist <b>Age:</b> 68 years <b>DIN:</b> 01284132	Non-executive Director	Postgraduate in Commerce	December 26, 1986	1. Penaka Pharma (India) Private Limited 2. RPR Sons Advisors Private Limited 3. Aurovida Farmaceuticos SA Mexico 4. Aurobindo Pharma USA Inc
Penaka Sarath Chandra Reddy <b>Occupation:</b> Industrialist <b>Age:</b> 41 years <b>DIN:</b> 01628013	Non-executive Director	Graduate in Business Administration	September 27, 2007	1. PVR Chemphar Pvt. Ltd 2. STEPS Therapeutics Co. Ltd., Thailand, 3. Shreas Industries Limited 4. Aurobindo Pharma Foundation 5. Auro Property Management Services Limited
Punita Kumar Sinha <b>Occupation:</b> Professional <b>Age:</b> 63 years <b>DIN:</b> 05229262	Independent Director	PhD and Masters' in Finance from the Wharton School, University of Pennsylvania, CFA charterholder, and a degree in Chemical Engineering from IIT Delhi	February 09, 2026	1. Classic Legends Private Limited 2. One Mobikwik Systems Limited 3. Embassy Office Parks Management Services Private Limited 4. Paradigmarg Advisors Private Limited 5. Tata Asset Management Private Limited 6. Tata Capital Limited 7. Aadhar Housing Finance Limited 8. Ventive Hospitality Limited 9. Marelli Holdings Company Ltd, Japan 10. The Asia Opportunities Offshore Fund, Cayman Islands 11. The Asia Opportunities Offshore Master Fund, Cayman Islands

Name, Occupation, Age and DIN	Designation	Qualifications	Date of Appointment/ re-appointment	Other Directorships
<p>Girish Paman Vanvari  <b>Occupation:</b> Consultant/ Professional  <b>Age:</b> 54 years  <b>DIN:</b> 07376482</p>	Independent Director	Chartered Accountant	November 05, 2020	<ol style="list-style-type: none"> <li>1. Menon And Menon Limited</li> <li>2. Rategain Travel Technologies Limited</li> <li>3. Kolte-Patil Developers Limited</li> <li>4. Himadri Speciality Chemical Limited</li> <li>5. Blue Jet Healthcare Limited</li> <li>6. Rungta Greentech Limited</li> <li>7. CMR Green Technologies Limited</li> <li>8. Suzlon Energy Limited</li> <li>9. Garware Fulflex India Private Limited</li> </ol>
<p>Santanu Mukherjee  <b>Occupation:</b> Retired from banking sector  <b>Age:</b> 69 years  <b>DIN:</b> 07716452</p>	Independent Director	B.Sc. Honors (Chemistry and Mathematics) from Presidency College under Kolkata University and CAIB from the Indian Institute of Bankers.	February 09, 2023	<ol style="list-style-type: none"> <li>1. Suven Life Sciences Limited</li> <li>2. Rainbow Children's Medicare Limited</li> <li>3. Muthoot Housing Finance Company Limited</li> <li>4. Sumedha Fiscal Services Ltd</li> <li>5. Rainbow Speciality Hospitals Private Limited</li> <li>6. Apitoria Pharma Private Limited</li> <li>7. Pratiksha Women &amp; Child Care Hospital Private Limited</li> </ol>
<p>Dr. Satakarni Makkapati  <b>Occupation:</b> Private Service  <b>Age:</b> 45 years  <b>DIN:</b> 09377266</p>	Non-executive Director	Masters' in business administration (MBA) from the IMD Business School at Lausanne (Switzerland), Doctor of Philosophy (PhD) in faculty of Physical Sciences and Engineering from the Russell Group at the University of Manchester (UK) and a	November 09, 2023	<ol style="list-style-type: none"> <li>1. Theranym Biologics Private Limited</li> <li>2. Apitoria Pharma Private Limited</li> <li>3. Auro Peptides Limited</li> <li>4. Auro Vaccines Private Limited</li> <li>5. Engendra Biologics Private Limited</li> </ol>

Name, Occupation, Age and DIN	Designation	Qualifications	Date of Appointment/ re-appointment	Other Directorships
		bachelor's degree in chemical engineering		

14.8 The details of changes in Board of Directors during the last 3 (three) years preceding the date of the Public Announcement are as under:

Sr No	Name	Appointment/ Re-appointment/ Resignation/ Cessation	Effective Date	Reason
1.	Punita Kumar Sinha	Appointment	February 9, 2026	Appointed as Independent Director of the Company not liable to retire by rotation, for a period of 3 (three) consecutive years.
2.	Deepali Pant Joshi	Cessation	February 10, 2026	Ceased to be Independent Director upon completion of her term.
3.	P. Sarath Chandra Reddy	Appointment	September 10, 2025	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation.
4.	Satakarni Makkapati	Appointment	September 10, 2025	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation
5.	Santanu Mukherjee	Re-appointment	February 9, 2025	Reappointed as Independent Director of the Company for a second term of 5 (five) consecutive years.
6.	K. Nithyananda Reddy	Appointment	August 29, 2024	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation
7.	Mettu Madan Mohan Reddy	Appointment	August 29, 2024	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation
8.	K. Nithyananda Reddy	Re-appointment	June 01, 2024	Re-appointed as Vice Chairman and Managing Director of the Company for a period of 3 (three) consecutive years.
9.	Mettu Madan Mohan Reddy	Re-appointment	June 01, 2024	Re-appointed as whole-time director of the Company for a period of 3 (three) consecutive years.
10.	P.V. Ramprasad Reddy	Re-appointment	August 29, 2024	Approved to continue as a non-executive director not liable to retire by rotation subject to approval of the members at least once in every five years.
11.	Savita Mahajann	Cessation	December 16, 2024	Ceased to be Independent Director upon completion of her term.
12.	Mangalam Ramasubramanian Kumar	Appointment	April 01, 2024	Appointed as Independent Director of the Company not liable to retire by

Sr No	Name	Appointment/ Re-appointment/ Resignation/ Cessation	Effective Date	Reason
				rotation, for a period of 3 (three) consecutive years.
13.	K. Ragunathan	Cessation	April 01, 2024	Ceased to be Independent Director upon completion of his term.
14.	Dr. Avnit Bimal Singh	Resignation	February 11, 2024	Resigned as Independent Director.
15.	Deepali Pant Joshi	Appointment	February 10, 2024	Appointed as Independent Director of the Company not liable to retire by rotation, for a period of 2 (two) consecutive years.
16.	Satakarni Makkapati	Appointment	November 09, 2023	Appointed as non-executive and non-independent Director of the Company, liable to retire by rotation.
17.	M. Sivakumaran	Resignation	August 25, 2023	Resigned as director and whole-time director of the Company.
18.	Sarath Chandra Reddy Penaka	Re-appointment	August 25, 2023	Retired by rotation and, being eligible, was re-appointed as non-executive director liable to retire by rotation.
19.	Santanu Mukherjee	Appointment	February 9, 2023	Appointed as Independent Director of the Company for a period of 2 (two) consecutive years.

14.9 The Buyback will not result in any benefit to the members of the Promoter & Promoter Group, persons in control of the Company or any Directors of the Company except to the extent of the cash consideration received by them from the Company pursuant to their respective participation in the Buyback in their capacity as Equity Shareholders of the Company, and the change in their shareholding as per the response received in the Buyback, as a result of the extinguishment of Equity Shares which will lead to reduction in the equity share capital of the Company post Buyback.

14.10 No action has been taken by SEBI in the past against the members of the Promoter & Promoter Group or Directors of the Company, except as set out below:

Pursuant to SEBI's adjudication order dated September 23, 2019 (bearing reference no. Order/MC/VS/2019-20/4550-4556), certain members of the Promoter & Promoter Group of the Company (namely, Trident Chemphar Limited, Venkata Ramprasad Reddy Penaka, Suneela Rani Penaka and Prasada Reddy Kambham, together the "**Concerned Promoters**") had settled certain alleged non-compliances of the SEBI (Prohibition of Insider Trading) Regulations, 1992 and SEBI (Prohibition of Insider Trading) Regulations, 2015, pursuant to SEBI's settlement order dated May 6, 2020 (bearing reference no. SO/EFD-2/SD/346/MAY/2020) and in accordance with the SEBI (Settlement Proceedings) Regulations, 2018, as amended. However, *vide* an email dated October 23, 2020, SEBI informed the Concerned Promoters that there were some calculation errors in the settlement amounts (on account of the component of disgorgement (along with interest) being inadvertently omitted from the settlement terms) and asked the Concerned Promoters to make good the balance amounts. In this regard, the Concerned Promoters filed a writ petition before Hon'ble High Court of Telangana, at Hyderabad. The Hon'ble High Court *vide* its order dated November 18,

2020 had granted interim relief to the Concerned Promoters by way of suspension of the SEBI direction dated October 23, 2020, subject to deposit of ₹ 1.75 Crore with SEBI. Accordingly, the said amount was deposited by the Concerned Promoters and the matter is presently pending for disposal before Hon'ble High Court of Telangana, at Hyderabad.

## 15. FINANCIAL INFORMATION ABOUT THE COMPANY

15.1 The brief audited financial information of the Company as extracted from the audited standalone results for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 (based on the financial statements presented in financial year 2023-2024 restating the March 31, 2023 numbers) and limited reviewed unaudited standalone financial results for the nine months period ended December 31, 2025, are provided below:

(Amount in ₹ Million)

Particulars	Unaudited	Audited		
	For the nine months period ended December 31, 2025	For the year ended on March 31, 2025	For the year ended on March 31, 2024 <sup>1</sup>	For the year ended on March 31, 2023 <sup>1</sup>
Revenue from Operations	83,851.7	109,333.0	106,456.4	84,570.0
Other Income	3,734.4	3,281.2	6,160.6	4,439.2
<b>Total Income</b>	<b>87,586.1</b>	<b>112,614.2</b>	<b>112,617.0</b>	<b>89,009.2</b>
Total expenses (excluding Interest, Depreciation and Exceptional items)	60,746.5	83,757.3	84,216.0	69,520.9
Finance costs	1,658.8	2,300.4	1,826.0	745.8
Depreciation & Amortisation	2,134.3	2,972.0	2,545.8	2,432.6
Exceptional Items	173.8	-	-	-
<b>Profit Before Tax</b>	<b>22,872.7</b>	<b>23,584.5</b>	<b>24,029.2</b>	<b>16,309.9</b>
Tax Expenses (including Deferred Tax)	5,647.0	6,116.6	5,028.2	3,888.2
<b>Net Profit After Tax from continuing operations</b>	<b>17,225.7</b>	<b>17,467.9</b>	<b>19,001.0</b>	<b>12,421.7</b>
Other Comprehensive Income	(25.4)	(52.6)	(16.9)	58.7
<b>Total comprehensive income for the period from continuing operations</b>	<b>17,200.3</b>	<b>17,415.3</b>	<b>18,984.1</b>	<b>12,480.4</b>
Net Profit from discontinued operations (net of tax) <sup>2</sup>			540.4	(150.6)
<b>Total comprehensive income for the period</b>	<b>17,200.3</b>	<b>17,415.3</b>	<b>19,524.5</b>	<b>12,329.8</b>

### Notes:

(1) The composite scheme of amalgamation under Sections 230-232 and other applicable provisions of the Companies Act, 2013 for amalgamation of Mviyes Pharma Ventures Private limited ("Mviyes") and Auronext Pharma Private limited ("Auronext") (together referred to as "Amalgamating Companies") with the Company ("the Scheme") was sanctioned by Hon'ble National Company law Tribunal (NCLT) Hyderabad bench vide order dated April 29, 2024. The Scheme has become effective on May 17, 2024 upon filing of the certified copy of the orders passed by NCLT with the relevant Registrar of Companies. In terms of the Scheme, all the assets, liabilities, reserves and surplus of the Amalgamating Companies have been transferred to and vested in the Company. The amalgamation has been accounted under the 'pooling of interests' method in accordance with Appendix C of Indian Accounting Standard ('Ind AS') 103 'Business Combinations' at the carrying value of the assets and liabilities of the Amalgamating Companies as included in the financial statements of the respective Amalgamating Company. Accordingly, FY23 financials have been restated to give effect of the amalgamation from the beginning of the year.

(2) The Board of Directors of the Company at its meeting held on February 9, 2023 and April 1, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private limited) on a going concern basis by way of slump sale, subject to receipt of requisite regulatory approvals. Consequent to receipt of such approvals, the Company transferred the aforementioned API units to Apitoria Pharma Private Limited with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 "Non-Current Assets Held for Sale and Discontinued Operations", in the standalone financial results for FY2024 and FY2023 have been suitably presented.

(Amount in ₹ Million)

Particulars	Unaudited	Audited		
	For the nine months period ended December 31, 2025	As at March 31, 2025	As at March 31, 2024	As at March 31, 2023
Equity Share capital	580.8	580.8	585.9	585.9
Other Equity	NA	202,917.9	194,805.0	177,917.1
<b>Net Worth</b>	<b>NA</b>	<b>203,498.7</b>	<b>195,390.9</b>	<b>178,503.0</b>
Debt, excluding working capital loans	NA	11,700.0	-	-
Total Debt	NA	46,250.9	28,178.4	41,425.7
- Secured loans	NA	18,424.1	14,319.9	19,227.8
- Unsecured loans	NA	27,826.8	13,858.5	22,197.9

(Amount in ₹, except certain ratios)

Key Ratios	Unaudited	Audited		
	For the nine months period ended December 31, 2025	For the year ended on March 31, 2025	For the year ended on March 31, 2024	For the year ended on March 31, 2023
Basic and Diluted earnings per share from Continuing operations	29.66*	29.97	32.43	21.20
Basic and Diluted earnings per share from Total operations	29.66*	29.97	33.35	20.94
Book value (₹ per share)	NA	350.38	333.47	304.64
Total Debt Equity Ratio	NA	0.23	0.14	0.23
Return on Net Worth (in %)	NA	8.58%	10.00%	6.87%

**\*not annualised**

The key ratios have been computed as below:

Key Ratios	Basis
Basic Earnings per share	PAT / weighted average number of equity shares outstanding
Diluted Earnings per share	PAT / weighted average number of equity shares outstanding
Book value per share	Net worth / Total number of outstanding shares
Total Debt-Equity Ratio	Total Debt <sup>1</sup> / Net worth
Return on Net Worth excluding revaluation reserves (%)	Profit After Tax (PAT) / Net worth
Net Worth	Paid-up equity share capital + securities premium + general reserve + retained earnings of the Company

Other Equity	Securities premium + general reserve + retained earnings of the Company
--------------	---

**Notes:**

(1) Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Non-current borrowings

15.2 The brief audited financial information of the Company as extracted from the audited consolidated results for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023 and limited reviewed unaudited consolidated financial results for the nine months period ended December 31, 2025 are provided below:

(Amount in ₹ Million)

Particulars	Unaudited	Audited		
	For the nine months period ended December 31, 2025	For the year ended on March 31, 2025	For the year ended on March 31, 2024	For the year ended on March 31, 2023
Revenue from operations	247,997.4	317,237.3	290,018.7	248,553.8
Other Income	4,131.4	6,218.5	5,573.8	2,905.9
<b>Total Income</b>	<b>252,128.8</b>	<b>323,455.8</b>	<b>295,592.5</b>	<b>251,459.7</b>
Total Expenses (excluding Interest, Depreciation and Exceptional items)	197,448.8	251,409.4	231,588.7	211,367.4
Finance costs	2,857.6	4,572.4	2,897.1	1404.8
Depreciation & Amortisation	12,996.2	16,494.2	15,216.6	12,445.8
Profit Before Exceptional Items and Tax (Before share of profit from joint ventures)	38,826.2	50,979.8	45,890.1	26,241.7
Exceptional Items	653.3	0.0	1,918.6	-
Profit Before Tax (Before share of profit from joint ventures)	38,172.9	50,979.8	43,971.5	26,241.7
Tax Expenses (including Deferred Tax)	12,391.1	15,827.2	12,110.2	6,848.5
Profit After Tax (before share of profit from joint ventures)	25,781.8	35,152.6	31,861.3	19,393.2
Share of profit of Joint Ventures (Net of tax)	39.5	(316.9)	(171.6)	(116.7)
Profit After Tax from continuing operations	25,821.3	34,835.7	31,689.7	19,276.5
Profit from discontinued operations (Net of tax)	-	-	-	-
Profit for the year including non-controlling interest	25,821.3	34,835.7	31,689.7	19,276.5
Other Comprehensive Income	11,746.4	3,036.2	991.6	7,355.8
Total Comprehensive Income for the period	37,567.7	37,871.9	32,681.3	26,632.3
Profit attributable to				
- Owners of the Company	25,834.9	34,858.8	31,729.7	19,275.0
- Non-Controlling Interest	(13.6)	(23.1)	(40.0)	1.5
Total Comprehensive income attributable to				
- Owners of the Company	37,581.2	37,895.1	32,721.3	26,630.8
- Non-Controlling Interest	(13.5)	(23.2)	(40.0)	1.5

(Amount in ₹ Million)

Particulars	Unaudited	Audited		
	For the nine months period ended December 31, 2025	As at March 31, 2025	As at March 31, 2024	As at March 31, 2023
Equity Share capital	580.8	580.8	585.9	585.9
Other Equity	NA	305,224.6	280,324.7	251,414.6
Net Worth	NA	305,805.4	280,910.6	252,000.5
Debt, excluding working capital loans	NA	26,319.6	22,371.0	6,968.0
Total Debt	NA	79,416.8	63,152.2	48,615.2
- Secured loans	NA	38,272.0	39,683.7	25,573.7
- Unsecured loans	NA	41,144.8	23,468.5	23,041.5

(Amount in ₹, except certain ratios)

Key Ratios	Unaudited	Audited		
	For the nine months period ended December 31, 2025	For the year ended on March 31, 2025	For the year ended on March 31, 2024	For the year ended on March 31, 2023
Basic earnings per share	44.48*	59.81	54.16	32.90
Diluted earnings per share	44.48*	59.81	54.16	32.90
Book value (₹ per share)	NA	526.52	479.42	430.08
Total Debt Equity Ratio	NA	0.26	0.22	0.19
Return on Net Worth (in %)	NA	11.40%	11.28%	7.65%

\*not annualised

The key ratios have been computed as below:

Key Ratios	Basis
Basic Earnings per share	PAT / weighted average number of equity shares outstanding
Diluted Earnings per share	PAT / weighted average number of equity shares outstanding
Book value per share	Net worth / Total number of outstanding shares
Total Debt-Equity Ratio	Total Debt <sup>1</sup> / Net worth
Return on Net Worth excluding revaluation reserves (%)	Profit After Tax (PAT) / Net worth
Net Worth	Paid-up equity share capital + securities premium + general reserve + retained earnings of the Company
Other Equity	Securities premium + general reserve + retained earnings of the Company

Notes:

(1) Total Debt = Current Borrowings + Non-Current Borrowings + Current Portion of Non-current borrowings

15.3 The Company shall comply with the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, wherever and if applicable. The Company hereby declares that it has complied with and will comply with Sections 68, 69 and 70 and other applicable provisions of the Companies Act, as may be applicable to the Buyback.

## 16. STOCK MARKET DATA

16.1 The Shares of the Company are listed on BSE and NSE. The Equity Shares are currently traded under the scrip code 524804 at BSE and trading code AUROPHARMA at NSE.

16.2 The high, low and average market prices in preceding 3 (Three) financial years and the monthly high, low and average market prices for the 6 (Six) months preceding the date of the Public Announcement, and the corresponding volumes on BSE and NSE are given below:

### BSE:

Period	High# (₹)	Date of High	Number of Equity Shares traded on that date	Low# (₹)	Date of Low	Number of Equity Shares on that date	Average Price* (₹)	Total volume traded of Equity Shares in the period (number of Equity Shares)
<b>Preceding 3 (three) Years</b>								
April 1, 2025 to March 31, 2026	1,330.9	March 27, 2026	48,321	994.35	April 07, 2025	64,927	1,157.67	14,348,364
April 1, 2024 to March 31, 2025	1,592.55	September 13, 2024	69,272	1,030.65	March 04, 2025	11,107	1,283.58	8,140,071
April 1, 2023 to March 31, 2024	1,177	January 30, 2024	32,287	517	April 03, 2023	40,868	873.07	22,759,027
<b>Preceding 6 (six) months</b>								
March 1, 2026 to March 31, 2026	1,330.9	March 27, 2026	48,321	1,180	March 04, 2026	23,141	1,272.16	1,894,953
February 1, 2026 to February 28, 2026	1,250.85	February 26, 2026	222,816	1,106.25	February 10, 2026	270,367	1,179.45	2,618,256
January 1, 2026 to January 31, 2026	1,270.4	January 07, 2026	78,303	1,115.8	January 21, 2026	10,828	1,176.03	1,162,597
December 1, 2025 to December 31, 2025	1,240	December 19, 2025	31,605	1,157.05	December 09, 2025	61,66	1,198.88	466,888
November 1, 2025 to November 30, 2025	1,249.9	November 18, 2025	33,935	1,120.2	November 07, 2025	15,778	1,196.16	703,602
October 1, 2025 to October 31, 2025	1,156	October 31, 2025	228,796	1,066	October 08, 2025	13,434	1,104.57	916,504

Source: [www.bseindia.com](http://www.bseindia.com)

\*Arithmetical average of closing prices; #High and low are based on high and low of daily high and daily low prices respectively.

**NSE:**

Period	High# (₹)	Date of High	Number of Equity Shares traded on that date	Low# (₹)	Date of Low	Number of Equity Shares on that date	Average Price* (₹)	Total volume traded of Equity Shares in the period (number of Equity Shares)
<b>Preceding 3 (three) Years</b>								
April 1, 2025 to March 31, 2026	1,330	March 25, 2026	1,891,714	1,010	April 07, 2025	2,733,813	1,157.68	336,741,968
April 1, 2024 to March 31, 2025	1,592	September 13, 2024	1,185,312	1,031.05	March 04, 2025	730,626	1,283.69	312,321,123
April 1, 2023 to March 31, 2024	1,177.10	January 30, 2024	1,317,033	516.45	April 03, 2023	2,011,656	873.18	534,071,445
<b>Preceding 6 (six) months</b>								
March 1, 2026 to March 31, 2026	1,330	March 25, 2026	1,891,714	1,179.80	March 04, 2026	909,693	1,272.09	29,969,946
February 1, 2026 to February 28, 2026	1,250.90	February 26, 2026	2,372,711	1,106	February 10, 2026	8,584,671	1,179.10	45,889,763
January 1, 2026 to January 31, 2026	1,270.80	January 07, 2026	2,361,570	1,116.20	January 27, 2026	656,428	1,175.87	23,761,983
December 1, 2025 to December 31, 2025	1,240.70	December 19, 2025	1,396,499	1,160.50	December 09, 2025	585,926	1,199.24	15,459,233
November 1, 2025 to November 30, 2025	1,249.90	November 18, 2025	1,827,771	1,120	November 07, 2025	363,582	1,196.26	25,010,542
October 1, 2025 to October 31, 2025	1,155.80	October 31, 2025	3,557,298	1,066.80	October 08, 2025	549,749	1,104.57	27,031,830

Source: [www.nseindia.com](http://www.nseindia.com)

\*Arithmetical average of closing prices; #High and low are based on high and low of daily high and daily low prices respectively

- 16.3 The notice of the Board Meeting convened to consider the proposal of the Buyback was given to BSE and NSE on Tuesday, March 31, 2026, i.e. the Intimation Date. The Board, at its meeting held on Monday, April 6, 2026, approved the proposal for the Buyback at ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share and the intimation was sent to BSE and NSE on the same day. The closing market price of the Equity Shares on BSE and NSE during this period, are summarized below:

Event	Date	BSE (₹)	NSE (₹)
1 (one) trading day prior to the Intimation Date	March 30, 2026	1,303.20	1,304.40
1 (one) trading day post the Intimation Date	April 1, 2026	1,342.10	1,342.10

1 (one) trading day prior to the Board Meeting	April 2, 2026	1,335.95	1,333.70
Date of the Board Meeting	April 6, 2026	1,339.80	1,340.40
1 (one) trading day post the Board Meeting	April 7, 2026	1,329.60	1,330.00
Date of Public Announcement	April 7, 2026	1,329.60	1,330.00
Date of publication of the Public Announcement	April 8, 2026	1,335.10	1,335.70
1 (one) trading day post the publication of the Public Announcement	April 9, 2026	1,339.50	1,340.40

Source: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com)

## 17. DETAILS OF STATUTORY APPROVALS

- 17.1 The Board, at its meeting held on Monday, April 6, 2026, approved the proposal for the Buyback. The Buyback will be subject to such necessary approvals as may be required under the applicable laws including from SEBI and/ or BSE or NSE, and the Buyback from Non-Resident Shareholders, erstwhile overseas corporate bodies and other applicable categories will be subject to such approvals of the RBI, if any, under FEMA and/or such other applicable rules and regulations in force for the time being.
- 17.2 The Buyback from each Eligible Shareholder is subject to all statutory consents and approvals as may be required by such Eligible Shareholder under applicable laws and regulations. The Eligible Shareholder shall be solely responsible for obtaining all such statutory consents and approvals (including, without limitation the approval from the RBI, if any) as may be required by them in order to sell their Equity Shares to the Company pursuant to the Buyback. An Eligible Shareholder would be required to provide copies of all such consents and approvals obtained by them to the Registrar to the Buyback. The Buyback of Equity Shares from Non-Resident Shareholders will be subject to approvals, if any, of the appropriate authorities, including RBI under FEMA, as applicable. It is the obligation of such Non-Resident Shareholders, to obtain such approvals and submit such approvals along with the Tender Form, so as to enable them to tender Equity Shares in the Buyback and for the Company to purchase such Equity Shares, tendered. The Company will have the right to make payment to the Eligible Shareholders in respect of whom no prior RBI approval is required and not accept Equity Shares from the Eligible Shareholders in respect of whom prior RBI approval is required in the event copies of such approvals are not submitted.
- 17.3 By participating in the Buyback, the Non-Resident Shareholders give the Company the authority to make, sign, execute, deliver, acknowledge and perform all applications to file regulatory reporting(s), if required, and such Non-Resident Shareholders undertake to provide assistance to the Company for such regulatory reporting, if required by the Company
- 17.4 As of date, there is no other statutory or regulatory approval required to implement the Buyback, other than that indicated above. If any statutory or regulatory approval becomes applicable subsequently, the Buyback Offer will be subject to such statutory or regulatory approval(s). In the event of any delay in receipt of any statutory / regulatory approvals, changes to the proposed timetable of the Buyback Offer, if any, shall be intimated to the Stock Exchanges.

## 18. DETAILS OF THE REGISTRAR TO THE BUYBACK

- 18.1 Eligible Shareholders who wish to tender their Equity Shares in the Buyback can send the Tender Form by registered post/ speed post or hand deliver the same, along with the TRS generated by the exchange bidding system along with all relevant documents by super-scribing the envelope as “**Aurobindo Pharma Limited Buyback Offer 2026**”, to the Registrar to the Buyback at its office set out below, so that the same are received on or before the Buyback Closing Date i.e., Wednesday, April 29, 2026 by 5:00 pm (IST).



KFin Technologies Limited

**Address:** Selenium, Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana - 500032

**Tel. no.:** +91 40 6716 2222; **Tollfree no.:** 18003094001; **Fax no.:** +91 40 6716 1563;

**Contact person:** M Murali Krishna

**Toll Free number:** 18003094001

**Email:** [aurobindo.buyback2026@kfintech.com](mailto:aurobindo.buyback2026@kfintech.com)

**Website:** [www.kfintech.com](http://www.kfintech.com)

**Investor Grievance mail:** [inward.ris@kfintech.com](mailto:inward.ris@kfintech.com)

**SEBI Registration Number:** INR000000221

**Validity:** Permanent

**CIN:** L72400MH2017PLC444072

- 18.2 In case of any query, the Shareholders may contact the Registrar to the Buyback, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays at the above-mentioned address.
- 18.3 For the Eligible Shareholders holding Equity Shares in dematerialised form, the Tender Form and TRS are not required to be submitted to the Company, Manager or the Registrar. After the confirmation of lien marked in demat account of the Eligible Shareholders to the Clearing Corporation and a valid bid in the exchange bidding system, the bid for buyback shall be deemed to have been accepted for Eligible Shareholders holding the Equity Shares in dematerialised form.

**ELIGIBLE SHAREHOLDERS ARE REQUESTED TO NOTE THAT THE TENDER FORM, TRS AND OTHER RELEVANT DOCUMENTS SHOULD NOT BE SENT TO THE COMPANY OR TO THE MANAGER TO THE BUYBACK.**

**ELIGIBLE SHAREHOLDERS ARE ADVISED TO ENSURE THAT THE TENDER FORM, TRS AND OTHER RELEVANT DOCUMENTS ARE COMPLETE IN ALL RESPECTS. OTHERWISE, THE SAME ARE LIABLE TO BE REJECTED.**

## 19. PROCESS AND METHODOLOGY FOR THE BUYBACK

- 19.1 The Company proposes to Buyback up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares, representing approximately 0.93% of the total number of outstanding Equity Shares of the Company as of March 31, 2025 and December 31, 2025, from the Eligible Shareholders, on a proportionate basis, through the Tender Offer route, at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share, payable in cash for an aggregate amount up to ₹ 800,00,00,000/-

(Rupees Eight Hundred Crore only), which constitutes 3.93% and 2.62% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the latest audited standalone and consolidated financial statements of the Company as at March 31, 2025, respectively, and is within the statutory limit of 10% of the aggregate of the total paid-up equity share capital and free reserves (including securities premium) of the Company as per the audited standalone and consolidated financial statements of the Company as at March 31, 2025 (i.e., the last audited financial statements available as on the date of Board Meeting recommending the proposal of the Buyback), under the Board approval route as per Section 68 and other applicable provisions of the Companies Act and Regulation 5 and other applicable provisions of the Buyback Regulations. Further, since the Equity Shares proposed to be bought back represents approximately 0.93% of the total number of outstanding Equity Shares of the Company as of March 31, 2025 and December 31, 2025, the same is within the 25% limit as per the provisions of the Companies Act and Regulation 4(i) of the Buyback Regulations. The Buyback is in accordance with Article 40(b) of the Articles of Association of the Company and Sections 68, 69, 70 and all other applicable provisions, if any, of the Companies Act, and rules framed thereunder, including the Share Capital Rules, the Management Rules, the Listing Regulations to the extent applicable, Buyback Regulations read with SEBI Circulars, subject to such other approvals, permissions, consents, exemptions and sanctions, as may be necessary and subject to any modifications and conditions, if any, as may be prescribed by SEBI, ROC, NSE, BSE and/ or other authorities, institutions or bodies, as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions, sanctions and exemptions, which may be agreed by the Board.

- 19.2 The Company expresses no opinion as to whether Eligible Shareholders should participate in the Buyback and, accordingly, Eligible Shareholders may take their own decision after consulting their own advisors, as they may deem fit, regarding their participation in the Buyback.
- 19.3 The aggregate shareholding of the members of the Promoter & Promoter Group as on the date of the Public Announcement and the date of this Letter of Offer is 30,09,48,721 Equity Shares, which represents 51.82% of the existing equity share capital of the Company. In terms of the Buyback Regulations, under the Tender Offer route, the members of the Promoter & Promoter Group and persons in control of the Company have the option to participate in the Buyback. In this regard, the members of the Promoter & Promoter Group *vide* their letters dated Tuesday, April 7, 2026, have expressed their intention to participate in the Buyback and tender up to the number of Equity Shares set out in the table below, or such lower number of Equity Shares as permitted under the applicable law:

Sr. No.	Name	Number of Equity Shares held	Maximum number of Equity Shares intended to be tendered up to
1.	Venkata Ramprasad Reddy Penaka	1,78,33,646	3,22,000
2.	K Nithyananda Reddy	2,53,59,572	4,58,000
3.	M Sivakumaran	1,43,57,432	2,60,000
4.	K Rajeshwari	18,08,631	33,000
5.	Suneela Rani Penaka	1,28,799	3,000
6.	Prasada Reddy Kambham	2,98,373	6,000
7.	K Suryaprakash Reddy	7,380	Nil

8.	M Sumanth Kumar Reddy	15,85,214	29,000
9.	Kirthi Reddy Kambam	2,00,62,852	3,62,000
10.	Kambam Spoorthi	69,39,173	1,26,000
11.	Trident Chemphar Limited	7,82,241	15,000
12.	Axis Clinicals Limited	6,51,920	12,000
13.	RPR Sons Advisors Private Limited, Suneela Rani Penaka (joint holding)	19,45,61,357	35,07,000
14.	Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Private Limited (joint holding)	1,65,72,131	3,00,000
<b>Total</b>		<b>30,09,48,721</b>	<b>54,33,000</b>

19.4 Assuming the response to the Buyback is to the extent of 100% (full acceptance) from all the Eligible Shareholders up to their Entitlement including the members of the Promoter & Promoter Group, the aggregate shareholding and the voting rights of the members of the Promoter & Promoter Group, may increase to 51.88% post Buyback from the current pre Buyback shareholding of 51.82%, and the aggregate shareholding of the public Shareholders in the Company may decrease to 48.12% post Buyback from the current pre Buyback shareholding of 48.18%.

#### 19.5 Record Date and Ratio of Buyback as per the Buyback Entitlement of each category

19.5.1 As required under the Buyback Regulations, the Board has fixed Friday, April 17, 2026 as the Record Date for the purpose of determining the Entitlement and the names of the Eligible Shareholders, who are eligible to participate in the Buyback.

19.5.2 The Equity Shares proposed to be bought back by the Company shall be divided into two categories:

- (i) Reserved category for Small Shareholders (“**Reserved Category**”); and
- (ii) General category for other Eligible Shareholders (“**General Category**”).

19.5.3 As defined in Regulation 2(i)(n) of the Buyback Regulations, a “**Small Shareholder**” is a shareholder of the Company who holds Equity Shares whose market value, on the basis of the closing price of the Equity Shares on BSE and NSE having the highest trading volume as on the Record Date, is not more than ₹ 2,00,000/- (Rupees Two Lakh only). As on the Record Date, the closing price on NSE, having the highest trading volume, was ₹ 1,386.00/- per Equity Share. Accordingly, all Eligible Shareholders holding not more than 144 Equity Shares as on the Record Date are classified as ‘Small Shareholders’ for the purpose of the Buyback.

19.5.4 Based on the above definition, there are 2,22,775 Small Shareholders with aggregate shareholding of 70,90,045 Equity Shares, as on the Record Date, which constitutes 1.22% of the outstanding number of Equity Shares of the Company and 130.72% of the maximum number of Equity Shares which are proposed to be bought back as part of this Buyback. 57,37,11,578 Equity Shares were held by the other Eligible Shareholders in the General Category as on the Record Date.

19.5.5 In accordance with Regulation 6 of the Buyback Regulations, the reservation for the Small Shareholders, will be higher of:

- (i) 15% of the number of Equity Shares which the Company proposes to Buyback i.e., 15% of 54,23,728 Equity Shares which works out to 8,13,560 Equity Shares; or
- (ii) The number of Equity Shares to which the Small Shareholders are entitled, as per their shareholding as on Record Date i.e.,  $[(70,90,045 / 58,08,01,623) \times 54,23,728]$  which works out to 66,210 Equity Shares.

All the outstanding Equity Shares have been taken into account for computing the Entitlement.

19.5.6 Based on the above analysis and in accordance with Regulation 6 of the Buyback Regulations, 8,13,560 Equity Shares have been reserved for the Small Shareholders (“**Reserved Category**”) and accordingly, the General Category for all other Eligible Shareholders shall consist of 46,10,168 Equity Shares (“**General Category**”).

## 19.6 Category wise Entitlement Ratio of Buyback

Based on the above, the Entitlement ratio of Buyback for both categories is decided as below:

Category	Indicative Entitlement Ratio of Buyback*
<b>Reserved Category</b>	7 Equity Shares out of every 61 Equity Shares held on the Record Date
<b>General Category</b>	2 Equity Shares out of every 249 Equity Shares held on the Record Date

*\*The above Ratio of Buyback is approximate and providing indicative Buyback Entitlement. Any computation of entitled Equity Shares using the above Ratio of Buyback may provide a slightly different number due to rounding-off. The actual Buyback Entitlement for Reserved Category for Small Shareholders is 11.4746803440599% and General Category for all other Eligible Shareholders is 0.8035689319835%.*

## 19.7 Illustration of Entitlement Ratio

19.7.1 For Small Shareholders – Eligible Shareholder holding 1000 Equity Shares will receive an entitlement of 114 Equity Shares (11.4746803440599% of 1000 Equity shares held on the Record Date). The Company will accept 100% Equity Shares who have validly tendered their Equity Shares to the extent of their Buyback Entitlement or the number of Equity Shares tendered by them, whichever is less. Additional equity shares will be accepted based on proportionate basis as described in Paragraph 19 on page no. 53 of this Letter of Offer.

19.7.2 For General Shareholders – Eligible Shareholder holding 1000 Equity Shares will receive an entitlement of 8 Equity shares (0.8035689319835% of 1000 Equity shares held on the Record Date). The Company will accept 100% Equity Shares who have validly tendered their Equity Shares to the extent of their Buyback Entitlement or the number of Equity Shares tendered by them, whichever is less. Additional equity shares will be accepted based on proportionate basis as described in Paragraph 19 on page no. 53 of this Letter of Offer.

## 19.8 Fractional Entitlements

If the Entitlement under Buyback, after applying the above mentioned ratios to the Equity Shares held on Record Date, is not a round number (i.e., not in the multiple of 1 Equity Share) then the fractional Entitlement shall be ignored for computation of Buyback Entitlement to tender Equity Shares in the Buyback Offer, for both categories of Eligible Shareholders.

On account of ignoring the fractional Entitlement, those Small Shareholders who hold 8 or less Equity Shares as on Record Date, will be dispatched a Tender Form with zero Entitlement. Such Small Shareholders are entitled to tender Additional Equity Shares as part of the Buyback Offer and will be given preference in the acceptance of one Equity Share, if such Small Shareholders have tendered Additional Equity Shares.

#### 19.9 **Basis of Acceptance of Equity Shares validly tendered in the Reserved Category**

Subject to the provisions contained in this Letter of Offer, the Company will accept the Equity Shares tendered in the Buyback by the Small Shareholders in the Reserved Category in the following order of priority:

- 19.9.1 Acceptance of 100% Equity Shares from Small Shareholders in the Reserved Category who have validly tendered their Equity Shares, to the extent of their Buyback Entitlement, or the number of Equity Shares tendered by them, whichever is less.
- 19.9.2 Post the Acceptance as described in paragraph 19.9.1 above, in case, there are any Equity Shares left to be bought back from the Small Shareholders in the Reserved Category, the Small Shareholders who were entitled to tender zero Equity Shares (on account of fractional Entitlement), and have tendered Additional Equity Shares as part of the Buyback, shall be given preference and one Equity Share each from the Additional Equity Shares tendered by these Small Shareholders shall be bought back in the Reserved Category.
- 19.9.3 Post the Acceptance as described in paragraphs 19.9.1 and 19.9.2 above, in case, there are any validly tendered unaccepted Equity Shares in the Reserved Category ("**Reserved Category Additional Shares**") and Equity Shares left to be bought back in Reserved Category, the Reserved Category Additional Shares shall be accepted in a proportionate manner and the Acceptances shall be made in accordance with the Buyback Regulations, i.e., valid Acceptances per Eligible Shareholder shall be equal to the Reserved Category Additional Shares validly tendered by the Eligible Shareholder divided by the total Reserved Category Additional Shares and multiplied by the total number of Equity Shares remaining to be bought back in Reserved Category. For the purpose of this calculation, the Reserved Category Additional Shares taken into account for such Small Shareholders, from whom one Equity Share has been Accepted in accordance with paragraph 19.9.2 above, shall be reduced by one.
- 19.9.4 Adjustment for fractional results in case of proportionate Acceptance, as described in paragraph 19.9.3 above, will be made as follows:
  - (i) For any Small Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50 (point five zero), then the fraction would be rounded off to the next higher integer.
  - (ii) For any Small Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.10 **Basis of Acceptance of Equity Shares validly tendered in the General Category**

Subject to the provisions contained in this Letter of Offer, the Company will Accept the Equity Shares tendered in the Buyback Offer by Eligible Shareholders (other than Small Shareholders) in the General Category in the following order of priority:

19.10.1 Acceptance of 100% Equity Shares from Eligible Shareholders in the General Category who have validly tendered their Equity Shares, to the extent of their Buyback Entitlement, or the number of Shares tendered by them, whichever is less.

19.10.2 Post the Acceptance as described in paragraph 19.10.1 above, in case, there are any validly tendered unaccepted Equity Shares in the General Category (“**General Category Additional Shares**”) and Equity Shares left to be bought back in General Category, the General Category Additional Shares shall be accepted in a proportionate manner and the Acceptances shall be made in accordance with the Buyback Regulations, i.e., valid Acceptances per Eligible Shareholder shall be equal to the General Category Additional Shares validly tendered by the Eligible Shareholder divided by the total General Category Additional Shares and multiplied by the total number of Shares remaining to be bought back in General Category.

19.10.3 Adjustment for fractional results in case of proportionate Acceptance, as described in paragraph 19.10.2 above, will be made as follows:

- (i) For any Eligible Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50 (point five zero), then the fraction would be rounded off to the next higher integer.
- (ii) For any Eligible Shareholder, if the number of Additional Equity Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

#### 19.11 **Basis of Acceptance of Equity Shares between the two categories**

19.11.1 After Acceptances of Equity Shares, as mentioned in paragraphs 19.9 and 19.10 above, in case, there are any Equity Shares left to be bought back in one category (“**Partially Filled Category**”) and there are additional unaccepted validly tendered

Equity Shares (“**Further Additional Shares**”) in the second category (“**Over Tendered Category**”), then the Further Additional Shares in the Over Tendered Category shall be Accepted in a proportionate manner i.e., valid Acceptances per Eligible Shareholder shall be equal to Further Additional Shares validly tendered by the Eligible Shareholder in the Over Tendered Category divided by the total Further Additional Shares in the Over Tendered Category and multiplied by the total Shares left to be bought back in the Partially Filled Category.

- 19.11.2 If the Partially Filled Category is the General Category and the Over Tendered Category is the Reserved Category, then any Small Shareholder who has received a Tender Form with zero Buyback Entitlement and who has tendered Additional Equity Shares shall be eligible for priority Acceptance of one Equity Share before Acceptance in paragraph 19.11.1 out of the Equity Shares left to be bought back in the Partially Filled Category provided no Acceptance could take place from such Shareholder in accordance with paragraph 19.9 of this Letter of Offer.
- 19.11.3 Adjustment for fraction results in case of proportionate Acceptance, as defined in paragraphs 19.11.1 and 19.11.2 above:
- (i) For any Eligible Shareholder, if the number of Further Additional Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is greater than or equal to 0.50 (point five zero), then the fraction would be rounded off to the next higher integer.
  - (ii) For any Eligible Shareholder, if the number of Further Additional Shares to be Accepted, calculated on a proportionate basis is not in the multiple of 1 (one) and the fractional Acceptance is less than 0.50 (point five zero), then the fraction shall be ignored.

In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, the Buyback Committee or any person(s) authorized by the Buyback Committee will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

**19.12 For avoidance of doubt, it is clarified that, in accordance with the clauses above:**

- 19.12.1 Equity Shares Accepted under the Buyback from each Eligible Shareholder, shall be lower of the following:
- (i) the number of Equity Shares tendered by the respective Eligible Shareholder; and
  - (ii) the number of Equity Shares held by the respective Eligible Shareholder, as on the Record Date.
- 19.12.2 Equity Shares tendered by any Eligible Shareholder over and above the number of Equity Shares held by such Eligible Shareholder as on the Record Date shall not be considered for the purpose of Acceptance.
- 19.12.3 In case of any practical issues, resulting out of rounding-off of Equity Shares or otherwise, any person(s) authorized by the Board will have the authority to decide such final allocation with respect to such rounding-off or any excess of Equity Shares

or any shortage of Equity Shares after allocation of Equity Shares as set out in the process described in paragraph 19 of this Letter of Offer.

### **19.13 Clubbing of Entitlement**

In accordance with Regulation 9(ix) of the Buyback Regulations, in order to ensure that the same Eligible Shareholders with multiple demat accounts/ folios do not receive a higher Entitlement under the Small Shareholder category, the Company proposes to club together the Equity Shares held by such Eligible Shareholders with a common PAN for determining the category (Small Shareholder or General) and Entitlement under the Buyback. In case of joint shareholding, the Company will club together the Equity Shares held in cases where the sequence of the PANs of the joint Shareholders is identical and where the PANs of all joint Shareholders are not available, the Company will check the sequence of the names of the joint holders and club together the Equity Shares held in such cases where the name of joint Shareholders is identical. In case of Eligible Shareholders holding Equity Shares in physical form, where the sequence of PANs is identical and where the PANs of all joint Shareholders are not available, the Company will check the sequence of the names of the joint holders and club together the Equity Shares held in such cases where the sequence of the PANs and name of joint Shareholders are identical. The shareholding of institutional investors like mutual funds, pension funds/trusts and insurance companies etc., with common PAN will not be clubbed together for determining the category and will be considered separately, where these Equity Shares are held for different schemes and have a different demat account nomenclature based on information prepared by the Registrar to the Buyback as per the Shareholder records received from the Depositories. Further, the Equity Shares held under the category of “clearing members” or “corporate body margin account” or “corporate body –broker” as per the beneficial position data as on the Record Date, with common PAN, are not proposed to be clubbed together for determining their Entitlement and will be considered separately, where these Equity Shares are assumed to be held on behalf of clients.

## **20. PROCEDURE FOR TENDERING SHARES AND SETTLEMENT**

- 20.1 The Buyback is open to all Eligible Shareholders holding Equity Shares either in physical and/or in dematerialized form as on Record Date.
- 20.2 The Company proposes to effect the Buyback through the Tender Offer route through Stock Exchange Mechanism, on a proportionate basis. The Letter of Offer and Tender Form, outlining the terms of the Buyback as well as the detailed disclosures as specified in the Buyback Regulations, will be e-mailed to Eligible Shareholders. The Eligible Shareholders who have registered their email IDs with the Depositories/ the Company, shall be dispatched the Letter of Offer through electronic means.
- 20.3 In case an Eligible Shareholder requests for a copy of this Letter of Offer in physical form, the same shall be provided by the Company. In case of non-receipt of Letter of Offer and the Tender Form, please follow the procedure as mentioned in paragraph 20.28 of this Letter of Offer.
- 20.4 The Company will not accept any Equity Shares tendered for Buyback which are under any restraint order of the court/ any other competent authority for transfer/ sale and/ or title in respect of which is otherwise under dispute or where loss of share certificates has been notified to the Company and the duplicate share certificates have not been issued either due to such request being under process as per the provisions of law or otherwise. The Company shall comply with Regulation 24(v) of the Buyback Regulations which states that the Company

shall not buyback locked-in Equity Shares and non-transferable Equity Shares till the pendency of the lock-in or till such Equity Shares become transferable. The Company shall also not accept the Equity Shares offered for Buyback where the title to such Equity Shares is under dispute or otherwise not clear.

- 20.5 Eligible Shareholders will have to transfer the Equity Shares from the same demat account in which they were holding the Equity Shares as on the Record Date and in case of multiple demat accounts, Eligible Shareholders are required to tender the applications separately from each demat account. In case of any changes in the demat account in which the Equity Shares were held as on Record Date, such Eligible Shareholders should provide sufficient proof of the same to the Registrar to the Buyback and such tendered Equity Shares may be accepted subject to appropriate verification and validation by the Registrar to the Buyback. The Board or Buyback Committee authorized by the Board will have the authority to decide such final allocation in case of non-receipt of sufficient proof by such Eligible Shareholder.

For the Clearing Corporation to make a payout of more than ₹ 50,00,00,000 (Rupees Fifty Crore only), a Legal Entity Identifier (LEI) number of the Eligible Shareholder will have to be provided. Accordingly, an Eligible Shareholder who is tendering shares of value more than ₹ 50,00,00,000 (Rupees Fifty Crore only) will have to provide LEI number with the relevant supporting documents such as the LEI registration certificate to the Registrar through email at aurobindo.buyback2026@kfintech.com latest by 5:00 p.m. (IST) on the Buyback Closing Date.

- 20.6 As elaborated under paragraphs 19.6 and 19.7 above, the Equity Shares proposed to be bought as a part of the Buyback are divided into two categories: (a) Reserved Category for Small Shareholders and (b) the General Category for all other Eligible Shareholders. The Buyback Entitlement of Eligible Shareholders in each category shall be calculated accordingly.
- 20.7 Post Acceptance of the Equity Shares tendered on the basis of Buyback Entitlement, Equity Shares left to be bought as a part of the Buyback, if any, in one category shall first be accepted, in proportion to the Equity Shares tendered, over and above their Buyback Entitlement, by Eligible Shareholders in that category, and thereafter, from Eligible Shareholders who have tendered over and above their Buyback Entitlement, in the other category.
- 20.8 All purchases pursuant to the Buyback will be paid for in ₹, including to holders of Equity Shares who are resident outside India. Payment of consideration to Eligible Shareholders shall be made within 5 (Five) Working Days of the Buyback Closing Date as required under the Buyback Regulations. Accordingly, the Registrar to the Buyback will process the bids under the Buyback as promptly as practicable after the Buyback Closing Date, and the Company expects to start making payments for accepted bids as promptly as practicable and within 5 (Five) Working Days after the Buyback Closing Date.
- 20.9 The participation of Eligible Shareholders in the Buyback is voluntary. Eligible Shareholders holding Equity Shares of the Company may choose to participate, in full or in part, and get cash in lieu of shares to be accepted under the Buyback or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post-Buyback, without additional investment. Eligible Shareholders holding Equity Shares of the Company may also accept a part of their Entitlement. Eligible Shareholders holding Equity Shares of the Company also have the option of tendering Additional Equity Shares (over and above their Entitlement) and participate in the shortfall created due to non-participation of some other Eligible Shareholders, if any. If the Buyback Entitlement for any Eligible Shareholder is not a round number, the fractional entitlement shall be ignored for computation of entitlement to tender

Equity Shares in the Buyback. The Acceptance of any Equity Shares tendered in excess of the Buyback Entitlement by the Eligible Shareholder shall be in terms of the procedure outlined herein. In case any Eligible Shareholder or any person claiming to be an Eligible Shareholder cannot participate in the Buyback Offer for any reason, the Company, the Manager and Registrar to the Buyback and their officers shall not be liable in any manner for such non-participation.

- 20.10 The maximum number of Equity Shares that can be tendered under the Buyback by any Eligible Shareholder cannot exceed the number of Equity Shares held by the Eligible Shareholder as on the Record Date. In case the Eligible Shareholder holds Equity Shares through multiple demat accounts, the tender through a demat account cannot exceed the number of Equity Shares held in that demat account.
- 20.11 The Company shall accept all the Equity Shares validly tendered for the Buyback by Eligible Shareholders, on the basis of their Buyback Entitlement as on the Record Date.
- 20.12 The Buyback shall be implemented using the “Mechanism for acquisition of shares through Stock Exchange” as specified by the SEBI Circulars and following the procedure prescribed in the Companies Act, the Share Capital Rules and the Buyback Regulations and as may be determined by the Board (including the Buyback Committee authorized to complete the formalities of the Buyback) and on such terms and conditions as may be permitted by law from time to time.
- 20.13 For implementation of the Buyback, the Company has appointed Axis Capital Limited as the registered broker to the Company (“**Company’s Broker**”) to facilitate the process of tendering of Equity Shares through the Stock Exchange Mechanism for the Buyback and through whom the purchases and settlements on account of the Buyback would be made by the Company. The contact details of the Company’s Broker are as follows:



**AXIS CAPITAL LIMITED**

1<sup>st</sup> Floor, Axis House, P. B. Marg, Worli, Mumbai - 400 025

**Tel:** +91 22 4325 5517; **Fax:** +91 22 4325 3000

**Contact Person:** Ankit Gala

**Email:** [apl.buyback@axiscap.in](mailto:apl.buyback@axiscap.in)

**SEBI Registration Number:** INZ000189931

- 20.14 BSE will be the Designated Stock Exchange for the purpose of this Buyback. The Company will request BSE to provide the separate acquisition window (“**Acquisition Window**”) to facilitate placing of sell orders by Eligible Shareholders who wish to tender Equity Shares in the Buyback. The details of the Acquisition Window will be specified by BSE from time to time.
- 20.15 During the tendering period, the order for selling the Equity Shares will be placed in the Acquisition Window by Eligible Shareholders through their respective stock broker(s) (“**Seller Member(s)**”) during normal trading hours of the secondary market. The Seller Member can enter orders for Equity Shares held in dematerialized form and physical form. In the tendering process, the Company’s Broker may also process the orders received from the Eligible Shareholders.

- 20.16 In the event the Seller Member(s) of any Eligible Shareholder is not registered with BSE as a trading member/ stock broker, then that Eligible Shareholder can approach any BSE registered stock broker and can register themselves by using quick unique client code (“UCC”) facility through the BSE registered stock broker (after submitting all details as may be required by such BSE registered stock broker in compliance with applicable law). In case the Eligible Shareholders are unable to register using UCC facility through any other BSE registered broker, Eligible Shareholders may approach Company’s Broker i.e., Axis Capital Limited to place their bids, subject to completion of KYC requirements as required by the Company’s Broker.
- 20.17 Eligible Shareholders approaching a stockbroker registered with the BSE (with whom they do not have an account) may have to submit the requisite documents as may be required. The requirement of documents and procedures may vary from broker to broker, and may *inter alia* include:

**In case of Eligible Seller being an individual**

**If Eligible Seller is registered with KYC Registration Agency (“KRA”):** Forms required:

- Central Know Your Client (CKYC) form including FATCA, IPV, OSV if applicable
- Know Your Client (KYC) form documents required (all documents self-attested):
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

**If Eligible Seller is not registered with KRA:** Forms required:

- CKYC form including FATCA, IPV, OSV if applicable
- KRA form
- KYC form documents required (all documents self-attested):
  - PAN card copy
  - Address proof
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

It may be noted that other than submission of above forms and documents in person verification may be required.

**In case of Eligible Seller is HUF:**

**If Eligible Seller is registered with KRA:** Forms required:

- CKYC form of karta including FATCA, IPV, OSV if applicable
- KYC form documents required (all documents self-attested):
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

**If Eligible Seller is not registered with KRA:** Forms required:

- CKYC form of karta including FATCA, IPV, OSV if applicable
- KRA form
- KYC form documents required (all documents self-attested):
  - PAN card copy of HUF & karta
  - Address proof of HUF & karta
  - HUF declaration
  - Bank details (cancelled cheque)

- Demat details only if Equity Shares are in dematerialised form (demat master/ latest demat statement)

It may be noted that other than submission of above forms and documents in person verification may be required.

**In case of Eligible Seller other than Individual and HUF:**

**If Eligible Seller is KRA registered:** Form required

- KYC form documents required (all documents certified true copy)
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master /latest demat statement)
- FATCA, IPV, OSV if applicable
- Latest list of directors/authorised signatories/partners/trustees
- Latest shareholding pattern
- Board resolution
- Details of ultimate beneficial owner along with PAN card and address proof
- Last 2 (two) years financial statements

**If Eligible Seller is not KRA registered:** Forms required:

- KRA form
- KYC form documents required (all documents certified true copy):
  - PAN card copy of company/ firm/trust
  - Address proof of company/ firm/trust
  - Bank details (cancelled cheque)
- Demat details only if Equity Shares are in dematerialised form (demat master /latest demat statement)
- FATCA, IPV, OSV if applicable
- Latest list of directors/authorised signatories/partners/trustees
- PAN card copies & address proof of Directors/authorised signatories/partners/trustees
- Latest shareholding pattern
- Board resolution/partnership declaration
- Details of ultimate beneficial owner along with PAN card and address proof
- Last 2 (two) years financial statements
- MOA/Partnership deed /trust deed

It may be noted that above mentioned list of documents is an indicative list. The requirement of documents and procedures may vary from broker to broker.

20.18 All Eligible Shareholders, through their respective Seller Member/ stock broker(s), will be eligible and responsible to place orders in the Acquisition Window.

20.19 During the Tendering Period, the order for selling the Equity Shares will be placed in the Acquisition Window by Eligible Shareholders through their respective Seller Member(s) during normal trading hours of the secondary market. The Seller Member can enter orders for Equity Shares held in dematerialized form and physical form.

20.20 The Buyback from the Eligible Shareholders who are residents outside India including foreign corporate bodies (including erstwhile overseas corporate bodies), foreign portfolio investors, non-resident Indians, members of foreign nationality, if any, shall be subject to the Foreign Exchange Management Act, 1999 and rules and regulations framed thereunder, if any, Income

Tax Act, 2025 and rules and regulations framed thereunder, as applicable, and also subject to the receipt / provision by such Eligible Shareholders of such approvals, if and to the extent necessary or required from concerned authorities including, but not limited to, approvals from the RBI under the Foreign Exchange Management Act, 1999 and rules and regulations framed thereunder, if any.

- 20.21 The reporting requirements for non-resident shareholders under RBI, Foreign Exchange Management Act, 1999, as amended and any other rules, regulations, guidelines, for remittance of funds, shall be made by the Eligible Shareholders and/ or the Eligible Shareholder's Broker through which the Eligible Shareholder places the bid.
- 20.22 Modification/ cancellation of orders and multiple bids from a single Eligible Shareholder will be allowed during the Tendering Period of the Buyback. Multiple bids made by a single Eligible Shareholder for selling Equity Shares shall be clubbed and considered as "one bid" for the purposes of acceptance.
- 20.23 The cumulative quantity tendered shall be made available on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) (throughout the trading session and will be updated at specific intervals during the Tendering Period).
- 20.24 All documents sent by the Eligible Shareholders will be at their own risk. Eligible Shareholders are advised to safeguard adequately their interests in this regard. Eligible Shareholders shall also provide all relevant documents, which are necessary to ensure transferability of the Equity Shares in respect of the Tender Form to be sent. Such documents may include (but not be limited to):
- 20.24.1 Duly attested power of attorney, if any person other than the Eligible Shareholder has signed the Tender Form;
- 20.24.2 Duly attested death certificate and succession certificate/legal heirship certificate, in case any Eligible Shareholder has expired; and
- 20.24.3 In case of companies, the necessary certified corporate authorizations (including board and/or general meeting resolutions).
- 20.25 **Procedure to be followed by Eligible Shareholders holding Equity Shares in dematerialized form:**
- 20.25.1 Eligible Shareholders who desire to tender their Equity Shares held by them in dematerialized form under the Buyback would have to do so through their respective Seller Member by indicating to the concerned Seller Member, the details of Equity Shares they intend to tender under the Buyback.
- 20.25.2 The Seller Member(s) would be required to place an order/ bid on behalf of the Eligible Shareholders who wish to tender Equity Shares in the Buyback using the Acquisition Window of BSE.
- 20.25.3 The details of the settlement number under which the lien will be marked on the Equity Shares tendered for the Buyback will be provided in a separate circular to be issued by BSE or the Clearing Corporation.

- 20.25.4 The lien shall be marked by the Seller Member in the demat account of the Eligible Shareholder for the shares tendered in Tender Offer. Details of shares marked as lien in the demat account of the Eligible Shareholder shall be provided by the Depositories to BSE Clearing Limited and Indian Clearing Corporation Limited (“**Clearing Corporation**”). In case, the Shareholders demat account is held with one Depository and clearing member pool and Clearing Corporation Account is held with other Depository, shares shall be blocked in the shareholders demat account at source Depository during the tendering period. Inter Depository Tender Offer (“**IDT**”) instructions shall be initiated by the shareholders at source Depository to clearing member/ Clearing Corporation account at target Depository. Source Depository shall block the shareholder’s securities (i.e., transfers from free balance to blocked balance) and send IDT message to target Depository for confirming creation of lien. Details of shares blocked in the shareholders demat account shall be provided by the target Depository to the Clearing Corporation.
- 20.25.5 For custodian participant orders for Equity Shares in dematerialised form, early pay-in is mandatory prior to confirmation of order by custodian. The custodian shall either confirm or reject the orders not later than the closing of trading hours on the last day of the Tendering Period. Thereafter, all unconfirmed orders shall be deemed to be rejected. For all confirmed custodian participant orders, order modification by the concerned Seller Member shall revoke the custodian confirmation and the revised order shall be sent to the custodian again for confirmation.
- 20.25.6 Upon placing the bid, the Seller Member(s) shall provide a Transaction Registration Slip (“**TRS**”) generated by the exchange bidding system to the Eligible Shareholder on whose behalf the bid has been placed. The TRS will contain the details of the order submitted like bid ID number, application number, DP ID, client ID, number of Equity Shares tendered etc. In case of non-receipt of the completed tender form and other documents, but lien marked on Equity Shares and a valid bid in the exchange bidding system, the bid by such Eligible Shareholder shall be deemed to have been submitted.
- 20.25.7 **IT IS CLARIFIED THAT IN CASE OF EQUITY SHARES IN DEMATERIALISED FORM, SUBMISSION OF THE TENDER FORM AND TRS IS NOT MANDATORY.** After the receipt of the Equity Shares in dematerialised form by the Clearing Corporation and a valid bid in the exchange bidding system, the Buyback shall be deemed to have been accepted, for Eligible Shareholders holding Equity Shares in dematerialised form.
- 20.25.8 The Eligible Shareholders will have to ensure that they keep the Depository participant (“**DP**”) account active and unblocked to receive credit in case of return of Equity Shares due to rejection or due to prorated Buyback decided by the Company. Further, Eligible Shareholders will have to ensure that they keep the bank account attached with the DP account active and updated to receive credit remittance due to acceptance of Buyback of shares by the Company.

## 20.26 **Procedure to be followed by Eligible Shareholders holding Equity Shares in physical form**

In accordance with SEBI’s circular dated July 31, 2020 (circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/144), shareholders holding Equity Shares in physical form are allowed to tender such shares in a buyback undertaken through the Tender Offer route. However, such tendering

shall be as per the provisions of the Buyback Regulations. Nevertheless, Eligible Shareholders holding Equity Shares in physical form are urged to have their Equity Shares dematerialized so as to be able to freely transfer them and participate in corporate actions in a convenient and effective manner. The procedure for tendering equity shares in physical form is as below:

- 20.26.1 Eligible Shareholders who are holding Equity Shares in physical form and intend to participate in the Buyback will be required to approach their respective Seller Member along with the complete set of documents for verification procedures to be carried out before placement of the bid. Such documents will include the (a) Tender Form duly signed by all Eligible Shareholders (in case shares are in joint names, in the same order in which they hold the shares), (b) original share certificate(s), (c) valid share transfer form(s)/ Form SH-4 duly filled and signed by the transferors (i.e., by all registered Shareholders in the same order and as per the specimen signatures registered with the Company) and duly witnessed at the appropriate place authorizing the transfer in favour of the Company, (d) self-attested copy of PAN card(s) of all Eligible Shareholders, (e) any other relevant documents such as power of attorney, corporate authorization (including board resolution/ specimen signature), notarized copy of death certificate and succession certificate or probated will, if the original shareholder is deceased, etc., as applicable. In addition, if the address of the Eligible Shareholder has undergone a change from the address registered in the register of members of the Company, the Eligible Shareholder would be required to submit a self-attested copy of address proof consisting of any one of the following documents: valid Aadhar card, voter identity card or passport.
- 20.26.2 Based on documents mentioned in paragraph 20.26.1 above, the concerned Seller Member shall place an order/ bid on behalf of the Eligible Shareholders holding Equity Shares in physical form who wish to tender Equity Shares in the Buyback, using the Acquisition Window of BSE. Upon placing the bid, the Seller Member shall provide a TRS generated by the exchange bidding system to the Eligible Shareholder. TRS will contain the details of order submitted like folio number, certificate number, distinctive number, number of Equity Shares tendered etc.
- 20.26.3 Any Seller Member/ Eligible Shareholder who places a bid for Equity Shares in physical form, is required to deliver the original share certificate(s) and documents (as mentioned above) along with TRS generated by exchange bidding system upon placing of bid, either by registered post, speed post or courier or hand delivery to the Registrar to the Buyback i.e., KFin Technologies Limited (at the address mentioned on cover page) on or before the Buyback Closing Date i.e., Wednesday, April 29, 2026 by 5:00 pm (IST). The envelope should be super scribed as "**Aurobindo Pharma Limited Buyback 2026**". One copy of the TRS will be retained by Registrar to the Buyback and it will provide acknowledgement of the same to the Seller Member.
- 20.26.4 The Eligible Shareholders holding Equity Shares in physical form should note that Equity Shares in physical form will not be accepted unless the complete set of documents are submitted. Acceptance of the Equity Shares in physical form for Buyback by the Company shall be subject to verification as per the Buyback Regulations and any further directions issued in this regard. The Registrar to the Buyback will verify such bids based on the documents submitted on a daily basis and till such verification, BSE shall display such bids as 'unconfirmed physical bids'.

Once Registrar to the Buyback confirms the bids, they will be treated as 'confirmed bids'.

- 20.26.5 In case any Eligible Shareholder has submitted Equity Shares in physical form for dematerialization, such Eligible Shareholders should ensure that the process of getting the Equity Shares dematerialized is completed well in time so that they can participate in the Buyback before the closure of the tendering period of the Buyback.
- 20.26.6 All documents as mentioned above shall be enclosed with the valid Tender Form, failing which the Equity Shares tendered will be liable for rejection. The Equity Shares shall be liable for rejection on the following grounds amongst others: (i) If there is any other company's equity share certificate(s) enclosed with the Tender Form instead of the Equity Share certificate(s) of the Company; (ii) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders; (iii) If the Eligible Shareholders tender Equity Shares but the Registrar to the Buyback does not receive the Equity Share certificate(s); (iv) In case the signature on the Tender Form and Form SH-4 does not match as per the specimen signature recorded with Company/ Registrar of the Company.
- 20.26.7 An unregistered shareholder holding Equity Shares in physical form may also tender their Equity Shares in the Buyback by submitting the duly executed transfer deed for transfer of shares, purchased prior to the Record Date, in their name, along with the offer form, copy of their PAN card and of the person from whom they have purchased shares and other relevant documents as required for transfer, if any.
- 20.27 For Equity Shares held by Eligible Shareholders, being Non-Resident Shareholders of Equity Shares (Read with paragraph 17 "Details of Statutory Approvals"):**
- 20.27.1 Eligible Shareholders, being Non-Resident Shareholders of Equity Shares (excluding FIIs) shall also enclose a copy of the permission received by them from RBI, if applicable, to acquire the Equity Shares held by them.
- 20.27.2 Eligible Shareholders who are FIIs/FPIs should also enclose a copy of their SEBI registration certificate.
- 20.27.3 In case the Equity Shares are held on repatriation basis, the Non-Resident Shareholder shall obtain and enclose a letter from its authorised dealer / bank confirming that at the time of acquiring such Equity Shares, payment for the same was made by the Non-Resident Shareholder from the appropriate account (e.g., NRE a/c.) as specified by RBI in its approval. In case the Non-Resident Shareholder is not in a position to produce the said certificate, the Equity Shares would be deemed to have been acquired on non-repatriation basis and in that case the Non-Resident Shareholder shall submit a consent letter addressed to the Company, allowing the Company to make the payment on a non-repatriation basis in respect of the valid Equity Shares accepted under the Buyback.
- 20.27.4 If any of the above stated documents (as applicable) are not enclosed along with the Tender Form, the Equity Shares tendered under the Buyback are liable to be rejected.

THE NON RECEIPT OF THIS LETTER OF OFFER BY, OR ACCIDENTAL OMISSION TO DISPATCH THE LETTER OF OFFER TO ANY PERSON WHO IS ELIGIBLE TO RECEIVE THE SAME TO PARTICIPATE IN THE BUYBACK, SHALL NOT INVALIDATE THE BUYBACK OFFER IN ANY WAY. PLEASE NOTE THAT THE COMPANY SHALL ACCEPT EQUITY SHARES VALIDLY TENDERED FOR THE BUYBACK OFFER ON THE BASIS OF THEIR HOLDING AND ENTITLEMENT AS APPEARING IN THE RECORDS OF THE COMPANY AS ON THE RECORD DATE.

20.28 **In case of non-receipt of the Letter of Offer and the Tender Form:**

20.28.1 **In case the Eligible Shareholders hold Equity Shares in dematerialized form:** If any Eligible Shareholder who is holding Equity Shares in dematerialized form and has been sent the Letter of Offer through electronic means wishes to obtain a physical copy of the Letter of Offer, they may send a request in writing to the Company or Registrar at the address or email ID mentioned at the cover page of the Letter of Offer stating name, address, number of Equity Shares held on Record Date, client ID number, DP name/ ID, beneficiary account number. Upon receipt of such request, a physical copy of the Letter of Offer shall be provided to such Eligible Shareholder. An Eligible Shareholder may participate in the Buyback by downloading the Tender Form from the websites of the Company ([www.aurobindo.com](http://www.aurobindo.com)), the Manager to the Buyback ([www.axiscapital.co.in](http://www.axiscapital.co.in)), Registrar to the Buyback ([kosmic.kfintech.com/karisma/buybackofferv2.aspx](http://kosmic.kfintech.com/karisma/buybackofferv2.aspx)), SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)) or by providing his/her/its application in writing on a plain paper, signed by all Eligible Shareholders (in case of joint holding), stating name and address of the Eligible Shareholder(s), number of Equity Shares held as on the Record Date, Client ID number, DP name, DP ID, beneficiary account number and number of Equity Shares tendered for the Buyback.

20.28.2 **In case the Eligible Shareholders hold in physical form:** An Eligible Shareholder may participate in the Buyback by providing his/her/its application in writing on a plain paper signed by all Eligible Shareholders (in case of joint holding) stating name, address, folio number, number of Equity Shares held, Equity Share certificate number, number of Equity Shares tendered for the Buyback and the distinctive numbers thereof, enclosing the original Equity Share certificate(s), copy of Eligible Shareholder's PAN card(s) and executed share transfer form in favour of the Company. An Eligible Shareholder may participate in the Buyback by downloading the Tender Form from the websites of the Company ([www.aurobindo.com](http://www.aurobindo.com)), the Manager to the Buyback ([www.axiscapital.co.in](http://www.axiscapital.co.in)), Registrar to the Buyback ([kosmic.kfintech.com/karisma/buybackofferv2.aspx](http://kosmic.kfintech.com/karisma/buybackofferv2.aspx)), SEBI ([www.sebi.gov.in](http://www.sebi.gov.in)), NSE ([www.nseindia.com](http://www.nseindia.com)) and BSE ([www.bseindia.com](http://www.bseindia.com)), and must ensure that the Tender Form, along with the TRS and requisite documents, reach the Registrar to the Buyback on or before the Buyback Closing Date i.e., Wednesday, April 29, 2026 by 5:00 pm (IST). If the signature(s) of the Eligible Shareholders provided in the plain paper application differs from the specimen signature(s) recorded with the registrar of the Company or are not in the same order (although attested), such Tender Forms are liable to be rejected under this Buyback.

**Please note that Eligible Shareholder(s) who intend to participate in the Buyback will be required to approach their respective Seller Member (along with the complete set of documents for verification procedures in case of Equity Shares held in physical form) and**

have to ensure that their bid is entered by their respective Seller Member in the electronic platform to be made available by BSE before the Buyback Closing Date.

The Company shall accept Equity Shares validly tendered by the Eligible Shareholder(s) in the Buyback on the basis of their shareholding as on the Record Date and the Buyback Entitlement. Eligible Shareholder(s) who intend to participate in the Buyback using the 'plain paper' option as mentioned in this paragraph are advised to confirm their Entitlement from the Registrar to the Buyback Offer, before participating in the Buyback.

The participation of the Eligible Shareholders in the Buyback is entirely at the discretion of the Eligible Shareholders. The Company does not accept any responsibility for the decision of any Eligible Shareholder to either participate or to not participate in the Buyback. The Company will not be responsible in any manner for any loss of share certificate(s) and other documents during transit and the Eligible Shareholders are advised to adequately safeguard their interest in this regard.

#### 20.29 Acceptance of Orders

The Registrar to the Buyback shall provide details of order Acceptance to the Clearing Corporation within specified timelines.

#### 20.30 Method of Settlement

Upon finalization of the basis of Acceptance as per Buyback Regulations:

- 20.30.1 The settlement of trades shall be carried out in the manner similar to settlement of trades in the secondary market and as intimated by the Clearing Corporation from time to time, and in compliance with the SEBI Circulars.
- 20.30.2 The Company will pay the consideration to the Company's Broker who will transfer the funds pertaining to the Buyback to the Clearing Corporation's bank accounts as per the prescribed schedule. For Equity Shares accepted under the Buyback, the Clearing Corporation will make direct funds payout to respective Eligible Shareholders. For Eligible Shareholders holding Equity Shares in dematerialized form, if the Eligible Shareholders' bank account details are not available or if the funds transfer instruction is rejected by RBI/bank, due to any reason, then such funds will be transferred to the concerned Seller Member's settlement bank account for onward transfer to such Eligible Shareholders.
- 20.30.3 For the Eligible Shareholders holding Equity Shares in physical form, the funds pay-out would be given to their respective Seller Member's settlement accounts for releasing the same to the respective Eligible Shareholder's account.
- 20.30.4 In case of certain client types viz. Non-Resident Shareholders (where there are specific RBI and other regulatory requirements pertaining to funds pay-out) who do not opt to settle through custodians, the funds pay-out would be given to their respective Seller Member's settlement accounts for releasing the same to the respective Eligible Shareholder's account. For this purpose, the client type details would be collected from the Depositories, whereas funds payout pertaining to the bids settled through custodians will be transferred to the settlement bank account

of the custodian, each in accordance with the applicable mechanism prescribed by BSE and the Clearing Corporation from time to time.

- 20.30.5 Details in respect of Eligible Shareholder's Entitlement for Tender Offer process will be provided to the Clearing Corporation by the Company or Registrar to the Buyback. On receipt of the same, Clearing Corporation will cancel the excess or unaccepted blocked Equity Shares in the demat account of the Eligible Shareholder. On settlement date, all blocked Equity Shares mentioned in the accepted bid will be transferred to the Clearing Corporation.
- 20.30.6 In the case of inter Depository, Clearing Corporation will cancel the excess or unaccepted shares in target Depository. Source Depository will not be able to release the lien without a release of IDT message from target Depository. Further, release of IDT message shall be sent by target Depository either based on cancellation request received from Clearing Corporation or automatically generated after matching with bid accepted detail as received from the Company or the Registrar to the Buyback. Post receiving the IDT message from target Depository, source Depository will cancel/ release excess or unaccepted block shares in the demat account of the shareholder. Post completion of tendering period and receiving the requisite details viz., demat account details and accepted bid quantity, source Depository shall debit the securities as per the communication/ message received from target Depository to the extent of accepted bid shares from shareholder's demat account and credit it to Clearing Corporation settlement account in target Depository on settlement date.
- 20.30.7 In relation to Equity Shares held in physical form: (a) If Equity Shares held in physical form tendered by Eligible Shareholders are not Accepted, then the Equity Share certificate would be returned to such Eligible Shareholders by registered post or by ordinary post or courier at the Eligible Shareholders' sole risk. The Company also encourages Eligible Shareholders holding Equity Shares in physical form to dematerialize them. (b) If however, only a portion of the Equity Shares held in physical form by an Eligible Shareholder is Accepted in the Buyback then the Company shall instead of issuing a split share certificate towards the unaccepted Equity Shares, issue a Letter of Confirmation ("**LOC**") in accordance with SEBI Master Circular No. SEBI/HO/MIRSD/POD1/P/CIR/2023/70 dated May 17, 2023. The LOC shall be dispatched to the address registered with the Company. The Company shall retain the original Equity Share certificates and deface such certificates with a stamp "Letter of Confirmation Issued" on the face / reverse of the certificate to the extent of the excess Equity Shares in physical form. The LOC shall be valid for a period of 120 days from the date of its issuance, within which the Eligible Shareholder shall be required to make a request to their depository participant for dematerializing the Equity Shares. In case the Eligible Shareholder fails to submit the demat request within the aforementioned period, the RTA shall arrange to credit the Equity Shares to a separate demat account of the Company opened for the said purpose.
- 20.30.8 The Equity Shares bought back in dematerialized form would be transferred directly to the demat escrow account of the Company opened for the Buyback ("**Company Demat Escrow Account**") provided it is indicated by the Company's Broker or it will be transferred by the Company's Broker to the Company Demat Escrow Account on receipt of the Equity Shares from the clearing and settlement mechanism of BSE.

- 20.30.9 Eligible Shareholders who intend to participate in the Buyback should consult their respective Seller Member(s) for details of any cost, applicable taxes, charges and expenses (including brokerage) etc., that may be levied by the Seller Member(s) upon the selling shareholders for tendering Equity Shares in the Buyback (secondary market transaction). The Buyback consideration received by the Eligible Shareholders in respect of accepted Equity Shares could be net of such costs, applicable taxes, charges and expenses (including brokerage) and the Manager to the Buyback and Company accepts no responsibility to bear or pay such additional cost, charges and expenses (including brokerage) incurred solely by the Eligible Shareholders.
- 20.30.10 The Seller Member(s) would issue contract note and pay the consideration for the Equity Shares accepted under the Buyback and return the balance unaccepted Equity Shares to their respective clients/ will unblock the excess unaccepted Equity Shares. The Company's Broker would also issue a contract note to the Company for the Equity Shares accepted under the Buyback.
- 20.30.11 The Equity Shares accepted, bought and lying to the credit of the Company Demat Escrow Account will be extinguished in the manner and following the procedure prescribed in the Buyback Regulations.

#### 20.31 **Rejection Criteria**

The Equity Shares tendered by Eligible Shareholders would be liable to be rejected on the following grounds:

- 20.31.1 For Eligible Shareholders holding Equity Shares in dematerialized form:
- (i) If the Shareholder is not an Eligible Shareholder of the Company as on the Record Date;
  - (ii) If there is a name mismatch in demat account of the Shareholder and PAN;  
or
  - (iii) There exists any restraint order of a court/any other competent authority for transfer/disposal/ sale or where loss of share certificates has been notified to the Company or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists.
- 20.31.2 For Eligible Shareholders holding Equity Shares in physical form:
- (i) If the documents mentioned in the Tender Form for Eligible Shareholders holding Equity Shares in physical form are not received by the Registrar on or before the Buyback Closing Date i.e., Wednesday, April 29, 2026 by 5:00 pm (IST);
  - (ii) If there is any other company's share certificate enclosed with the Tender Form instead of the share certificate of the Company;
  - (iii) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders;
  - (iv) If the Eligible Shareholders bid the Equity Shares but the Registrar does not receive the physical share certificate;
  - (v) If the PAN cards (self-attested) of the shareholder and all the joint holders, are not submitted with the form;

- (vi) In the event the signature in the Tender Form and Form SH-4 do not match as per the specimen signature recorded with Company or Registrar;
- (vii) If the shareholder is not an Eligible Shareholder of the Company on the Record Date;
- (viii) If there is a name mismatch in the share certificate of the shareholder;
- (ix) If the Eligible Shareholder has made a duplicate bid; or
- (x) Where there exists any restraint order of a court/ any other competent authority for transfer/ disposal/ sale or where loss of share certificates has been notified to the Company or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists.

## **21. NOTE ON TAXATION**

**THE SUMMARY OF THE TAX CONSIDERATIONS IN THIS SECTION ARE BASED ON THE CURRENT PROVISIONS OF THE INCOME TAX LAWS OF INDIA AND THE REGULATIONS THEREUNDER, THE JUDICIAL AND THE ADMINISTRATIVE INTERPRETATIONS THEREOF, WHICH ARE SUBJECT TO CHANGE OR MODIFICATION BY SUBSEQUENT LEGISLATIVE, REGULATORY, ADMINISTRATIVE OR JUDICIAL DECISIONS. ANY SUCH CHANGES COULD HAVE DIFFERENT TAX IMPLICATIONS ON THESE TAX CONSIDERATIONS.**

**IN VIEW OF THE PARTICULARIZED NATURE OF TAX CONSEQUENCES, SHAREHOLDERS ARE REQUIRED TO CONSULT THEIR TAX ADVISORS FOR THE APPLICABLE TAX PROVISIONS INCLUDING THE TREATMENT THAT MAY BE GIVEN BY THEIR RESPECTIVE TAX OFFICERS IN THEIR CASE, AND THE APPROPRIATE COURSE OF ACTION THAT THEY SHOULD TAKE.**

**THE COMPANY DOES NOT ACCEPT ANY RESPONSIBILITY FOR THE ACCURACY OR OTHERWISE OF THIS TAX SUMMARY AND THERE CAN BE NO LIABILITY ON THE COMPANY IF ANY ACTION IS TAKEN BY THE SHAREHOLDER SOLELY BASED ON THIS TAX SUMMARY. THEREFORE, SHAREHOLDERS CANNOT RELY ON THIS ADVICE AND THE SUMMARY TAX IMPLICATIONS RELATING TO THE TREATMENT OF INCOME TAX IN THE CASE OF BUYBACK OF EQUITY SHARES LISTED ON THE STOCK EXCHANGE SET OUT BELOW SHOULD BE TREATED AS INDICATIVE AND FOR GUIDANCE PURPOSES ONLY.**

### **21.1 GENERAL**

The Indian tax year runs from April 1 to March 31. The basis of charge of Indian income-tax depends upon the residential status of the taxpayer during a tax year. A person who is a tax resident of India is liable to taxation in India on his worldwide income, subject to certain prescribed tax exemptions provided under the IT Act.

A person who is treated as a non-resident for Indian tax purposes is generally liable to tax in India only on his / her Indian sourced income or income received by such person in India.

In case of shares of a company, the source of income from shares would depend on the “situs” of the shares. As per the IT Act and Judicial precedents, generally the “situs” of the shares is where company is “incorporated” and where its shares can be transferred. Accordingly, since the Company is incorporated in India, the shares of the Company would be “situated” in India and any gains arising to a non-resident on transfer of such shares should be taxable in India under the IT Act subject to any specific exemption in this regard. Further, the non-resident can avail the beneficial tax treatment prescribed under the Double Taxation Avoidance Agreement (“**DTAA**”), as modified by the Multilateral Instrument (“**MLI**”), if the same is

applicable to the relevant DTAA between India and the respective country of which the said shareholder is tax resident.

The above benefit may be available subject to satisfying relevant conditions prescribed under the IT Act including but not limited to availability of Tax Residency Certificate, non-applicability of General Anti-Avoidance Rule (“GAAR”) and providing and maintaining necessary information and documents as prescribed under the IT Act as well as satisfying the relevant conditions under the respective DTAA including anti-abuse measures under the MLI, if applicable.

## 21.2 CLASSIFICATION OF SHAREHOLDERS

Section 6 of the IT Act determines the residential status of an assessee. Accordingly, shareholders can be classified broadly in two categories as below:

### 21.2.1 Resident Shareholders being:

- (i) Individuals, Hindu Undivided Family (“HUF”), Association of Persons (“AOP”), Body of Individuals (“BOI”), Firm and Limited Liability Partnership (“LLP”)
- (ii) Others (corporate bodies):
  - Company
  - Other than Company

### 21.2.2 Non-Resident Shareholders being:

- (i) Non-Resident Indians (NRIs)
- (ii) Foreign Institutional Investors (FIIs) / Foreign Portfolio Investors (FPIs)
- (iii) Others:
  - Foreign Company
  - Foreign non-corporate shareholders Other than Company

## 21.3 INCOME TAX PROVISIONS IN RESPECT OF BUYBACK OF EQUITY SHARES LISTED ON RECOGNISED STOCK EXCHANGE

As per the provisions of Section 69 of the IT Act

21.3.1 If a shareholder or a holder of other specified securities receives any consideration from any company for the purchase of its own shares or other specified securities held by such shareholder or holder of other specified securities, then, subject to the provisions of section 72, the difference between the cost of acquisition and the value of consideration so received shall be deemed to be the “Capital gains” arising to such shareholder or the holder of other specified securities, as the case may be, in the year in which the company purchases the shares or other specified securities.

21.3.2 In respect of capital gains referred to in sub-section (1), where a company purchases its own shares or other specified securities in accordance with the provisions of section 68 of the Companies Act, 2013 and the shareholder or holder of other specified securities is a promoter, the aggregate income-tax payable on such capital gains shall be—

- (i) the income-tax payable on such capital gains in accordance with the provisions of this IT Act; and
- (ii) an additional income tax in respect of capital gains specified in column B of the Table below, computed at the rate specified in column C or column D of the said Table.

Sl. No	Income	Rate, where the promoter is a domestic company	Rate, where the promoter is other than a domestic company
A	B	C	D
1	Short-term capital gains referred to in section 196 arising from the transfer of such securities.	2%	10%
2	Long-term capital gains referred to in section 197 or section 198 arising from the transfer of such securities.	9.50%	17.50%

(plus, applicable surcharge and cess as notified).

21.3.3 For the purposes of this section, —

- (i) in the case of a company whose shares are listed on a recognized stock exchange in India, ‘promoter’ shall have the same meaning as assigned to it in regulation 2(k) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 made under the Securities and Exchange Board of India Act, 1992;
- (ii) in any other case, “promoter” means, —
  - o a “promoter” as defined in section 2(69) of the Companies Act, 2013 (18 of 2013); or
  - o a person who holds, directly or indirectly, more than 10% of the shareholding in the company;
- (iii) “specified securities” shall have the same meaning as assigned to it in Explanation 1 to section 68 of the Companies Act, 2013.

## 21.4 TAX DEDUCTION AT SOURCE

For Resident Shareholders, the company is not required to deduct any Tax at Source.

For Non–resident shareholders, the Company is required to deduct tax at source on payment made to Non–resident, if such payment is chargeable to tax in India under the provisions of the IT Act, at the time of payment or credit whichever is earlier, at the rates in force.

The term “rates in force” is defined under section 2(90) of the IT Act to include rates specified under the Finance Act for the relevant year or the rates specified under the double taxation avoidance agreement with the respective countries. In this regard, the Finance Act, 2026 provides rates in force on capital gain<sup>1</sup> as below:

---

<sup>1</sup> Consideration received on buy back less cost of acquisition

Sl. No (A)	Income (B)	Promoters (c)			Non – promoters (D)
		Rates in force	Additional tax	Total	Rates in force
1	Short term Capital gain referred in section 196 arising from the transfer of such securities	20%	10%	30%	20%
2	Long term Capital gain referred in section 197 or section 198 arising from the transfer of such securities	12.50%	17.50%	30%	12.50%

(plus, applicable surcharge and cess as notified).

However, section 159(8) of the IT Act provides that in order to be eligible to claim the relief under a DTAA, a non-resident will need to provide a TRC issued by the relevant foreign government. Further, Income tax Rules, 2026 also prescribes to maintain following to avail benefits under the relevant DTAA:

- Copy of the PAN card allotted by the Indian income tax authorities duly attested by the shareholders or details as prescribed rule 158 under the Income-tax Rules, 2026 in absence of PAN Card.
- Copy of the Tax Residency Certificate for financial year 2026-27 obtained from the revenue or tax authorities of the country of tax residence, duly attested by shareholders/authorized signatory
- Electronic Form 41 can be obtained electronically through the e-filing portal of the income tax website at <https://www.incometax.gov.in/iec/foportal/>.
- Self-declaration by the shareholders of having no permanent establishment in India in accordance with the applicable tax treaty
- Self-declaration of beneficial ownership of equity shares by the non-resident shareholder
- Self-declaration of fulfilling all conditions of tax treaty for being eligible to claim benefit of the tax treaty (DTAA) read with Multilateral Instrument (MLI).
- Any other documents as prescribed under the IT Act for lower withholding of taxes, if applicable, duly attested by the shareholders.

Kindly note that any relief in withholding tax rate is subject to the DTAA provisions applicable, and would depend on the documents submitted.

Non-resident shareholders may also provide a Lower Tax Deduction Certificate (LTDC) certificate issued by the Income Tax Department under Section 395 of the IT Act, which authorizes company to deduct WHT at a lower rate instead of the standard prescribed rate under IT Act.

The non-resident shareholders need to consult their tax advisors with regard to availability of such a tax credit.

## 21.5 SECURITIES TRANSACTION TAX

Since the Buyback of shares shall take place through the settlement mechanism of the Stock Exchange, Securities Transaction Tax will be applicable at the applicable rate.

**CAVEAT:**

**THE SUMMARY OF THE TAX CONSIDERATIONS AS ABOVE IS BASED ON THE CURRENT PROVISIONS OF THE TAX LAWS OF INDIA, WHICH ARE SUBJECT TO CHANGE OR MODIFICATION BY SUBSEQUENT LEGISLATIVE, REGULATORY, ADMINISTRATIVE OR JUDICIAL DECISIONS.**

**IN VIEW OF THE SPECIFIC NATURE OF TAX CONSEQUENCES, SHAREHOLDERS WHO ARE NOT TAX RESIDENTS OF INDIA ARE REQUIRED TO CONSULT THEIR TAX ADVISORS FOR THE APPLICABLE TAX AND THE APPROPRIATE COURSE OF ACTION THAT THEY SHOULD TAKE CONSIDERING THE PROVISIONS OF THE RELEVANT COUNTRY OR STATE TAX LAW AND PROVISIONS OF DTAA WHERE APPLICABLE.**

**22. DECLARATION FROM THE BOARD OF DIRECTORS**

**Declaration as required by clause (ix) and clause (x) of Schedule I of the Buyback Regulations:**

- 22.1 The Board confirms that there are no defaults (either in the past or subsisting) in the repayment of any deposits (including interest payable thereon), redemption of debentures or preference shares, payment of dividend or repayment of any term loans to any financial institution or banks (including interest payable thereon), as the case may be, and in case of defaults which have ceased to subsist, if any, a period of more than 3 (three) years has lapsed.

As required by Clause (x) of Schedule I of the Buyback Regulations, the Board has confirmed that it has made full enquiry into the affairs and prospects of the Company and has formed an opinion, that:

- (i) immediately following the date of the Board Meeting, i.e., Monday, April 6, 2026, approving the Buyback, there will be no grounds on which the Company could be found unable to pay its debts, if any;
- (ii) as regards the Company's prospects for the year immediately following the date of Board Meeting, and having regard to the Board's intention with respect to the management of the Company's business during that year and to the amount and character of the financial resources, which will, in the Board's view, be available to the Company during that year, the Company will be able to meet its liabilities as and when they fall due and will not be rendered insolvent within a period of 1 (One) year from the date of the Board Meeting; and
- (iii) in forming its opinion aforesaid, the Board has taken into account the liabilities (including prospective and contingent liabilities) as if the Company were being wound up under the provisions of the Companies Act, or the Insolvency and Bankruptcy Code, 2016, as applicable.

This declaration is made and issued under the authority of the Board of Directors in terms of the resolution passed at the meeting held on Monday, April 6, 2026.

For and on behalf of the Board of Directors

Sd/-

K. Nithyananda Reddy  
Managing Director  
**DIN: 01284195**

Sd/-

Mettu Madan Mohan  
Reddy  
Whole-time Director  
**DIN: 01284266**

### 23. STATUTORY AUDITOR'S REPORT

The text of the report dated Monday, April 6, 2026, of M/s. Deloitte Haskins & Sells, Chartered Accountants, the statutory auditors of the Company, addressed to the Board of the Company is reproduced below:

#### Quote

To,  
Board of Directors,  
Aurobindo Pharma Limited  
Galaxy, Floor 22-24  
Plot No 1, Sy No 83/1 Hyderabad Knowledge City,  
Raidurg Panmaktha Hyderabad, Telangana – 500032

**Re: Statutory Auditor's Report in respect of proposed buyback of equity shares by Aurobindo Pharma Limited (the "Company") in terms of Clause (xi) of Schedule I of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended ("the Buyback Regulations")**

1. This Report is issued in accordance with the terms of our engagement letter March 25, 2026.
2. The Board of Directors of the Company have approved a proposal for buyback of Equity Shares by the Company at its meeting held on April 6, 2026, in pursuance of the provisions of Sections 68, 69 and 70 of the Companies Act, 2013, as amended (the "Act") and the Buyback Regulations.
3. We have been requested by the Management of the Company to provide a report on the accompanying "Statement of Permissible Capital Payment for the year ended and as at March 31, 2025" ('Annexure A') (hereinafter referred to as the "Statement"). This Statement has been prepared by the Management, which we have stamped for the purposes of identification only.

#### **Management's Responsibility:**

4. The preparation of the Statement in compliance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations and compliance with the Buyback Regulations, is the responsibility of the Management of the Company, including the computation of the amount of the permissible capital payment, the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal controls relevant to the preparation and presentation of the Statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

5. As the Buyback Regulations and the Act do not define the term “insolvent”, the Company has applied the guidance provided in paragraphs 25 and 26 of Ind AS 1, Presentation of Financial Statements, which relate to the assessment of the Company’s ability to continue as a going concern for a period of one year from April 06, 2026. The Board of Directors are responsible to make a full inquiry into the affairs and prospects of the Company and to form an opinion as specified in (x) of Schedule I to the SEBI Buyback Regulations and that the Company will not, having regard to its state of affairs, be rendered insolvent within a period of one year from April 06, 2026 (date of passing of the Board Meeting resolution).

**Auditor's Responsibility:**

6. Pursuant to the requirements of the Buyback Regulations, it is our responsibility to provide a reasonable assurance that:
  - i. we have inquired into the state of affairs of the Company in relation to the annual audited standalone and consolidated financial statements for the year ended and as at March 31, 2025 which were approved by the Board of Directors of the Company at their meeting held on May 26, 2025, and adopted by the shareholders of the Company in the Annual General Meeting held on September 10, 2025.
  - ii. the amount of permissible capital payment as stated in Annexure A, has been properly determined considering the annual audited standalone and consolidated financial statements for the year ended and as at March 31, 2025 in accordance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations; and
  - iii. the Board of Directors of the Company, in their Meeting held on April 06, 2026 have formed the opinion as specified in Clause (x) of Schedule I to the Buyback Regulations, on reasonable grounds and that the Company will not, having regard to its state of affairs, be rendered insolvent (as defined in management responsibility above) within a period of one year from the aforesaid date with regard to the proposed buyback is approved at Board meeting.
7. The annual standalone and consolidated financial statements referred to in paragraph 6 above, have been audited by us, on which we have issued an unmodified audit opinion in our reports each dated May 26, 2025. We conducted our audit of the annual standalone and consolidated financial statements in accordance with the Standards on Auditing specified under Section 143(10) of the Act and other applicable authoritative pronouncements issued by the Institute of Chartered Accountants of India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. Our audit was not planned and performed in connection with any transactions to identify matters that may be of potential interest to third parties.
8. We conducted our examination of the Statement in accordance with the Guidance Note on Audit Reports and Certificates for Special Purposes (Revised 2016), issued by the Institute of Chartered Accountants of India (the “Guidance Note”) and Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, in so far as applicable for the purpose of this report. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.
9. We have complied with the relevant applicable requirements of the Standard on Quality Control

(SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements. Further our examination did not extend to any other parts and aspects of a legal or proprietary nature in the aforesaid Buyback.

## **Opinion**

10. Based on inquiries conducted and our examination as above, we report that:

- i. We have inquired into the state of affairs of the Company in relation to its annual audited standalone and consolidated financial statements for the year ended and as at March 31, 2025, which have been approved by the Board of Directors of the Company in their meeting held on May 26, 2025.
- ii. The amount of permissible capital payment towards the proposed buy back of equity shares as computed in the Statement attached herewith, as Annexure A, in our view has been properly determined in accordance with the proviso to Section 68(2)(b) of the Act and the proviso to Regulation 5(i)(b) of the Buyback Regulations.
- iii. The Board of Directors of the Company, at their meeting held on April 06, 2026 have formed their opinion as specified in clause (x) of Schedule I to the Buyback Regulations, on reasonable grounds and that the Company having regard to its state of affairs, will not be rendered insolvent (as defined in management responsibility above) within a period of one year from the date of passing the Board Resolution dated April 06, 2026.

## **Restriction on use**

11. This report has been issued at the request of the Company solely for use of the Company

- (i) in connection with the proposed buyback of equity shares of the Company as mentioned in paragraph 2 above,
- (ii) to enable the Board of Directors of the Company to include in the Letter of offer and other documents pertaining to buyback to be filed with
  - a) the Registrar of Companies, Securities and Exchange Board of India, stock exchanges, and any other regulatory authority as per applicable law; and
  - b) the Central Depository Services (India) Limited, National Securities Depository Limited and
  - c) to share with the Manager to Buyback offer in connection with the proposed buyback of equity shares of the Company for onward submission to relevant authorities in pursuance to the provisions of Section 68 and other applicable provisions of the Act and the Buyback Regulations, and may not be suitable for any other purpose.

This report should not be used for any other purpose without our prior written consent. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

**For Deloitte Haskins & Sells**  
Chartered Accountants

Sd/-  
**C Manish Muralidhar**  
(Partner)  
(Membership No. 213649)  
(UDIN: 26213649FRKCFB8227)

Place: Denver, USA  
Date: April 06, 2026

**Annexure A - Statement of Permissible Capital Payment as at March 31, 2025:**

Computation of amount of permissible capital payment towards buyback of equity shares in accordance with the proviso to Section 68(2)(b) of the Companies Act, 2013 ("the Act") and read with proviso to Regulation 5(i)(b) of Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended, based on annual audited standalone and consolidated financial statements as at and for the year ended March 31, 2025.

(Amount in ₹ millions)

Particulars		Amount - Standalone	Amount - Consolidated
<b>Paid up Equity Share Capital as on March 31, 2025</b> (580,801,623 fully paid-up Equity Shares of ₹ 1 each)	(A)	580.8	580.8
<b>Free Reserves as on March 31, 2025</b>			
Securities Premium			751.1
General Reserve		2,013.9	2,257.0
Retained Earnings		200,904.0	302,216.5
<b>Total Free Reserves</b>	<b>(B)</b>	<b>202,917.9</b>	<b>305,224.6</b>
<b>Total</b>	<b>C=(A+B)</b>	<b>203,498.7</b>	<b>305,805.4</b>
Maximum amount permissible towards buyback of equity shares in accordance with the proviso to Section 68(2)(b) of the Companies Act, 2013 and read with proviso to Regulation 5(i)(b) of Buyback Regulations (10% of the total Paid-up equity capital and free reserves of standalone and consolidated financial statements)	C * 10%	<b>20,349.9</b>	<b>30,580.5</b>
Maximum amount permissible for buyback lower of Standalone and Consolidated amounts			<b>20,349.9</b>

**Notes:**

- 1) The amount of paid-up equity share capital and free reserves as at March 31, 2025 have been extracted from the annual audited standalone and consolidated financial statements of the Company as at and for the year ended March 31, 2025.
- 2) As the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended and the Act do not define the term "insolvent", the Company has applied the guidance provided in paragraphs 25 and 26 of Ind AS 1, Presentation of Financial Statements, which relate to the assessment of the Company's ability to continue as a going concern for a period of one year

from April 06, 2026 as well as for a period of one year immediately following the date of passing of the Board Meeting resolution.

For and on behalf of Board of Directors of **Aurobindo Pharma Limited**

Sd/-

K. Nithyananda Reddy  
Vice Chairman and Managing Director

Date: April 06, 2026

**Unquote**

**24. DOCUMENTS FOR INSPECTION**

Copies of the following documents will be available for inspection at the registered office of the Company Plot No. 2, Maithrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays during the Buyback Period:

- 24.1 Copies of the certificate of incorporation, memorandum and articles of association of the Company;
- 24.2 Copies of the annual reports of the Company for the financial years ended March 31, 2025, March 31, 2024 and March 31, 2023, and the unaudited financial statements for the nine months period ended December 31, 2025;
- 24.3 Copy of the resolution passed by the Board of Directors at the meeting held on Monday, April 6, 2026 approving proposal for Buyback;
- 24.4 Copy of the report dated Monday, April 6, 2026 of M/s. Deloitte Haskins & Sells, Chartered Accountants, the Statutory Auditors of the Company, in terms of clause (xi) of Schedule I of the Buyback Regulations;
- 24.5 Copy of the Public Announcement dated Tuesday, April 7, 2026 and published in the newspapers on Wednesday, April 8, 2026 regarding the Buyback;
- 24.6 Copy of declaration of solvency as prescribed under Section 68(6) of the Companies Act;
- 24.7 Copy of Escrow Agreement dated Tuesday, April 7, 2026 between the Company, the Escrow Agent and the Manager to the Buyback;
- 24.8 Letter from Escrow Bank dated April 10, 2026, that the Escrow Account in the name of "Aurobindo Pharma Limited - Buyback Escrow Account" has been opened and confirming deposit of funds;
- 24.9 Certificate dated Monday, April 6, 2026 of G Pavan Kumar Reddy (Membership No. 229495), partner at G P M & Associates, Chartered Accountants (Firm Registration No. 015343S), confirming that the Company has firm and adequate financial arrangements to fulfil the obligations under the Buyback; and

- 24.10 Note on taxation, dated Monday, April 6, 2026, obtained by the Company from G P M & Associates, Chartered Accountants.

## 25. DETAILS OF THE COMPLIANCE OFFICER

The Company has designated the following as the Compliance Officer for the Buyback:

**Name:** Mr B Adi Reddy  
**Designation:** Company Secretary and Compliance Officer  
**Address:** Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad - 500 032, Telangana, India.  
**Tel no.:** +91 40 6672 5333  
**Email:** [cs@aurobindo.com](mailto:cs@aurobindo.com)

In case of any clarifications or to address investor grievance, the shareholders may contact the Compliance Officer, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays, at the above-mentioned address.

## 26. DETAILS OF REMEDIES AVAILABLE TO SHAREHOLDERS/ BENEFICIAL OWNERS

- 26.1 In case of any grievances relating to the Buyback (including non-receipt of the Buyback consideration, share certificate, demat credit, etc.), the Eligible Shareholders can approach the Compliance Officer and/or Manager to the Buyback and/or Registrar to the Buyback for redressal.
- 26.2 If the Company makes any default in complying with the requirements under the Companies Act or any rules made thereunder as may be applicable to the Buyback, the Company or any officer of the Company who is in default shall be liable in terms of the Companies Act.
- 26.3 The address of the concerned office of the Registrar of Companies is as follows:

**Registrar of Companies, Telangana at Hyderabad**  
2ND Floor, Corporate Bhawan, GSI Post, Nagole,  
Bandlaguda, Hyderabad-500068, Telangana, India  
**Tel. no.:** +91 40 2980 5427

## 27. DETAILS OF THE INVESTOR SERVICE CENTRE

In case of any query, the Eligible Shareholders may also contact the Registrar to the Buyback appointed as the Investor Service Centre for the purposes of the Buyback, from Monday to Friday between 10:00 am (IST) to 5:00 pm (IST) on all working days except public holidays, at the address at the following address:



### **KFin Technologies Limited**

**Address:** Selenium Tower- B, Plot No 31 & 32  
Gachibowli, Financial District Nanakramguda,  
Serilingampally, Hyderabad, Telangana - 500032

**Tel. no.:** +91 40 6716 2222

**Fax no.:** +91 40 6716 1563

**Tollfree number:** 18003094001

**Contact person:** M Murali Krishna

**Email:** [aurobindo.buyback2026@kfintech.com](mailto:aurobindo.buyback2026@kfintech.com)  
**Website:** [www.kfintech.com](http://www.kfintech.com)  
**Investor Grievance mail:** [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com)  
**SEBI Registration Number:** INR000000221  
**Validity:** Permanent  
**CIN:** L72400MH2017PLC444072

**28. DETAILS OF THE MANAGER TO THE BUYBACK**

The Company has appointed the following as Manager to the Buyback:



**AXIS CAPITAL LIMITED**  
1st Floor, Axis House, P. B. Marg, Worli  
Mumbai - 400 025, Maharashtra, India  
**Tel.:** +91 22 4325 2183  
**Fax:** +91 22 4325 3000  
**Contact Person:** Harish Patel/ Simran Gadh  
**Email:** [apl.buyback@axiscap.in](mailto:apl.buyback@axiscap.in)  
**Website:** [www.axiscapital.co.in](http://www.axiscapital.co.in)  
**SEBI Registration Number:** INM000012029

**29. DECLARATION BY THE DIRECTORS**

In terms of Regulation 24(i)(a) of the Buyback Regulations, the Board accepts full responsibility for all the information contained in this Letter of Offer and confirms that this Letter of Offer contains and will contain true, factual and material information and does not contain any misleading information. This Letter of Offer is issued under the authority of the Board and in terms of the resolution passed by the Board on Monday, April 6, 2026.

For and on behalf of the Board of Directors of **Aurobindo Pharma Limited**

Sd/-

**K. Nithyananda Reddy**  
Managing Director  
**DIN:** 01284195

Sd/-

**Mettu Madan Mohan Reddy**  
Whole-time Director  
**DIN:** 01284266

Sd/-

**B. Adi Reddy**  
Company Secretary and Compliance Officer  
**Membership No.:** ACS 13709

**Date:** April 21, 2026

**Place:** Hyderabad

**TENDER FORM**  
**FORM OF ACCEPTANCE-CUM-ACKNOWLEDGEMENT**  
**(FOR ELIGIBLE SHAREHOLDERS HOLDING EQUITY SHARES IN DEMATERIALIZED FORM)**

**Bid Number:**  
**Date:**

BUYBACK OPENS ON		THURSDAY, APRIL 23, 2026	
BUYBACK CLOSING ON		WEDNESDAY, APRIL 29, 2026	
For Registrar use			
Inward No.	Date	Stamp	
Status (please tick appropriate box)			
<input type="checkbox"/> Individual	<input type="checkbox"/> FII/FPI	<input type="checkbox"/> Insurance Co	
<input type="checkbox"/> Foreign Co.	<input type="checkbox"/> NRI/OCB	<input type="checkbox"/> FVCI	
<input type="checkbox"/> Body Corporate	<input type="checkbox"/> Bank/FI	<input type="checkbox"/> Pension/PF	
<input type="checkbox"/> VCF	<input type="checkbox"/> Partnership/LLP	<input type="checkbox"/> Mutual Fund	
<input type="checkbox"/> Others (Specify)			
India Tax Residency Status: Please tick appropriate box			
<input type="checkbox"/> Resident in India	<input type="checkbox"/> Non-Resident in India	<input type="checkbox"/> Resident of _____ (Shareholder to fill country of residence)	
Route of Investment (For NR Shareholders only)			
<input type="checkbox"/> Portfolio Investment Scheme		<input type="checkbox"/> Foreign Investment Scheme	

To,  
The Board of Directors,  
**AUROBINDO PHARMA LIMITED**  
**C/o. KFin Technologies Limited**  
Selenium Tower- B, Plot No 31 & 32 Gachibowli,  
Financial District Nanakramguda,  
Serilingampally, Hyderabad, Telangana – 500032  
Tel. no.: +91 40 6716 2222

Dear Sir/ Madam,

**Sub: Letter of Offer dated Tuesday, April 21, 2026 in relation to the buyback of up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares of Aurobindo Pharma Limited (hereinafter referred as “the Company”) at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share (“Buyback Price”) payable in cash (the “Buyback”)**

- I / We (having read and understood the Letter of Offer dated Tuesday, April 21, 2026 issued by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.
- I / We authorize the Company to buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.
- I / We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.
- I / We declare that there are no restraints / injunctions or other order(s) / covenants of any nature which limits / restricts in any manner my / our right to tender Equity Shares for Buyback and that I / we am / are legally entitled to tender the Equity Shares for Buyback.
- I / We agree that the Company will pay the Buyback Price only after due verification of the validity of documents and that the consideration will be paid as per the secondary market mechanism.
- The Eligible Shareholders will have to ensure that they keep the DP Account active and unblocked to receive credit in case of return of Equity Shares due to rejection or due to prorated Buyback decided by the Company. Further, Eligible Shareholders will have to ensure that they keep the bank account attached with the DP account active and updated to receive credit remittance due to acceptance of Buyback of shares by the Company.
- I / We agree that the consideration for the accepted Equity Shares will be paid to the Eligible Shareholder as per the provisions of Buyback Regulations and circulars issued by SEBI.
- I / We agree to return to the Company any Buyback consideration that may be wrongfully received by me / us.
- I / We undertake to execute any further documents and give any further assurances that may be required or expedient to give effect to my / our tender / offer and agree to abide by any decision that may be taken by the Company to effect the Buyback in accordance with the Companies Act, Buyback Regulations, the extant applicable foreign exchange regulations and any other applicable laws.
- I / We acknowledge that the responsibility to discharge the tax due on any gains arising on buyback is on me/us. I / We agree to compute gains on this transaction and immediately pay applicable taxes in India and file tax return in consultation with our custodians/ authorized dealers/ tax advisors appropriately.
- I / We undertake to indemnify the Company if any tax demand is raised on the Company on account of gains arising to me / us on buyback of shares. I / We also undertake to provide the Company, the relevant details in respect of the taxability / non-taxability of the proceeds arising on buyback of shares by the Company, copy of tax return filed in India, evidence of the tax paid etc., whenever called for.
- Non-Resident Shareholders (including NRIs, OCBs, FPI, Foreign Nationals and FIIs) are requested to enclose a consent letter indicating the details of transfer i.e., number of Equity Shares to be transferred, the name of the investee company whose shares are being transferred i.e., “Aurobindo Pharma Limited” and the price at which the Equity Shares are being transferred i.e., “Price determined in accordance with the Buyback Regulations” duly signed by the Shareholder or his/its duly appointed agent and in the latter case, also enclose the power of attorney.
- Details of Equity Shares held and tendered / offered for Buyback:

Particulars	In Figures	In Words
Number of Equity Shares held as on Record Date (Friday, April 17, 2026)		
Number of Equity Shares Entitled for Buyback (Buyback Entitlement)		
Number of Equity Shares offered for Buyback (Including Additional Shares, if any)		

**Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the Buyback Entitlement of such Eligible Shareholder shall be accepted to the full extent. The Equity Shares tendered by any Eligible Shareholder over and above the Buyback Entitlement of such Eligible Shareholder shall be accepted in accordance with paragraph 20 (Procedure for Tendering Shares and Settlement) of the Letter of Offer. Equity Shares tendered by any Eligible Shareholder over and above the number of Equity Shares held by such Eligible Shareholder as on the Record Date shall not be considered for the purpose of Acceptance.**

- I / We agree that the Clearing Corporation will cancel the excess or unaccepted blocked shares in the demat account of the Equity Shareholder.

-----Tear along this line-----

**ACKNOWLEDGMENT SLIP: AUROBINDO PHARMA LIMITED – BUYBACK OFFER**  
*(To be filled by the Eligible Shareholder) (Subject to verification)*

DP ID		Client ID	
Received from Mr./Ms./Mrs.			
<b>Form of Acceptance-cum-Acknowledgement, Original TRS along with:</b>			
No. of Equity Shares offered for Buyback (In Figures)		(in words)	
Please quote Client ID No. & DP ID No. for all future correspondence			Stamp of Stock Broker

## 15. Details of Account with Depository Participant (DP):

Name of the Depository (tick whichever is applicable)		NSDL		CDSL
Name of the Depository Participant				
DP ID No.				
Client ID No. with the DP				

## 16. Equity Shareholders Details:

Particulars	First/Sole Holder	Joint Holder 1	Joint Holder 2	Joint Holder 3
Full Name(s) Of the Holder				
Signature(s)*				
PAN				
Address of the Sole/First Equity Shareholder				
Telephone No. of Sole/First Equity Shareholder		Email ID of Sole/First Equity Shareholder		

\* Non-individual Shareholders must affix rubber stamp and sign under valid authority. The relevant authorization should be enclosed with the application form submitted.

## 17. Applicable for all Non-Resident Shareholders only:

- I / We undertake to pay income taxes in India on any income arising on such Buyback accordance with prevailing income tax laws in India. I / We also undertake to indemnify the Company against any income tax liability on any income earned on such Buyback of shares by me / us. I / We undertake to return to the Company any consideration in respect of the Buyback that may be wrongfully received by me/us.
- I / We, being a Non-Resident Shareholder, agree to obtain and submit all necessary approvals, if any, and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

**INSTRUCTIONS**

**This Tender Form has to be read along with the Letter of Offer and is subject to the terms and conditions mentioned in the Letter of Offer and this Tender Form**

- This Buyback will open on Thursday, April 23, 2026 and close on Wednesday, April 29, 2026.
- Eligible Shareholders who desire to tender their Equity Shares in dematerialized form under the Buyback would have to do so through their respective Seller Member by indicating the details of Equity Shares they intend to tender under the Buyback offer. For further details, please see the procedure as specified in the section entitled "Procedure for Tendering Shares and Settlement" in paragraph 20 on page no. 60 of the Letter of Offer.
- Eligible Shareholders may submit their duly filled Tender Form to the office of Registrar to the Buyback Offer (as mentioned in paragraph 20 (Procedure for Tendering Shares and Settlement) of the Letter of Offer) only post placing the bid via the Seller Member.
- In case any registered entity that has merged with another entity and the merger has been approved and has come into effect but the process of getting the successor company as the registered Shareholder is still incomplete, then such entity along with the Tender Form should file a copy of the following documents: (i) Approval from the appropriate authority for such merger; (ii) The scheme of merger; and (iii) The requisite form filed with MCA intimating the merger.
- The Buyback shall be rejected for Shareholders in case of receipt of the completed Tender Form and other documents, but non-receipt of Shares in the special account of the Clearing Corporation or a non-receipt of valid bid in the exchange bidding system.**
- The shares in the Offer would be liable to be rejected if (i) the tenderer is not an Eligible Shareholder of the Company as on the Record Date (ii) if there is a name and PAN mismatch in the demat account of the Eligible Shareholder (iii) in the event of non-receipt of the completed Tender Form and other documents from the Eligible Shareholders who were holding shares in physical form as on the Record Date and have placed their bid in dematerialized form.
- The Eligible Shareholders will have to ensure that they keep the DP Account active and unblocked to receive credit in case of return of Equity Shares due to rejection or due to prorated Buyback as may be decided by the Company / Registrar to the Buyback, in accordance with the Buyback Regulations.
- Eligible Shareholders to whom the Offer is made are free to tender shares to the extent of their Entitlement in whole or in part or in excess of their Entitlement, but not exceeding their holding as on Record Date.
- All documents sent by Eligible Shareholders will be at their own risk. Eligible Shareholders are advised to safeguard adequately their interests in this regard.
- By agreeing to participate in the Buyback, each Eligible Shareholder (including the Non-Resident Shareholder) undertakes to complete all relevant regulatory / statutory filings and compliances to be made by it under applicable law, including filing of Form FC-TRS. Further, by agreeing to participate in the Buyback, each Eligible Shareholder hereby (a) authorises the Company to take all necessary action, solely to the extent required, and if necessary, to be undertaken by the Company, for making any regulatory / statutory filings and compliances on behalf of such Shareholder; and (b) undertakes to provide the requisite assistance to the Company for making any such regulatory / statutory filings and compliances.
- Non-Resident Shareholders must obtain and submit all necessary approvals, if any and to the extent required from the concerned authorities including approvals from the RBI under FEMA and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.
- In case of non-receipt of the Letter of Offer, Eligible Shareholders holding Equity Shares may participate in the Buyback by providing their application in plain paper in writing signed by all Eligible Shareholders (in case of joint holding), stating name and address of the Eligible Shareholder(s), number of Equity Shares held as on the Record Date, Client ID number, DP Name, DP ID, beneficiary account number and number of Equity Shares tendered for the Buyback.
- Eligible Sellers have to fill up the EVENT number issued by Depository in the column for settlement details along with the market type as "Buyback", ISIN, Quantity of shares and CM BP ID of broker and execution date in the Delivery Instruction Slips (DIS) so that Equity Shares can be tendered for Buyback Offer
- For the Eligible Shareholders holding Equity Shares in dematerialised form, the Tender Form and TRS is not required to be submitted to the Company, Manager or the Registrar. After the receipt of the Equity Shares in dematerialized form by the Clearing Corporation and a valid bid in the exchange bidding system, the Buyback shall be deemed to have been accepted for the Eligible Shareholders holding Equity Shares in dematerialized form.**

All capitalised items not defined herein shall have the meaning ascribed to them in the Letter of Offer.

-----Tear along this line-----

**ALL FUTURE CORRESPONDENCE IN CONNECTION WITH THIS BUYBACK, IF ANY, SHOULD BE ADDRESSED TO REGISTRAR TO THE BUYBACK AT THE FOLLOWING ADDRESS QUOTING YOUR CLIENT ID AND DP ID:**

**Investor Service Centre: Aurobindo Pharma Limited - Buyback offer  
KFin Technologies Limited**

Selenium Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana – 500032

**Contact Person:** M Murali Krishna; **Tel. no.:** +91 40 6716 2222; **Fax no.:** +91 40 6716 1563; **Tollfree No.:** 18003094001

**E-mail:** [aurobindo.buyback2026@kfintech.com](mailto:aurobindo.buyback2026@kfintech.com); **Website:** [www.kfintech.com](http://www.kfintech.com); **Investor Grievance Email:** [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com)

**SEBI Registration Number:** INR000000221; **CIN:** L72400MH2017PLC444072

**TENDER FORM**

**FORM OF ACCEPTANCE-CUM-ACKNOWLEDGEMENT (FOR ELIGIBLE SHAREHOLDERS HOLDING EQUITY SHARES IN PHYSICAL FORM)**

Eligible Shareholders holding Equity Shares in physical form are requested to refer to paragraph 20.26 of the Letter of Offer titled 'Procedure to be followed by Eligible Shareholders holding Equity Shares in physical form', for details regarding permissibility of acceptance of Equity Shares held in physical form and for details regarding the procedure for tendering, before submitting the Tender Form and Securities Transfer Form with respect to Equity Shares held in physical form.

**Bid Number:**

**Date:**

BUYBACK OPENS ON		THURSDAY, APRIL 23, 2026	
BUYBACK CLOSES ON		WEDNESDAY, APRIL 29, 2026	
<b>For Registrar use</b>			
<b>Inward No.</b>	<b>Date</b>	<b>Stamp</b>	
<b>Status (please tick appropriate box)</b>			
<input type="checkbox"/> Individual	<input type="checkbox"/> FII/FPI	<input type="checkbox"/> Insurance Co	
<input type="checkbox"/> Foreign Co.	<input type="checkbox"/> NRI/OCB	<input type="checkbox"/> FVCI	
<input type="checkbox"/> Body Corporate	<input type="checkbox"/> Bank/FI	<input type="checkbox"/> Pension/PF	
<input type="checkbox"/> VCF	<input type="checkbox"/> Partnership/LLP	<input type="checkbox"/> Mutual fund	
<input type="checkbox"/> Others (Specify)			
<b>India Tax Residency Status: Please tick appropriate box</b>			
<input type="checkbox"/> Resident in India	<input type="checkbox"/> Non-Resident in India	Resident of _____ (Shareholder to fill country of residence)	
<b>Route of Investment (For NR Shareholders only)</b>			
<input type="checkbox"/> Portfolio Investment Scheme	<input type="checkbox"/> Foreign Investment Scheme		

To,  
The Board of Directors,  
**AUROBINDO PHARMA LIMITED**  
C/o. KFin Technologies Limited

Selenium Tower- B, Plot No 31 & 32 Gachibowli,  
Financial District Nanakramguda,  
Serilingampally, Hyderabad, Telangana – 500032  
Tel. no.: +91 40 6716 2222

**Dear Sir/ Madam,**

**Sub: Letter of Offer dated Tuesday, April 21, 2026 in relation to the buyback of up to 54,23,728 (Fifty Four Lakh Twenty Three Thousand Seven Hundred and Twenty Eight only) Equity Shares of Aurobindo Pharma Limited (hereinafter referred as "the Company") at a price of ₹ 1,475/- (Rupees One Thousand Four Hundred and Seventy Five only) per Equity Share ("Buyback Price") payable in cash (the "Buyback")**

- I / We (having read and understood the Letter of Offer dated Tuesday, April 21, 2026 issued by the Company) hereby tender / offer my / our Equity Shares in response to the Buyback on the terms and conditions set out below and in the Letter of Offer.
- I / We authorize the Company to Buyback the Equity Shares offered (as mentioned above) and to issue instruction(s) to the Registrar to the Buyback to extinguish the Equity Shares.
- I / We hereby affirm that the Equity Shares comprised in this Tender Offer are offered for Buyback by me / us free from all liens, equitable interest, charges and encumbrance.
- I / We declare that there are no restraints / injunctions or other covenants of any nature which limits / restricts in any manner my/ our right to tender Equity Shares for Buyback and that I / we am / are legally entitled to tender the Equity Shares for Buyback.
- I / We agree that the consideration for the accepted Equity Shares will be paid to the Eligible Shareholder as per the provisions of Buyback Regulations and circulars issued by SEBI.
- I / We agree that the Company is not obliged to accept any Equity Shares offered for Buyback where loss of share certificates has been notified to the Company.
- I / We agree that the Company will pay the Buyback Price only after due verification of the validity of the documents and that the consideration will be paid as per secondary market mechanism to first named Eligible Shareholder.
- I / We agree to return to the Company any Buyback consideration that may be wrongfully received by me / us.
- I / We authorize the Company to issue a Letter of Confirmation ("LOC") for the unaccepted Equity shares in case only a portion of the physical shares held by me is accepted in the Buyback.
- I / We undertake to execute any further documents and give any further assurances that may be required or expedient to give effect to my / our tender / offer and agree to abide by any decision that may be taken by the Company to effect the Buyback in accordance with the Companies Act, Buyback Regulations, the extant applicable foreign exchange regulations and any other applicable laws.
- I / We acknowledge that the responsibility to discharge the tax due on any gains arising on buyback is on me/us. I / We agree to compute gains on this transaction and immediately pay applicable taxes in India and file tax return in consultation with our custodians/ authorized dealers/ tax advisors appropriately.
- I / We undertake to indemnify the Company if any tax demand is raised on the Company on account of gains arising to me / us on buyback of shares. I / We also undertake to provide the Company, the relevant details in respect of the taxability / non-taxability of the proceeds arising on buyback of shares by the Company, copy of tax return filed in India, evidence of the tax paid etc., whenever called for.
- Details of Equity Shares held and tendered / offered for Buyback:

Particulars	In Figures	In Words
Number of Equity Shares held as on Record Date (Friday, April 17, 2026)		
Number of Equity Shares Entitled for Buyback (Buyback Entitlement)		
Number of Equity Shares offered for Buyback (including Additional Shares, if any)		

**Note: An Eligible Shareholder may tender Equity Shares over and above his / her Buyback Entitlement. Number of Equity Shares validly tendered by any Eligible Shareholder up to the Buyback Entitlement of such Eligible Shareholder shall be accepted to the full extent. The Equity Shares tendered by any Eligible Shareholder over and above the Buyback Entitlement of such Eligible Shareholder shall be accepted in accordance with paragraph 20 (Procedure for Tendering Shares and Settlement) of the Letter of Offer. Equity Shares tendered by any Eligible Shareholder over and above the number of Equity Shares held by such Eligible Shareholder as on the Record Date shall not be considered for the purpose of Acceptance.**

14. Details of Share Certificate(s) enclosed:

Total No. of Share Certificates Submitted:

Sr. No.	Folio No.	Share Certificate No.	Distinctive No(s)		No. of Shares
			From	To	
<b>Total</b>					

In case the number of folios and share certificates enclosed exceed 3 nos., Please attach a separate sheet giving details in the same format as above.

-----Tear along this line-----

**ACKNOWLEDGMENT SLIP: AUROBINDO PHARMA LIMITED – BUYBACK OFFER**  
(To be filled by the Equity Shareholder) (Subject to verification)

Folio No.	
Received from Mr./ Ms./Mrs.	
<b>Form of Acceptance-cum-Acknowledgement, Original TRS along with:</b>	
No. of Equity Shares offered for Buyback (In figures)	(in words)
Please quote Folio No. for all future correspondence	Stamp of Broker

15. Details of the bank account of the sole or first Eligible Shareholder to be incorporated in the consideration warrant (to be mandatorily filled):

Name of the Bank	Branch and City	IFSC and MICR Code	Account Number (indicate type of account)

16. Details of other Documents (Please v as appropriate, if applicable) enclosed:

Power of Attorney	Previous RBI approvals for acquiring the Equity Shares hereby tendered in the Buyback
Death Certificate	Succession Certificate
Self-attested copy of PAN	Corporate authorisations
TRS	Others (please specify)

17. Equity Shareholders Details:

Particulars	First/Sole Holder	Joint Holder 1	Joint Holder 2	Joint Holder 3
Full Name(s) Of the Holder				
Signature(s)*				
PAN				
Address of the Sole/First Equity Shareholder				
Telephone No. of Sole/First Equity Shareholder		Email ID of Sole/First Equity Shareholder		

\* Non-individual Shareholders must affix rubber stamp and sign. The relevant authorisation should be enclosed with the application form submitted.

18. Applicable for all Non-Resident Shareholders

- I / We undertake to pay income taxes in India on any income arising on such Buyback and taxable in accordance with prevailing income tax laws in India within 7th day of the succeeding months in which the Shares are bought back by the Company. I / We also undertake to indemnify the Company against any income tax liability on any income earned on such Buyback of shares by me / us. I / We undertake to return to the Company any consideration in respect of the Buyback that may be wrongfully received by me/us.
- I / We, being a Non-Resident Shareholder, agree to obtain and submit all necessary approvals, if any, and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

#### INSTRUCTIONS

**This Tender Form has to be read along with the Letter of Offer and is subject to the terms and conditions mentioned in the Letter of Offer and this Tender Form**

- This Buyback will open on Thursday, April 23, 2026 and close on Wednesday, April 29, 2026.
- Eligible Shareholders who wish to tender their Equity Shares in response to this Buyback Offer should submit the following documents to their Seller Member, who in turn would deliver the said documents along with the Transaction Registration Slip (TRS) to the Registrar; the documents should be sent to the Registrar only after the placement of a valid bid; non-submission of the below mentioned documents directly to the Registrar shall result in the rejection of the tendered Equity Shares: (i) The Tender Form duly signed (by all Equity Shareholders in case shares are in joint names) the same order in which they hold the shares. (ii) Original share certificates (iii) Valid share transfer form(s) (SH-4) duly filled and signed by the transferors (i.e., by all registered Shareholders in same order and as per the specimen signatures registered with the Company / Registrar) and duly witnessed at the appropriate place authorizing the transfer in favour of the Company (iv) Self-attested copy of the Permanent Account Number (PAN) Card (by all Eligible Shareholders in case shares are in joint names). (v) Any other relevant documents such as (but not limited to): Duly attested Power of Attorney if any person other than the Equity Shareholder has signed the relevant Tender Form, Notarized copy of death certificate and succession certificate or probated will, as applicable, if the original Shareholder has deceased, necessary corporate authorisations, such as board resolutions etc., in case of companies. (vi) In addition to the above, if the address of the Shareholder has undergone a change from the address registered in the Register of Members of the Company, the Shareholder would be required to submit a self-attested copy of address proof consisting of any one of the following documents: valid Aadhar Card, Voter Identity Card or Passport.
- In case any registered entity that has merged with another entity and the merger has been approved and has come into effect but the process of getting the successor company as the registered Shareholder is still incomplete, then such entity along with the Tender Form file a copy of the following documents: (i) Approval from the appropriate authority for such merger; (ii) the scheme of merger and (iii) the requisite form filed with MCA intimating the merger.
- Eligible Shareholders whom the Buyback Offer is made are free to tender Equity Shares to the extent of their Entitlement in whole or in part or in excess of their Entitlement, but not exceeding the number of Shares held by them as on Record Date.
- All documents / remittances sent by or to Eligible Shareholders will be at their own risk and the Eligible Shareholders are advised to adequately safeguard their interests in this regard.
- In case of non-receipt of the Letter of Offer, Eligible Shareholders holding Equity Shares may participate in the offer by providing their application in plain paper in writing signed by all Eligible Shareholders (in case of joint holding), stating name, address, folio number, number of Equity Shares held, Equity Share certificate number, number of Equity Shares tendered for the Buyback and the distinctive numbers thereof, enclosing the original Equity Share certificate(s), copy of Eligible Shareholder's PAN card(s) and executed share transfer form in favour of the Company. Eligible Shareholders must ensure that the Tender Form, along with the TRS and requisite documents, reach the Registrar to the Buyback on or before the Buyback Closing Date, i.e., Wednesday, April 29, 2026 by 5:00 pm (IST).
- For procedure followed by Eligible Shareholders for tendering shares in the buyback offer, please refer to paragraph 20 (Procedure for Tendering Shares and Settlement) of the Letter of Offer.
- All documents as mentioned above shall be enclosed with the valid Tender Form otherwise the shares will be liable for rejection. The shares shall be liable for rejection on the following grounds amongst others: (a) If any other company share certificates are enclosed with the Tender Form instead of the share certificate of the Company; (b) Non-submission of Notarized copy of death certificate and succession certificate / probated / Will, as applicable in case any Eligible Shareholder has deceased; (c) If the Eligible Shareholder(s) bid the shares but the Registrar does not receive the physical share certificate; or (d) In case the signature in the Tender Form and Form SH-4 doesn't match as per the specimen signature recorded with Company / Registrar; (e) If necessary corporate authorizations under official stamp are not accompanied with Tender Form; (f) If the transmission of Equity Shares is not completed, and the Equity Shares are not in the name of the Eligible Shareholders; (g) the Form SH-4 is not witnessed
- The Equity Shares tendered in the buyback shall be rejected if (i) the Shareholder is not a Eligible Shareholder of the Company on the Record Date; or (ii) if there is a name mismatch in the share certificate of the Shareholder; or (iii) where there exists any restraint order of a Court/ any other competent authority for transfer / disposal/ sale; or (iv) or where the title to the Equity Shares is under dispute or otherwise not clear or where any other restraint subsists; or (v) the documents mentioned in the Tender Form for Eligible Shareholders holding Equity Shares in physical form are not received by the Registrar on or before the close of business hours of Wednesday, April 29, 2026 by 5:00 pm (IST).
- By agreeing to participate in the Buyback, each Eligible Shareholder (including each Non-Resident Shareholder) undertakes to complete all relevant regulatory / statutory filings and compliances to be made by it under applicable law, including filing of Form FC-TRS. Further, by agreeing to participate in the Buyback, each Eligible Shareholder hereby (a) authorises the Company to take all necessary action, solely to the extent required, and if necessary, to be undertaken by the Company, for making any regulatory / statutory filings and compliances on behalf of such Shareholder; and (b) undertakes to provide the requisite assistance to the Company for making any such regulatory / statutory filings and compliances.
- Non-Resident Shareholders must obtain and submit all necessary approvals, if any and to the extent required from the concerned authorities including approvals from the Reserve Bank of India ("RBI") under Foreign Exchange Management Act, 1999, as amended ("FEMA") and the rules and regulations framed there under, for tendering Equity Shares in the Buyback, and also undertake to comply with the reporting requirements, if applicable, under the FEMA and any other rules, regulations and guidelines, in regard to remittance of funds outside India.

All capitalised items not defined herein shall have the meaning ascribed to them in the Letter of Offer.

-----Tear along this line-----

**ALL FUTURE CORRESPONDENCE IN CONNECTION WITH THIS BUYBACK, IF ANY, SHOULD BE ADDRESSED TO REGISTRAR TO THE BUYBACK AT THIS ADDRESS:**

**Investor Service Centre: Aurobindo Pharma Limited - Buyback offer**  
**KFin Technologies Limited**

Selenium Tower- B, Plot No 31 & 32 Gachibowli, Financial District Nanakramguda, Serilingampally, Hyderabad, Telangana – 500032

Contact Person: M Murali Krishna; Tel. no.: +91 40 6716 2222; Fax no.: +91 40 6716 1563; Toll free No.:18003094001

E-mail: [aurobindo.buyback2026@kfintech.com](mailto:aurobindo.buyback2026@kfintech.com); Website: [www.kfintech.com](http://www.kfintech.com); Investor Grievance Email: [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com)

SEBI Registration Number: INR00000221; CIN: L72400MH2017PLC444072

**Form No. SH-4 - Securities Transfer Form**

Pursuant to Section 56 of the Companies Act, 2013 and sub-rule (1) of Rule 11 of the Companies (Share Capital and Debentures) Rules 2014

Date of execution: \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_ 2026

**FOR THE CONSIDERATION** stated below the "Transferor(s)" named do hereby transfer to the "Transferee(s)" named the securities specified below subject to the conditions on which the said securities are now held by the Transferor(s) and the Transferee(s) do hereby agree to accept and hold the said securities subject to the conditions aforesaid.

CIN: 

L	2	4	2	3	9	T	G	1	9	8	6	P	L	C	0	1	5	1	9	0
---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---

Name of the company (in full): Aurobindo Pharma LimitedName of the Stock Exchange where the company is listed, (if any): BSE Limited and National Stock Exchange of India Limited**DESCRIPTION OF SECURITIES**

Kind/ class of securities (1)	Nominal value of each unit of security (2)	Amount called up per unit of security (3)	Amount paid up per unit of security (4)
Equity Share	₹ 1/-	₹ 1/-	₹ 1/-

No. of Securities being Transferred			Consideration received (₹)		
In Figures	In words		In words		In Figures
Distinctive Number	From				
	To				
Corresponding Certificate Nos.					

**Transferor's Particulars**Registered Folio Number 

Name(s) in full and PAN (attach copy of pan card)

Seller Signature(s)

- |          |       |
|----------|-------|
| 1. _____ | _____ |
| 2. _____ | _____ |
| 3. _____ | _____ |

I hereby confirm that the transferor has signed before me.

Signature of the Witness : \_\_\_\_\_

Name of the Witness : \_\_\_\_\_

Address of the Witness : \_\_\_\_\_  
\_\_\_\_\_

**Transferee's Particulars**

<b>Name in full (1)</b>	<b>Father's/Mother's /Spouse Name (2)</b>	<b>Address &amp; E-mail id (3)</b>
Aurobindo Pharma Limited	Not Applicable	<b>Address:</b> Plot No. 2, Maithrivihar, Ameerpet, Hyderabad- 500 038, Telangana, India  <b>Email:</b> <a href="mailto:info@aurobindo.com">info@aurobindo.com</a>

<b>Occupation (4)</b>	<b>Existing Folio No., if any (5)</b>	<b>Signature (6)</b>
Business		

**Folio No. of Transferee**

**Specimen Signature of Transferee(s)**

**Value of stamp affixed:**      ₹ \_\_\_\_\_

1. \_\_\_\_\_
2. \_\_\_\_\_
3. \_\_\_\_\_

**Enclosures:**

1. Certificate of shares or debentures or other securities
2. If no certificate is issued, letter of allotment
3. Copy of PAN Card of all the Transferees (For all listed Cos.)
4. Others, specify, \_\_\_\_\_

**STAMPS**

<b>For Office Use Only</b>	
<b>Checked by</b> _____	
<b>Signature Tallied by</b> _____	
<b>Entered in the Register of Transfer on</b> _____	
vide Transfer no _____	
<b>Approval Date</b> _____	
<b>Power of attorney / Probate / Death Certificate / Letter of Administration</b>	
<b>Registered on</b> _____	at
<b>No</b> _____	

On the reverse page of the certificate

Name of the Transferor	Name of the Transferee	No. of shares	Date of Transfer
------------------------	------------------------	---------------	------------------

Signature of the authorized signatory